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Abstract
 
Characterisation of expression of functional Peroxisome Proliferator Activated Receptor 
 
α
 
(PPAR
 
α)
 
 receptor in rodent species responsive and non-responsive to peroxisome proliferators is
important for our understanding of the molecular mechanism of peroxisome proliferation and
peroxisome proliferator induced hepatocarcinogenesis. In vitro electromobility shift assays,
demonstrated that rodent liver nuclear proteins (LNP) bound to a Peroxisome Proliferator
Response Element (PPRE) in a sequence specific manner and that LNP from methylclofenapate
(MCP) treated mice do not have enhanced binding to a PPRE. These results demonstrate that in
MCP treated mice, PPAR
 
α
 
 levels with functional DNA binding do not increase. The diurnal
expression of mouse PPAR
 
α 
 
(mPPAR
 
α
 
) protein in liver was examined by western blotting. There
was no observable difference in the expression of mPPAR
 
α
 
 across a 24 hour period. In C57 BL/
6 mice, PPAR
 
α
 
 protein levels are not regulated in a diurnal manner.
A comparison of mouse and guinea pig LNP revealed a PPAR
 
α
 
-immunoreactive protein in guinea
pig. Guinea Pig PPAR
 
α 
 
(gPPAR
 
α
 
) was cloned and found to encode a 467 amino acid protein.
Phylogenetic analysis of gPPAR
 
α
 
 showed a high substition rate: maximum likelihood analysis was
consistent with rodent monophyly, but could not exclude rodent polyphyly (p~0.07). The
gPPAR
 
α
 
 cDNA was expressed in 293 cells, and mediated the induction of the luciferase reporter
gene by the peroxisome proliferator Wy-14,643, dependent upon the presence of a PPRE. The
gPPAR
 
α
 
 mRNA and protein was expressed in guinea pig liver, although at lower levels compared
to PPAR
 
α
 
 expression in mice. The evidence presented here supports the idea that guinea pigs serve
as a useful model for human responses to peroxisome proliferators.
mPPAR
 
α
 
 DNA binding domain (mPPAR
 
α
 
-DBD) was cloned and expressed as a fusion protein.
Both His*6-mPPAR
 
α
 
-DBD and thioredoxin-mPPAR
 
α
 
-DBD were produced as insoluble
proteins when over expressed in 
 
E.coli
 
. 
 
In vitro
 
 translated mPPAR
 
α
 
-DBD did not bind to a PPRE
in an electromobility shift assay.
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Chapter 1 Introduction 
Σεχτιον 1.1 Περοξισοmε προλιφερατιον
Σεχτιον 1.1.1 Περοξισοmεσ ανδ τηειρ γενεραλ φυνχτιον
Peroxisomes were discovered to be a distinct biochemical subcellular organelle by the pioneering
studies of Christian De Duve in the 1960s (Baudhuin, P. et al 1965 and De Duve, C. and
Baudhuin, P. 1966). Peroxisomes were originally characterised on their content of  catalase and
oxidative enzymes. Initially there was an overlap of terminology between descriptions of
microbodies, peroxisomes and glyoxysomes due to stuctural and biochemical similarities. The
development of precise biochemical assays, and more refined structural assay techniques, has
allowed peroxisomes to be studied in detail. In general, animal peroxisome functions include
fatty acid oxidation, plasmalogen biosynthesis, alcohol oxidation, cholesterol synthesis,
transaminations and the metabolism of purines, polyamines and bile acids. Long chain fatty acids,
steroids, dicarboxylic acids, prostaglandins, and amino acids are some of the substrates required
for these metabolic processes ( Masters, C. and Crane, D. 1992, Van den Bosch, H. et al 1992
and Masters, C.J. 1996).
Σεχτιον 1.1.2 Μορπηολογψ οφ mαmmαλιαν περοξισοmεσ
Liver peroxisomes are spherical or ovoid, with a diameter of 0.3-1 mm. They are single
membraned organelles with a membrane thickness of 4.5-8 nm, thinner than most other single
membrane bound structures. In hepatocytes there can be up to 600 individual peroxisomes,
occupying a cell volume of approximately 2%. Hepatic peroxisomes often have a  crystalloid
core, called a nucleoid, containing urate oxidase. The detection of the presence of peroxisomes
is facilitated by 3,3’-diaminobenzidine staining using the peroxidative activity of catalase at
alkaline pH. In other tissues catalase positive particles are smaller with diameters of 0.05-0.2 mm
and lack crystalloid cores (Masters, C. and Crane, D. 1995). 
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Σεχτιον 1.1.3 Περοξισοmαλ β−Οξιδατιον 
The discovery of  peroxisomal involvement in β-oxidation of fatty acids by Lazarow and De
Duve 1976, revealed the broad scope of functions carried out by this organelle. The first step in
the peroxisomal β- oxidation pathway is to convert long chain free fatty acids to CoA-esters. The
reaction to produce the CoA derivative is carried out in the cytoplasm by a variety of acyl-CoA
synthetases, using co-enzyme A and ATP. The peroxisome membrane is permeable to CoA-
esters. Fatty acids converted to CoA-ester derivative are subject to oxidation in the peroxisome
by acyl-CoA oxidase,  a multi-subunit flavoprotein. The oxidation of a CoA-ester requires O2
and  produces H2O2 (Schultz, H 1991, Van den Bosch, H. et al 1992, and Gibson, G.and Lake,
B. 1993).The next two steps in the β-oxidation pathway of peroxisomes are  catalysed by
bifunctional enzyme. Peroxisomal bifunctional protein from rat liver was found to be a
trifunctional protein, possessing 2-enoyl-CoA hydratase, 3-hydroxyacyl-CoA dehydrogenase
and  D3,D2-enoyl-CoA isomerase activites (Palosaari and Hiltunen 1990). The last stage in the β-
oxidation of long chain fatty acids utilises the oxo-acyl-CoA product of step three to form a
medium chain fatty acid and acyl-CoA. This reaction is performed by thiolase enzyme. Medium
chain fatty acyl-CoAs can be utilised by carnitine acyltransferases and  be transported out of the
peroxisome into the cytoplasm. From the cytoplasm medium chain fatty acids can be transported
to mitochondria for further oxidation, or they may be used for the synthesis of more complex
lipids. The function of catalase in the peroxisome is to remove H2O2. The hydrogen donor for
the peroxidatic reaction could come from substrates such as phenols, formate, alcohols, nitrites
and primary amines (Schultz, H 1991, Van den Bosch, H. et al 1992, and Gibson, G.and Lake,
B. 1993)
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Σεχτιον 1.1.4 Περοξισοmαλ δισεασεσ ανδ δισορδερσ
Zellweger syndrome is an inherited general peroxisomal disorder characterised by the absence of
functional peroxisomes. Persons born with Zellweger syndrome will die prematurely. An
example of impairment of a peroxisomal biochemical pathway in Zellweger syndrome is lack of
β-oxidation of fatty acids. This is due to the deficiency of all peroxisomal β-oxidation enzymes,
leading to the accumulation of very long chain fatty acids in tissues and blood (Schutgens, R.B.H.
et al 1986, Moser H.W. 1987 and Lazarow, P.B. and Moser, H.W. 1989). Other general
peroxisomal disorders are infantile Refsuns disease, neonatal adrenoleukodystrophy and
hyperpipecolic acidaemia. These disorders are characterised by multiple peroxisomal enzyme
deficiencies, morphologically abnormal peroxisomes, as well as a reduced number or absence of
peroxisomes (Moser, H.W. 1993). Two other catagories of peroxisomal disorder have been
characterised. One catagory involves limited impairment of peroxisomal function, found in the
rhizomelic type of chondrodysplasia punctata and in zellweger-like syndrome. The other
category contains disorders in which a single peroxisomal enzyme has impaired expression or
activity, leading to a disease state (Van den Bosch, H. et al 1992). The existence of such serious
peroxisomal diseases highlights the essential need for correctly functioning peroxisomes in
humans.
Σεχτιον 1.1.5 Περοξισοmε προλιφερατινγ χηεmιχαλσ.
Peroxisome proliferators are a family of compounds which when given to rodent species such as
rat or mouse, cause common changes to the morphology and biochemistry of the liver.
Peroxisome proliferators (PPs) are structurally diverse with no easily identifiable common
molecular structure or physical property. The normal functions of the chemicals which make up
the peroxisome proliferator family are diverse, ranging from pharmaceutical agents to agricultural
herbicides. Physiological conditions such as temperature acclimatisation and nutritional
deficiencies can act in the same manner as a peroxisome proliferator (Nedergaard, J. et al 1980
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and Neat, C.E et al 1980). Table 1.1 shows a list of peroxisome proliferators .
Table 1.1 Examples of peroxisome proliferators. 
Abbreviations : Fib-HLD,  Fibrate hypolipidaemic drug; Non-Fib-HLD ,Non fibrate
hypolipidaemic drug; In-Chem., Industrial and agro-chemical  compounds  such as herbicide,
insecticide, wood preservative, and water treatment by-products; Phys.,  Physiological condition
or endogenous substance.
(Green, S. 1992, and Masters, C. and Crane, D. 1995)
Peroxisome 
Proliferator (PP)
Type of  PP Peroxisome Proliferator
(PP)
Type of 
PP
Clofibrate Fib-HLD 2,4-Dichlorophenoxy acetic 
acid
In-Chem
Nafenopin Fib-HLD 2,4,5-Trichlorophenoxy 
acetic acid
In-Chem
methylclofenapate Fib-HLD Trichloroacetic acid In-Chem
Gemfibrozil Fib-HLD Lactofen In-Chem
Bezafibrate Fib-HLD Dicamba In-Chem
Ciprofibrate Fib-HLD Cold acclimatization Phys
Fenofibrate Fib-HLD High fat diet Phys
Clobuzarit Fib-HLD Thyroxine Hormone
Wy-14,643 Non-Fib-
HLD
Triiodothyronine Hormone
Tibric Acid Non-Fib-
HLD
Dehydroepiandrosterone Hormone
BR-931 Non-Fib-
HLD
Dimethrin In-Chem
Tiadenol Non-Fib-
HLD
Perchloroethylene In-Chem
Acetylsalicyclic Acid Drug Chlorophenolate In-Chem
Ly-171883 Drug High phytol diet Phys
Valproic Acid Drug Vitamin E- deficiency Phys
Di-2-
ethylhexylphthalate
In-Chem Long Chain Fatty Acids Phys
Di-2-
ethylheyladipate
In-Chem 2-Ethylhexanoic acid In-Chem
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Σεχτιον 1.1.6 Περοξισοmε προλιφερατιον 
Peroxisome proliferators cause liver enlargement, an increase in the number of hepatic
peroxisomes and an increase in the size and volume of hepatic peroxisomes (Price, R.J. et al 1992,
Elcombe, C.R. and Mitchell, A.M. 1986, Baumgart, E. et al 1990, Lake, B.G. et al 1989a,
McGuire, E.J. et al 1992, Pacot, C. et al 1993, Stott, W.T. et al 1995, Pacot, C. et al 1996, Gray,
R.H. et al 1984). Liver enlargement occurs a result of both hyperplasia and hypertrophy.
Associated with these changes in peroxisome biogenesis are alterations in peroxisomal enzyme
activities, microsomal enzyme activities and cytosolic enzyme activites. The enzyme activities
and gene expression of acyl-CoA oxidase and cytochrome P450 4A are extensively used as
characteristic markers of peroxisome proliferation. See table 1.2 for a list of enyzmes induced by
peroxisome proliferators. 
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Table 1.2 Liver enzymes induced by peroxisome proliferators. 
Enzyme References
cyanide insensitive palmitoyl-CoA oxidase (Price, R.J. et al 1992, Elcombe, 
C.R. and Mitchell, A.M. 1986, 
Lake, B.G. et al 1989a, 
Blaauboer, B.J. et al 1990, Pacot, 
C. et al 1993, Lake, B.G., et al 
1993, Latruffe, N. et al  1995, 
Stott, W.T. et al 1995, Sausen, 
P.J. et al 1995, Cornu, M-C. et al 
1992, Sakuma, M. et al 1992, 
Espandiari, P. et al 1995, 
Elcombe, C.R. 1985 and  Pacot, 
C. et al 1996)
catalase (Pacot, C. et al 1993, Stott, W.T. 
et al 1995, Sakuma, M. et al 1992 
and Pacot, C. et al 1996)
bifunctional enzyme ( Baumgart, E. et al 1990).
thiolase ( Baumgart, E. et al 1990).
carnitine palmitoyl-CoA transferase (Sakuma, M. et al 1992)
palmitoyl-CoA hydrolase ( Oesch, F. et al 1988, Sakuma 
and M. et al 1992)
enoyl-CoA hydratase (Pacot, C. et al 1996 and Lake, 
B.G. et al 1986)
epoxide hydrolase (Oesch, F. et al 1988)
cytochrome P450 4A
(lauric acid ω- and ω-1 hydroxylase)
( Bell, D.R. et al 1991 and 1993, 
Stott, W.T. et al 1995, 
Espandiari, P. et al 1995, Lake, 
B.G. et al 1986, Sato, T. et al 1995 
and Sabzevari, O. et al 1995, 
Close, I. et al 1992, Sakuma, M. 
et al 1992 and Lake, B.G. et al 
1989a)
D-9, D-6, D-5 desaturases (Alegret, M. et al 1995),
palmitoyl-CoA elongation enzyme (Alegret, M. et al 1995)
NADPH cytochrome c reductase (Alegret, M. et al 1995)
malic enzyme (Sakuma, M. et al 1992)
1-acylglycerophosphocholine acetyltransferase (Sakuma, M. et al 1992)
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Σεχτιον 1.1.7 Περοξισοmε προλιφερατορσ αρε ηεπατοχελλυλαρ χαρχινογενσ
Long term dosing studies of peroxisome proliferators on rats and mice demonstrated that
peroxisome proliferators are tumourigenic subtances. Rats and mice dosed with Wy14,643,
gemfibrozil , DEHP, clofibrate, methylclofenapate or nafenopin caused liver tumour formation
(Lalwani, N.D. et al 1981, Fitzgerald, J.E. et al 1981, Kluwe, W.M. et al 1982, Reddy, J.K. and
Qureshi, S.A. 1979, Reddy, J.K. et al 1982 and Reddy, J.K. and Rao, M.S. 1977, Cohen, A.J.
and Crasso, P. 1981, Reddy, J.K. and Lalwani, N.D, 1983). The mechanism by which
peroxisome proliferators cause cancer is not known, but there are several proposed possible
mechanisms which could explain their action. 
Σεχτιον 1.1.8 Περοξισοmε προλιφερατορσ αρε νον−γενοτοξινσ
It was originally considered that peroxisome proliferators act as direct mutagens, that is they can
covalently interact with DNA, causing mutations to occur during DNA replication, or
transcription of DNA, leading ultimately to tumour formation. The Ames Salmonella
mutagenesis assay (Warren, J.R. et al 1980), [32P]-post labelling experiments, chromosomal
deletion analysis experiments and DNA repair assays have all been used to examine the genotoxic
potential of peroxisome proliferators. Butterworth, B.E. et al 1989 used a DNA repair assay in
primary human hepatocytes to determine the genotoxic potential of  DEHP, MEHP, Wy-
14,643 and nafenopin to human liver cells. No DNA repair response was seen for any of the
peroxisome proliferators. Ashby et al 1994 reviewed the extensive experimental data on the
genotoxicity of peroxisome proliferator chemicals, concluding that peroxisome proliferators are
predominantly non-genotoxic. 
Given that peroxisome proliferators are non-genotoxic, two principle hypotheses have been
considered as mechanisms by which peroxisome proliferators cause cancer. One hypothesis
proposes that peroxisome proliferators could act as tumour promoting agents. Here peroxisome
proliferators would not damage the DNA, but instead cause the promotion of cells that have
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already suffered mutational damage, leading to the formation of a tumour cell. 
Σεχτιον 1.1.9 Περοξισοmε προλιφερατορσ ανδ τυmουρ προmοτιον
DEHP and clofibrate can act as tumour promoting agents. Ward, J.M. et al 1983, 1984 and 1986
showed that DEHP promotes N-nitrosodiethylamine (DEN) initiated hepatocellular
proliferative lesions after short term exposure in male B6C3F1 mice. A significant increase in
focal hepatocellular proliferative lesions was seen compared to mice dosed with DEN alone.
Mochizuki, Y. et al 1983 demonstrated that co-administration of DEN and clofibrate to F344
rats resulted in a significant increase in the number of hepatic tumours formed, over rats given
DEN alone. 
Peroxisome proliferators could act as tumour promoting agents by  promoting the expansion of
cells through cell proliferation. Nafenopin, BR931, methylclofenapate and Wy14,643 have all
been shown to induce hepatocyte cell replication and increase nuclear ploidy. The induction of
liver cell proliferation by peroxisome proliferators occurs in periportal hepatocytes. Non-
parenchymal liver cells do not undergo proliferation in response to peroxisome proliferators
(James, N.H. and Roberts R.A. 1996, Price, R.J. et al 1992, Melchiorri, C. et al 1993, Ohmura,
T. et al 1996, Styles, J.A. et al 1988, Lake, B.G. et al 1993 and Lalwani, N.D. et al 1997). The
induction of DNA synthesis in the mouse by methylclofenapate peaked after 6 days of dosing in
a 10 day long dosing study (Styles, J.A. et al 1988). In rat, ciprofibrate was found to significantly
induce DNA synthesis in hepatocytes up to 24 days of treatment. At 6, 26 and 54 weeks no
significant induction of DNA synthesis was found (Chen, H. et al 1994). Price, R.J. et al 1992
found that nafenopin could induce replicative DNA synthesis in the rat approximately 10-fold
over control after 7 days of dosing and approximately 5-fold over control at 7.5 weeks. The
duration at which DNA synthesis can be sustained may be of importance in the tumour
promoting properties of peroxisome proliferators.
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Peroxisome proliferators not only affect DNA synthesis but also have an impact on the process of
apoptosis. The effects of peroxisome proliferators on spontaneous and transforming growth
factor-1 (TGFβ1 ) induced apoptosis were studied in rat and mouse hepatocytes.
methylclofenapate and Wy14,643 both suppressed spontaneous and induced apoptosis in rat
hepatocytes (James and Roberts 1996). It could be possible that initiated cells, targeted for
apoptosis escape this process by the action of peroxisome proliferators. These cells could then
undergo proliferation leading to possible tumour formation.
Σεχτιον 1.1.10 Περοξισοmε προλιφερατορσ ινδυχε χελλ τρανσφορmατιον
Using an in vitro cell culture based assay, Ward, J.M. et al 1986 examined the effect of DEHP on
promotable mouse epidermis derived JB6 cells. DEHP and MEHP, a metablite of DEHP,
promoted the JB6 cells to an anchorage independent phenotype. The syrian hamster embryo
(SHE) cell system has been used to examine the effects of clofibrate and methylclofenapate. Both
these peroxisome proliferators were able to induce morphological transformation of SHE
colonies (Cruciani, V. et al 1997). The JB6 cells and SHE cells are not related to liver cells, thus
the relevance of the morphological transforming properties of peroxisome proliferators identified
in these experiments, to peroxisome proliferator induced hepatocarcinogenesis is unclear.
Σεχτιον 1.1.11 Περοξισοmε προλιφερατορ ινδυχεδ οξιδατιϖε δαmαγε το DΝΑ
The other principal hypothesis to explain the carcinogenicity of peroxisome proliferators is the
oxidative stress hypothesis.The oxidative stress hypothesis (Reddy, J.K. and Lalwani, N.D. 1983,
Reddy, J.K. and Rao, M.S. 1986 and Rao, M.S. and Reddy, J.K. 1991) proposed that
peroxisome proliferators could cause tumour formation as a result of DNA damage by high levels
of H2O2 produced by the induction of acyl-CoA oxidase. The hypothesis proposed that the
increased activity of acyl-CoA oxidase ( induced by peroxisome proliferators) produces  a large
increase in the cellular levels of hydrogen peroxide. Reddy, Lalwani and Rao proposed that
DNA lesions formed by oxidative damage are critical in the formation of peroxisome proliferator
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induced hepatocarcinogenesis. Increased levels of hydrogen peroxide could be produced if the
processes of detoxifying hydrogen peroxide are decreased.
Catalase, an enzyme which can remove hydrogen peroxide is only marginally induced by
peroxisome proliferators.Therefore the balance of acyl-CoA oxidase and catalase levels after
peroxisome proliferator treatment effectively produces a net reduction in the detoxifying
capability of the liver. Peroxisome proliferators reduce the expression of other enzymes involved
in the removal of hydrogen peroxide, such as cellular GSH peroxidase (Tamura, H. et al 1990(a)
and 1990(b) and Furukawa, K. et al 1985), superoxide dismutase (Ciriolo, M.R et al 1982 and
Elliott, B.M and Elcombe, C.R 1987) and GSH transferase (Foliot, A. et al 1986, Lake, B.G. et
al 1989b, Furukawa, K. et al 1985 and Tamura, H. et al 1990(b)). The effects of peroxisome
proliferators on liver antioxidant status have been studied. It was found that levels of GSH or
vitamin E remain unchanged or decrease slightly (Conway, J.G. et al 1989, Foliot, A et al 1986,
Lake, B.G. et al 1989b and Weiss, P. and Bianchine, J.R. 1970). Two types of DNA lesions
which can be induced by oxidative damage have been investigated in rats and mice treated with
peroxisome proliferators.
Σεχτιον 1.1.12 Περοξισοmε προλιφερατορ−ινδυχεδ ηεπατιχ DΝΑ λεσιονσ
Hydrogen peroxide can induce 8-hydro-2’-deoxyguanosine (8-OHdG) lesions in DNA
(Clayson, D.B et al 1994). Wy-14,643, clofibric acid, ciprofibrate and perfluorodecanoic acid
have been investigated in rat to see if they cause an increase in 8-OHdG lesions in hepatic DNA.
8-OHdG lesions in hepatic DNA have been reported to be increased from 0.5 to 2.5 fold in F344
rats treated with DEHP, DEHA (Takagi, A. et al 1990 and 1991), PFOA, PFDA (Takagi, A. et
al 1991), Ciprofibrate (Kasai, H. et al 1989 and Huang, C. et al 1994) and Wy-14,643 (Cattley,
R.C. and Glover, S.E. 1993). Cattley, R.C and Glover, S.E 1993 found that when isolated
hepatic nuclei were examined, no increase in 8-OHdG levels were found for some peroxisome
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proliferators tested. Sausen, P.J. et al 1995 found that 8-OHdG lesions in DNA isolated from
whole liver homogenate increased 1.5-2 fold following treatment with Wy-14,643 and clofibric
acid, but the increase was found to be due to an increase in background levels arising from  a 3-
fold increase in mitochodrial DNA levels. It is not known if the observed peroxisome proliferator
induced levels of 8-OHdG found in other studies were due to peroxisome proliferator induced
synthesis of hepatic nuclear or mitochondrial DNA. These small inductions in the amounts of
DNA lesions were found to be statistically significant but their biological significance remains
unclear. Oxidative damage to DNA can cause DNA strand breaks.The induction of DNA strand
breaks by oxidative damage in hepatic DNA by peroxisome proliferators has not been found
(Elliott, B.M. and Elcombe, C.R. 1987 and Tamura, H. et al 1991). There is little evidence to
support the hypothesis that peroxisome proliferators act as DNA damaging agents either directly
or indirectly through the induction of oxidative stress. Therefore the carcinogenicity of
peroxisome proliferators must be due to another mechanism that has still to be elucidated.
Σεχτιον 1.1.13 Ηυmαν ηαζαρδ ρισκ ασσεσσmεντ οφ περοξισοmε προλιφερατορσ
Peroxisome proliferators have been shown to be carcinogenic in rat and mouse studies. It is
therefore important to determine if humans exposed to peroxisome proliferators are at any risk
of cancer. It should be possible to elucidate the molecular mechanism of peroxisome proliferator
induced hepatocarcinogenesis in rats and mice. Once that mechanism is found we can examine
humans to see if they have the same molecular components that make up the mechanism of
peroxisome proliferator induced hepatocarcinogenesis in rats and mice. It may then be possible
to determine if humans face a significant risk of getting hepatic cancer, based on the molecular
similarities of rats, mice and humans. Human experimentaion is not possible, therefore we must
study the effects  of peroxisome proliferators in a species which we believe to model the human
response to peroxisome proliferators. Experiments in other rodents such as hamster and guinea
pig, and in species of new world and old world monkeys, have shown that in many respects these
Alex R. Bell Section 1.1.14
Page 27
species have similarities to humans in the way in which they respond to peroxisome proliferators.
A greater understanding of species differences and similarities in response to peroxsiome
proliferators is needed. Analysis of the molecular aspects of species differences in peroxisome
proliferation could lead to the development of an animal model which displays the same
phenotyic response to peroxisome proliferators as that in humans.
Σεχτιον 1.1.14 Περοξισοmε προλιφερατιον ιν ηαmστερ
Studies involving hamsters or hamster hepatocyte culture revealed that peroxisome proliferators
do not affect all rodent species in the same manner. Where studied the hamster has been shown
to be much less sensitive to the effects of peroxisome proliferators, than rats and mice. An increase
in liver weight in hamsters has been observed in response to dosing with DEHP, MEHP,
clofibrate, Wy-14,643,  and nafenopin, though the observed increase was always less than that
observed in rat (Lake, B.G. et al 1986, 1989a and 1993). The number of peroxisomes in hamster
hepatocytes is induced by gemfibrozil, but with a concomitant reduction in peroxisome size
(Gray, R.H. et al 1984). Peroxisomal β-oxidation is induced by peroxisome proliferators in
hamster (Lake, B.G et al 1986, Lhuguenot, J.C. et al 1988 and Lake, B.G. et al 1989a), along with
carnitine acetyltransferase activity, carnitine palmitoyl transferase activity (Lake, B.G. et al 1986
and 1989a) and lauric acid ω and ω-1 hydroxylase activity (Lake B.G. et al 1989a and Sakuma,
M. et al 1992). The observed enzyme inductions  are smaller than those observed in the rat. There
is conflicting evidence for the effects of peroxisome proliferators on replicative DNA synthesis.
Styles, J.A et al 1988 demonstrated that in hamster only a high dose of  methyclofenopate ( 25mg/
kg body weight) caused induction of hepatic DNA synthesis. Doses of 12 mg / Kg and 5mg /
Kg had no effect on hamster hepatic DNA synthesis. Rats at the same dose exhibited 3-fold
higher induction. Price, R.J. et al 1992 and Lake, B.G. et al 1993 using nafenopin (0.25% in the
diet) and Wy-14,643 (0.025% in the diet) found no increase in hepatic replicative DNA synthesis
as measured by incorporation of labelled nucleotide into liver whole homogenate DNA or by
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hepatocyte labelling index. Suppression of spontaneous apoptosis of hamster primary hepatocytes
by nafenopin has been observed ( James, N.H and Roberts R.A. 1996). Histological examination
of hamster livers from long term dosing studies of hamsters dosed with clobuzarit, DEHP,
nafenopin or Wy-14,643 revealed no abnormalities. No peroxisome proliferator induced liver
foci, nodules, adenomas or carcinomas were observed (Tucker, M.J. and Orton, T.C. 1995,
Schmezer, P. et al 1988, Lake, B.G. et al 1993 and 1995). The hamster is regarded as a species
that is intermediate in liver toxicity response to peroxisome proliferators and is non-responsive
in hepatocarcinogensis assays.
Σεχτιον 1.1.15 Περοξισοmε προλιφερατιον ιν γυινεα πιγ
DEHA, MEHA, fenofibrate, clofibrate, DHEA and nafenopin do not induce peroxisomal β-
oxidation, do not increase peroxisomal numbers or increase liver weight ( Cornu, M.C. et al
1992, Cornu-Chagnon, M.C. et al 1995, Reo, N.V. et  al 1994, Oesch, F. et al 1988 and Sakuma,
M. et al 1992). Guinea pigs dosed with ciprofibrate, that had equivalent plasma concentrations of
ciprofibrate to those measured in rats dosed with ciprofibrate, induced peroxisomal palmitoyl-
CoA oxidase activity in the guinea pig 1.6 fold. In the rat, peroxisomal palmitoyl-CoA oxidase
activity was induced 8.7 fold (Latruffe, N. et al 1995 and Pacot, C. et al 1996). These experiments
show that for ciprofibrate, differences in the extent of peroxisome proliferation are not due to
differing pharmcokinetics of ciprofibrate. Studies by Elcombe, C.R. and Mitchell, A.M. 1986
and Lake, B.G. et al 1986 found that MEHP or metabolites of MEHP had little or no effect on
peroxisome number or peroxisomal β-oxidation. Dirven, H. et al 1993 showed that a 30-fold
higher concentration of MEHP than that used in rat was needed to induce peroxisomal
palmitoyl-CoA oxidase activity 50 % above control levels in guinea pig. Such a small induction
is not likely to be biologically significant. Lake, B.G. 1989a et al found that peroxisome
proliferators could induce a very small increase in microsomal cytochrome P450 content of
guinea pig hepatocytes, and Pacot, C. et al 1996 demonstrated that cytochrome P450 4A lauric
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acid ω-hydroxylase activity could be slightly augmented by ciprofibrate. However Dirven, H. et
al 1993 and Latruffe, N. et al 1995 found no such inducibilty of microsomal cytochrome P450
content of guinea pig hepatocytes or induction of lauric acid ω-hydroxylase activity. Bell, D.R.
ετ αλ 1993 demonstrated that methylclofenapate did not induce Cyp 4A13 mRNA in guinea pig
liver. The lack of induction of the peroxisomal β-oxidation system by peroxisome proliferators
in guinea pig is not due to a lack of components which make up the system. Yamamoto, K. et al
1992 demonstrated by immunoblotting and immunohistochemistry that guinea pigs have the
same molecular weight subunits and proteins of acyl-CoA oxidase, bifunctional enzyme, thiolase
and catalase as in the rat. These enzymes were all exclusively located in the peroxisomal
compartment, with the exception of catalase, which was also present in the cytoplasm and
nucleus of guinea pig hepatocytes. These data strongly suggest that guinea pigs are non-
responsive to peroxisome proliferators.
Σεχτιον 1.1.16 Περοξισοmε προλιφερατιον ιν  πριmατεσ
The rhesus monkey, cynomolgus monkey and marmoset monkey have been tested with
peroxisome proliferators. Reddy, J.K et al 1984 found that ciprofibrate could cause a 1.3 fold and
1.7 fold induction in relative liver weights of rhesus and cynomolgus monkeys. Lake B.G. et al
1989a found no change in the relative liver weight of marmoset monkeys dosed with nafenopin.
Gemfibrozil has been shown to increase the number of peroxisomes in rhesus monkey
hepatocytes 3-5 fold, along with a concomitant decrease in mean peroxisomal volume (Gray,
R.H. et al 1984). Reddy, J.K. et al 1984 found that ciprofibrate could cause a 3-fold increase in
peroxisomal volume in rhesus monkey. Blaauboer, B.J. et al 1990, Foxworthy, P.S. et al 1990
and Lake B.G. et al 1989a observed no increase in the number of peroxisomes or change in their
size in rhesus monkey cultured hepatocytes, cynomolgus monkey cultured hepatocytes or
marmoset monkey dosed with peroxisome proliferators. The induction of peroxisomal β-
oxidation has not been observed in primary hepatocyte culture from cynomolgus, rhesus or
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marmoset monkey dosed with ciprofibrate, bezafibrate, LY171883 ( Foxworthy, P.S. et al 1990
and 1994), clofibric acid, beclobric acid (Blaauboer, B.J. et al 1990),  DEHA or DEHA
metabolites (Cornu, M.C. et al 1992), DEHP or DEHP metabolites ( Elcombe, C.R. and
Mitchell, A.M. 1986). However Reddy, J.K. et al 1984, Lake, B.G. et al 1989a and Dirven, H.
et al 1993 observed small inductions in the activities of palmitoyl-CoA oxidase, catalase, enoyl-
CoA hydratase and carnitine acetyl transferase in their monkey studies. The majority of published
data on peroxisome proliferation in monkey species indicates that they are poorly responsive.
Σεχτιον 1.1.17 Περοξισοmε προλιφερατιον ιν ηυmανσ
Studies with primary human hepatocyte culture, transformed human liver cell lines, and studies
of humans exposed to fibrate hypolipidaemic drugs have examined what effects peroxisome
proliferators have on human liver cells. Primary human hepatocyte cultures have been tested
with peroxisome proliferators that produce a large response in rats and mice. Ciprofibrate,
clofibric acid, beclobric acid, trichlororacetic acid, MEHP, Wy-14,643, DEHP and metabolites
of DEHP used to dose human hepatocytes do not cause induction of peroxisomal β-oxidation
or induction of other fatty acid metabolising enzymes ( Duclos, S. et al 1997, Blaauboer, B.J. et
al 1990, Butterworth, B.E. et al 1989, Elcombe, C.R 1985, Elcombe, C.R. and Mitchell, A.M.
1986). Experiments using the human hepatoma cell line HepG2 have demonstrated very small
inductions  (1.4-2 fold) in palmitoyl-CoA oxidase activity with ciprofibrate (Duclos, S. et al 1997
and Latruffe, N. et al 1995) and clofibric acid ( Chance, D.S. et al 1995). In Hep G2 cells clofibrate
can induce catalase and acyl-CoA oxidase, but to levels less than 3-fold above control values
(Chance, D.S. et al 1995 and Scotto, C. et al 1995). Also in HepG2 cells clofibric acid has been
shown to reduce the activity of the mitochondrial enzymes carnitine palmitoyl-CoA transferase
and succinate-iodonitrotetrazolium-reductase ( Chance, D.S. et al 1995). The extent to which
gene expression and peroxisomal metabolism  in Hep G2 cells (a transformed cell line) is the same
as in human hepatocytes is unknown. Therefore extrapolation of data from Hep G2 cell
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experiments to humans must be treated with great caution. Liver biopsies of human volunteers
dosed with gemfibrozil exhibited no change in  peroxisomal number or size ( De La Inglesia,
F.A. et al 1982, Blumcke, S. et al 1983 and Gariot, P. et al 1987). Liver biopsies of volunteers
dosed with clofibrate showed that a 50% increase in peroxisomal number occurred (Hanefeld,
M. et al 1983) and with ciprofibrate a 30% increase in peroxisomal volume (Bently, P. et al 1993).
These biopsy data must be treated with caution as  examination of all lobes and sections of the
liver cannot be carried out. One must be able to eliminate the possibility of intra-regional
variance within the liver before firm conclusions as to the effect of peroxisome proliferators can
be measured.
Epidemiological studies have examined the tumour incidence in patients receiving clofibrate and
gemfibrozil hypolipidaemic drugs. No significant rise in tumour incidence was found from either
study ( Oliver, M.F. et al 1978 and Frick, H. et al 1987). Carcinogenic studies in rats and mice
have used dosing regimes which cover the majority of the life span of the animal. These human
carcinogenic studies cover patients who have been treated for up to 5 years, limiting the
interpretation of the results.  Any increases in the incidences of tumour formation  could be
attributed to the preclinical state of the patients treated with the hypolipidaemic drugs. Present
experimental data currently supports the view that humans are non-responsive to peroxisome
proliferators. 
Σεχτιον 1.1.18 Μοδελσ οφ  περοξισοmε προλιφερατιον ιν νον−ρεσπονσιϖε σπεχιεσ
The experimental data indicate that the guinea pig rodent species respond to peroxisome
proliferators in a manner very simmilar to humans. It could be proposed that the guinea pig
species is the strongest candidate for an animal model to study the non-responsive phenotype
exhibited by humans. In order to validate an animal model, the molecular mechanism underlying
the responsive nature of that species must be elucidated.  The mechanism of non-responsiveness
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in guinea pigs is not well characterised, and it is therefore important to elucidate the mechanism
of non-responsiveness in guinea pigs and determine whether or not that this species is suitable
for modelling peroxisome proliferation in humans.
Σεχτιον 1.2 Περοξισοmε προλιφερατεδ αχτιϖατεδ ρεχεπτορ
Σεχτιον 1.2.1 Χλονινγ οφ α ρεχεπτορ ωηιχη mεδιατεσ περοξισοmε προλιφερατιον
In 1990 Issemann and Green screened a mouse cDNA library using a probe derived from the
consensus sequence of several steroid hormone receptors. A cDNA was cloned that encoded for
a 468 amino acid protein, (molecular weight = 52 kDa) that could be activated by
hypolipidaemic drugs and a plasticizer. This receptor was termed Peroxisome Proliferator
Activated Receptor  alpha (PPARα). Analysis of the amino acid sequence demonstrated that
PPARα belonged to the steroid hormone receptor superfamily. The PPARα amino acid
sequence displayed high homology to the DNA binding domain of nuclear steroid hormone
receptors such as glucocorticoid receptor, estrogen receptor, retinoid X receptor, vitamin D
receptor and retinoic acid receptor. Steroid hormone receptors are described as having six distinct
regions, A to F (Argos,P. 1985, Krust,A. et al  1986, and Laudet, V. et al 1992). The regions have
been clasified into four distinct domains. The A/B domain has transactivational function
(Folkers, G.E. et al 1996), the C domain is a DNA binding domain and has role in
heterodimerisation ( Zechel, C. et al 1994 and  Jiang, G. and Sladek, F.M. 1997) , D is a hinge
domain and E/F domain has ligand binding activity, transactivational activity and also has a role
in heterodimerisation for some receptors (Schulman, I.G. et al 1995, Leng, X. et al 1995 and Qi,
J-S. et al 1995). Conclusive proof that PPARα is required for peroxisome proliferation action
came from studying mice that expressed a PPARα receptor disrupted in the ligand binding
domain (Lee, S. S-T. et al 1995). Mice homozygous for the mutation lacked expression of the
wild type receptor. These homozygous mice when dosed with clofibrate or Wy-14,643 did not
exhibit proliferation of peroxisomes or induction of peroxisome proliferation marker enzymes.
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Σεχτιον 1.2.2 Χλονινγ οφ ΠΠΑΡ γενεσ
Three distinct PPAR isoforms α , β (also known as δ and FAAR) , and γ have been cloned from
mouse(Issemann, I. and Green, S. 1990, Chen, F. et al 1993, Kliewer, S.A. et al 1994 and Amri,
E. et al 1995), rat (Bocos, C. et al 1995 and Xing, G. et al 1995), hamster (Aperlo, C. et al 1995),
human (Jow, L. and Mukherjee, R. 1994, Greene, M.E. et al 1995,  Lambe, K.G. and Tugwood,
J.D. 1996 and Elbrecht, A. et al 1996), and Xenopus species (Krey, G. et al 1993). A partial
PPARγ cDNA has been cloned from Atlantic Salmon (Ruyter, B. et al 1997). In mouse
alternative promoter use and differential splicing gives rise to two distinct isoforms of PPARγ.
mPPARγ1 and mPPARγ2 mRNAs differ by 300bp. mPPARγ2 mRNA has a different 5’
untranslated region  and encodes for 30 additional amino acids N-terminal to the ATG
translation start of mPPARγ1 (Zhu, Y. et al 1995). Human PPARγ1 (hPPARγ1) and hPPARγ2
cDNAs have also been cloned. hPPARγ1 and hPPARγ2 are homologous to mPPARγ1 and
mPPARγ2 with the exception that the 5’ end of hPPARγ2 has a 84bp extension (90 for the
mouse), encoding an additional 28 amino acids (Elbrecht, A. et al 1996). 
Σεχτιον 1.2.3 Γυινεα πιγσ ασ α mοδελ φορ περοξισοmε προλιφερατιον ιν ηυmανσ
The human species is considered to be non-responsive to peroxisome proliferators, yet they
possess an expressed PPARα gene (Muhkherjee, R. et al 1994 and Braissant, O. et al 1996). The
lack of response observed in humans may be due to lower levels of expression of PPARα in
human hepatocytes compared to rat and mouse hepatocytes (Schoonjans, K. ετ αλ 1996). It is not
known if guinea pigs, a species proposed to model the human response to peroxisome
proliferation has a functionally expressed PPARα gene. This must be determined in order to
strengthen the validation of this species as a proposed model. It is not known if hypolipidaemic
drugs can lower serum triglyceride levels in guinea pigs, as they can do in humans (De La Iglesia,
F.A. ετ αλ 1982 and Hanefeld, M ετ αλ 1983). If hypolipidaemic drugs can lower serum
triglyceride levels in guinea pigs , then this would be supporting evidence for the presence of a
functional PPARα. 
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Σεχτιον 1.2.4 Εξπρεσσιον οφ ΠΠΑΡα γενε
The expression of rat and mouse PPARα mRNA has been characterised for several tissues
(Issemann, I. and Green, S. 1990, Beck, F. et al 1992, Muhkherjee, R. et al 1994, Kliewer, S. et
al 1994, Jones, P. et al 1995 , Mansen, A. et al 1996 and Braissant, O. et al 1996). The highest
levels of expression were found in liver, stomach and kidney , with moderate expression in
brown adipose tissue, heart, muscle, small intestine, adrenal gland and retina. Low levels were
found in white adipose tissue, spleen, smooth muscle, brain and central nervous system tissue.
The pattern of expression of a gene should reflect where that gene is known to function or
proposed to function. The high expression of PPARα in the liver correlates well with the fact
that peroxisome proliferators have their greatest effect in liver. The expression of  PPARα in
numerous other tissues would indicate that PPARα  possibly plays an important role in biological
processes other than peroxisomal metabolism.  Human PPARα has been shown to be highly
expressed in liver, heart, skeletal muscle and kidney, and expressed in low levels in the lung and
brain ( Braissant, O. et al 1996). Different strains of mice have been compared for the level of
liver PPARα expression in each strain. Both Jones, P. et al 1995 and Motojima, K. et al 1997 did
not find any differences between the strains examined in the expression of liver PPARα mRNA.
Σεχτιον 1.2.5 Περοξισοmε προλιφερατορσ ανδ ΠΠΑΡα γενε εξπρεσσιον
Jones, P et al 1995 found that mice dosed with peroxisome proliferators did not induce PPARα
gene expression. Rats treated with Wy14,643 for 22 weeks and 78 weeks, to induce liver
tumours had the expression of PPARα measured at each time point in non-tumour liver tissue
and in tumour liver tissue. In non-tumour tissue peroxisome proliferators did not induce PPARα
gene expression, but in tumorous liver tissue, PPARα gene expression was induced (Miller, R.
et al 1996). Schoonjans, K. et al 1996, found that in rats dosed with fenofibric acid PPΑRα
mRNA in the liver was not induced. Primary rat hepatocytes maintained on matrigel and a
chemically defined medium have had PPARα mRNA levels measured in the presence of
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peroxisome proliferators. The presence of either clofibric acid or dehydroepiandrosterone caused
a less than 2-fold induction in PPARα mRNA levels (Yamada, J. et al 1995). Such a small
induction is probably not biologically significant. McNae, F. et al 1994 found that clofibrate and
perflourodecanoic acid induced PPARα mRNA expression, but other peroxisome proliferators
examined in these studies had no effect on PPARa mRNA expression. Gebel, T. et al 1992 used
an antibody raised against a mPPARα Hinge domain-β-galactosidase fusion protein to examine
rat PPARα protein expression in liver cytosol and nuclear extracts from untreated and
fenofibrate treated rats. In untreated rats their antibody did not detect an immunoreactive 52 kDa
protein in either cytosolic or nuclear extracts, but in fenofibrate treated rats an immunoreactive
53 kDa protein was detected. They also used a cDNA probe derived from mPPARα cDNA to
probe for rat PPARα. A single 6 kb mRNA species was detected at very low levels in liver RNA
from untreated rats, but was induced in fenofibrate treated rats. Braissant,O. et al 1996 have
subsequently shown using an anti ratPPARα antibody and a riboprobe derived from rat PPARα
cDNA that rat PPARα mRNA is highly expressed in the liver and that the rat PPARα protein
is almost exclusively located in the nucleus. Sterchele, P.F. et al 1996 found that in rat liver,
PPARα mRNA accumulated after treatment with perfluorodecanoic acid (PFDA). Nuclear run-
on experiments demonstrated that the accumulation of PPARα mRNA was not due to an
induction of transcription. Pair-fed control animals, and animals which were nutritionally
deprived also accumulated PPARα mRNA. These results indicate that the increase in PPARα
mRNA levels observed after peroxisome proliferator dosing , were likely to be a result of
nutritional based, or stress based induction. The inductions observed by some groups is likely to
be due to a stress based induction mechanism, possibly arising from the dose of the peroxisome
proliferator used. Lemberger, T et al 1996 demonstrated that PPARα expression in the liver can
be induced by stressing the animals. The effects of clofibrate on the expression of hPPARα
mRNA in human glioblastoma A172 cells has been examined by Pineau, T. et al 1996. They
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found that clofibrate greatly induced PPARα expression in this cell line. Tumour derived cell
lines are not representative of normal tissue, and so the significance of this result in relation to
the effects of peroxisome proliferators on PPARα expression in normal tissue is unclear.
Σεχτιον 1.2.6 Ηορmοναλ ρεγυλατιον οφ ΠΠΑΡα γενε εξπρεσσιον
Yamada, J. et al 1995 also examined the effects of growth hormone (somatotropin) and thyroid
hormone (triiodthyronine) on the expression of PPARα in hepatocyte culture. After 5 days of
incubation with growth hormone the PPARα mRNA levels decreased to 50% of the control
levels. The incubation of hepatocytes with thyroid hormone caused a 50% increase in PPARα
mRNA levels over control values. Similar results were obtained when either gowth hormone or
thyroid hormone was co cultured with clofibric acid or dehydroepiandrosterone sulphate.
Lemberger, T. et al 1994 found that glucocorticoid hormones could induce rat PPARα gene
expression in primary hepatocyte culture. PPARα expression has also been claimed to follow a
diurnal pattern of expression, peaking at 5.30 pm (Lemberger, T. et al 1996), but the data from
these experiments was limited as expression of PPARα was not measured during the night. 
The levels of cytosolic and nuclear located glucocorticoid receptor have been studied in rats.
Peak expression of glucocorticoid receptor in both cellular compartments peaks between
11.00pm and 2.00 am (Xu, R.B. et al 1991). In rats the secretion of glucocorticoid hormones
oscillates with a circadian rhythm, with maximal levels being reached at the light / dark switch
in the evening (Dhabhar, F.S et al 1993, Holmes, M.C. et al 1997, Atkinson, H.C. and Waddell,
B.J. 1997). Both the peak release of glucocorticoid hormone and glucocorticoid receptor are out
of synchronisation with the circadian rhythm of PPARα measured by Lemberger,T. et al 1996.
If the glucocorticoid hormone and receptor circadian rhythms regulate PPARα gene expression,
one would expect PPARα gene expression to peak late at night or early morning, not early
evening.
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Σεχτιον 1.2.7 Εξπρεσσιον οφ ΠΠΑΡδ ανδ ΠΠΑΡγ γενεσ
The pattern of expression of other isoforms of PPAR could impinge on the signaling pathways
of PPARα. It is possible that PPARβ and γ could compete for binding to available ligands or
compete for binding to regulatory regions of genes controlled by PPARα. There is also the
possibilty of competition for binding to other transcription factors. The expression of PPARβ
mRNA has been studied in rat, mouse and human tissues and is found to be ubiquitously
expressed in all tissues studied. Highest expression is found in brain, placenta, skeletal muscle,
adipose tissue and intestine and lowest expression is found in liver, kidney, spleen and testis
(Kliewer, S. et al 1994, Amri. E-Z, et al 1995, Xing. G. et al 1995, Jones, P. et al 1995 and
Braissant, O. et al 1996). PPARγ expression has been studied in rat, mouse, hamster and human
tissues. In all the  species examined PPARγ mRNA expression was highest in adipose tissue and
spleen. Moderate expression  has been observed in heart, skeletal muscle, kidney, liver, lung,
bone marrow and testes (Kliewer, S. et al 1994, Tontonoz, P. et al 1994a and 1994b, Aperlo, C.
1995, Jones, P. et al 1995, Braissant, O. et al 1996, Elbrecht, A. et al 1996 and Mukherjee, R. et
al 1997). The expression of PPARγ has been examined in obese mice (gold thioglucose and ob/
ob), in mice with toxigene-induced brown fat ablation, and in mice with insulin deficient
diabetes. mPPARγ expression was not altered in adipose tissue of obese mice but was increased
in adipose tissue of mice with brown fat ablation (Vidal-Puig, A. et al 1996) . Mice fed high fat
diets had adipose expression of PPARγ induced, but in fasting mice the expression was reduced
compared to control mice (Rousseau, V. et al 1997).    
Σεχτιον 1.2.8 Περοξισοmε Προλιφερατορσ αρε λιγανδσ φορ ΠΠΑΡα
Four different experimental strategies have been employed to determine if PPs are ligands for
PPARα. A GST-xPPARα-Ligand-Binding-Domain fusion protein was used to demonstrate
that GW2331 ( a novel fibrate), palmitic acid, oleic acid, petroselenic acid, linolenic acid, linoleic
acid, arachidonic acid and hydroxyeicosatetraenoic acid are ligands for xPPARα as well as
Alex R. Bell Section 1.2.8
Page 38
activator compounds (Kliewer, S. et al 1997). Kliewer et al measured the amount of radiolabelled
GW2331 bound to the fusion protein and how effective the compounds listed were at competing
for binding. GW2331 has a Kd= 140nm for binding to the GST-xPPARα-LBD fusion protein.
GST-hPPARα-LBD and GST-mPPARα-LBD-GST fusion proteins exhibited ≈ 3.5 fold and ≈
6-fold weaker binding to GW2331. Forman, B. et al 1997 used gel retardation-based assays to
indirectly demonstrate that Wy14,643, ciprofibrate, clofibrate, long chain fatty acids and
inhibitors of β-oxidation are ligands for PPARα. PPs in the presence of low levels of mPPARα
and hRXRα receptors induced heterodimer binding to an acyl-CoA oxidase PPRE. At high
levels of receptor PPs were not able to increase heterodimer binding to the PPRE. These results
indicate that peroxisome proliferators influence PPARα / RXRα heterodimer function when
the levels of receptor are low. LG268, a ligand for RXRα induced RXRα homodimer binding
to a PPRE. Futher evidence to support the theory that PPs can bind to PPARα comes from a
study which shows that mPPARα has differential protease sensitivity in the presence of Wy-
14,643, clofibric acid, 5,8,11,14-eicosatetraynoic acid or LY-171883, indicating that mPPARα
undergoes a conformational change in the presence of these substances ( Dowell, P. et al 1997).
A novel ligand sensor assay has recently been developed by Krey, G. et al 1997, termed
coactivator dependent receptor ligand assay to screen for binding of peroxisome proliferators and
naturally occuring metabolites to all three xenopus PPAR isoforms. This assay uses a fusion of
glutathione S-transferase and PPAR ligand binding domain and the steroid coactivator-1 (SRC-
1) protein. The formation of PPAR/SRC-1 interactions occur only if the binding of a ligand to
the ligand binding domain of the PPAR is specific. Using this assay Krey, G. et al were able to
demonstrate specific ligand binding to PPARα for the following compounds, Wy-14,643,
Leukotriene-B4, ETYA, bezafibrate, clofibrate, eicosapentaenoic acid, linolenic acid, linoleic
acid, arachidonic acid, 8(S)-hydroxyeicosatetraenoic acid, petroselinic acid, oleic acid, elaidic
acid and erucic acid. Many of these peroxisome proliferators and fatty acids were also specific
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ligands for xenopus PPAR β and γ isoforms. This coactivator depedent assay has highlighted that
PPARs have overlapping ligand recognition.
Σεχτιον 1.2.9 Περοξισοmε Προλιφερατορ Ρεσπονσε Ελεmεντσ (ΠΠΡΕσ)
Gene transcription is controlled through the interaction of transcription factors with sequence
specific motifs in DNA. A functional promoter region containing TATA-box like sequences is
often required for the binding of the cells basal transcription machinery. Upstream of gene
promoters are regulatory  regions which can bind trans-acting factors that control the up-
regulation and down-regulation of the transcription of the gene. The third type of sequence
specific motif is the enhancer element. Enhancers also bind transcription factors to upregulate the
transcription of a gene, in an orientation and position independent manner.
The upstream regions of genes whose expression is modulated by peroxisome proliferators have
been examined for regulatory motifs. Rat acyl-CoA oxidase gene (Osumi, T. et al 1991,
Tugwood, J.D. et al 1992 and  Green, S. et al 1992) and rat peroxisomal enoyl-CoA hydratase/
3-hydroxyacyl-CoA dehydrogenase, bifunctional enzyme gene (Zhang, B. et al 1992) were
investigated first for the presence of regulatory regions which conferred peroxisome proliferator
transcriptional responsiveness. DNA containing the rat acyl-CoA oxidase gene upstream region
was cloned in front of a β-globin promoter and linked to a CAT reporter gene. The putative
response element-reporter gene construct was co-transfected in a mouse hepatoma cell line with
an expression plasmid for mouse PPARα. Dosing of transfected cells with peroxisome
proliferator caused the reporter gene to be expressed. In the absence of either PPAR or
peroxisome proliferator, stimulation of the reporter gene was much lower.  Using deletion
analysis of the upstream gene region the localisation of the PPRE was identified. The same
molecular strategy was used to identify a PPRE in the bifunctional gene. A distinct motif was
found and was termed a Peroxisome Proliferator Response Element (PPRE). PPREs consist of
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a tandem repeat of two hexameric nucleotide motifs (half-sites) spaced by a single nucleotide.
This motif is known as a direct repeat 1 (DR1). See figure 1.1 for the structure of the rat acyl-
CoA oxidase PPRE.
Figure 1.1 The rat acyl-CoA oxidase PPRE. 
PPREs from many liver genes have now been identified using similar experiments. Table 1.3
shows PPREs that have been identified to date. Rat bifunctional enzyme, human apolipoprotein
A-I and rat acyl-CoA synthetase PPREs all have a third half-site with high homology to the
TGACCT consensus half-site either two nucleotides 5’ or three nucleotides 3’ to the PPRE. The
influence of these close half-sites on the function of the PPRE is unclear. The sequence
specificity of each PPRE is not strict, as the sequence of the PPRE can deviate from the
consensus sequence by as many as 5 nucleotides, but mutations of  one or two nucleotides within
a particular PPRE can diminish or abolish its peroxisome proliferator responsiveness (Issemann,
I. et al 1993, Vu-Dac, N. et al 1994, Palmer, C.N.A. et al 1994 and Chu, R. et al 1995).
TCCCGAACG TGACCT T TGTCCT GGTCCCCT
-580 -570 -560 -550
Half-site Half-site
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Σεχτιον 1.2.10 ΠΠΑΡα βινδσ το ΠΠΡΕσ ωιτη Ρετινοιδ Ξ Ρεχεπτορ ασ α ηετεροδιmερ
It was postulated that PPARα would bind to a PPRE either as a homodimer or as a heterodimer
with retinoid X receptor α  (RXRα), a promiscuous binding partner for many steroid hormone
nuclear receptors. Using electromobility shift assays (EMSAs) with a labelled PPRE and
recombinantly expressed PPARα and RXRα receptors, it was found that PPARα only binds to
DNA as a heterodimer ( Issemann, I. et al  1993, Bardot, O. et al 1993, Gearing, K.L. et al 1993
and Keller, H. et al 1993). 
Gene PPRE sequence Reference
Rat acyl-CoA oxidase TGACCT  T  TGTCCT (Osumi, T. et al 1991 and 
Tugwood, J.D. et al 1992)
Rat bifunctional enzyme TGAACT  A  TTACCT (Zhang, B. et al 1992, Bardot, 
O. et al 1993)
Rabbit cytochrome P450 4A6  
(z-element)
TCAACT  T  TGCCCT (Muerhoff, A.S. et al 1992)
Rabbit cytochrome p450 4A6 
(-27 to -1 region)
TGACCC  T  TGCCCA (Palmer, C.N.A. et al 1994)
Human peroxisomal fatty acyl-
CoA oxidase
TGACCT  G  TGACCT (Varanasi, U. et al 1996)
Rat acyl-CoA synthetase TGACTG  A  TGCCCT (Schoonjans, K. et al 1995)
Rat acyl-CoA binding protein TCACCT  T  TGCACT (Elholm, M. et al 1996)
Human apolipoprotein A-I TGACCC  C  TGCCCT (Vu-Dac, N. et al 1994)
Human lipoprotein lipase TGCCCT  T  TCCCCC (Schoonjans, K. et al 1996)
Rat malic enzyme GGACCT  G  TGCCCT (Castelein, H. et al 1994)
Human apolipoprotein C-III TGACCT  T  TGCCCA (Hertz, R. et al 1995)
Rat apolipoprotein C-III TGACCT  T  TGACCA (Hertz, R. et al 1995)
Rat cytochrome p450 4A1 TCCCCT  C  TGACCT (Aldridge, T.C.  et al 1995) 
Fatty acid binding protein TGACCT  A  TGGCCT (Issemann, I. et al 1992)
3-hydroxy-3-methylglutaryl -
CoA synthase (HMG)
AGACCT  T  TGGCCC (Rodriguez, J.C. et al 1994)
Human transferrin CAATCT  T  TGACCT (Hertz, R. et al 1996)
Human Hepatitis B virus 
enhancer 1 element
GAACCT  T  TACCCC (Bingfang, H. et al 1995)
Table 1.3 Sequences of PPREs identified in peroxisome proliferator responsive genes. 
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Protein-DNA contact points have been identified in the PPREs of the rat acyl-CoA oxidase
gene, rat bifunctional enzyme gene, rabbit cytochrome p450 4A6 gene and human lipoprotein
lipase gene by DNase I protection mapping and by methylation interference experiments
(Tugwood, J.D. et al 1992, Bardot, O. et al 1993, Palmer, C.N.A. et al 1994 and Schoonjans, K.
et al 1996). These close points of contact are essential for determining the specificity of the
protein - DNA binding interaction. The importance of the spacing between the half-sites in a
PPRE was investigated by Issemann, I. et al 1993. Using a PPRE driven reporter gene system
they found that a spacer consisting of one nucleotide between the half-sites was essential for
maximal peroxisome proliferator responsiveness. A PPRE containing a spacer greater than or
equal to three nucleotides in length was not peroxisome proliferator responsive. PPREs with
either zero or two nucleotides as a spacer were very weakly responsive. The importance of the
immediate 5’ flanking sequence of PPREs has been investigated. Palmer C.N.A. et al 1995
determined that mutants in the 5’ flanking sequence of the cyp 4A6z PPRE dramatically
diminished the binding of PPARα/RXRα heterodimers, but did not affect the binding of
RXRα/RXRα homodimers. Osada, S. et al 1997 , Juge-Aubrey, C. et al 1997 and Ijpenberg,
A. et al 1997 have also demonstrated the importance of the 5’ flanking nucleotide in PPARα/
RXRα heterodimer binding. Castelain, H. et al 1997 using a binding site selection assay with
PPARα/RXRα heterodimers found that half of the binding sites recovered contained DR1,
DR2, two palindromic half sites with zero spacing (PAL0) and DR3 elements, in diminishing
order of frequency. The remaining half of the binding sites recovered contained three half sites
with varying spaces from 0 to 7 nucleotides. An element with three half sites spaced by one
nucleotide was most efficient at mediating the effects of peroxisome proliferators. These results
indicate that the upstream flanking sequence of a DR1 PPRE is important in influencing the
binding of PPARα/ RXRα heterodimers.
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Σεχτιον 1.3 Νυχλεαρ στεροιδ ηορmονε ρεχεπτορσ
Σεχτιον 1.3.1 Νυχλεαρ ρεχεπτορσ βινδ DΝΑ ιν α πολαριτψ σπεχι⇒χ mαννερ
The binding polarity of PPARα / RXRα and PPARγ / RXRα heterodimers on a DR1
element has been determined using two distinct methods. PPARγ and mutant PPARα and
RXRα containing the P-box of glucocorticoid receptor (GR), giving both PPARα-P-GR and
RXR-P-GR the binding specificity of GR were tested for binding to a DR1 containing a GR
half-site in either the 5’ or 3’ position.(Direnzo, J. et al 1997, Ijpenberg, A. et al 1997 and Osada,
S. et al 1997) PPARα-P-GR / RXRα heterodimers were shown to bind to the DR-1 elements
in which the 5’ half site contained a GR half site. PPARγ / RXR-P-GR binding was only
observed for the GR half-site in the 3’ position. Photo cross-linking of PPARγ / RXRα
heterodimers to an acyl-CoA oxidase PPRE found that PPARγ occupies the 5’ half-site and
RXRα the 3’ half-site (Direnzo, J. et al 1997). Thus the polarity of PPAR binding is conserved
between both the α and γ isoforms. Vitamin D receptor (VDR) / thyroid hormone receptor
(TR) heterodimer polarity directs the ligand sensitivity of transactivation. On the Vitamin D
response element (VDRE) of rat 9k calbindin gene promoter the polarity is 5’-TR/VDR-3’, but
on the mouse 28k calbindin VDRE the polarity is 5’-VDR/TR-3’. The ligand for the
downstream receptor controls the transcriptional activity of the heterodimeric complex
(Schrader, M. et al 1994). RAR / RXR heterodimers bind to both DR1 and DR5 elemnets.
On a DR1 RAR binds to the 5’ half-site, but on a DR5 it binds to the 3’ half-site. RAR has
ligand induced transcriptional activation only on DR5 sites. Mutations that reverse the polarity
of RAR / RXR heterodimers on DR5 elements reverse the ligand activated transcriptional
response (Kurokawa, R. et al 1993 and 1994).
Σεχτιον 1.3.2 Νυχλεαρ ρεχεπτορ χροσσ ταλκ ρεγυλατεσ τρανσχριπτιον.
PPARα receptor signaling occurs through heterodimerisation with RXRα, and subsequent
binding to DNA response elements. Proteins which can influence this signaling by competing
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for binding to PPARα or RXRα or to the DNA response element are described to “cross-talk”
with the signaling pathway. The affinity of binding of other nuclear steroid hormone receptors
with either PPARα or RXRα will vary. Therefore the concentration of each type of receptor
will be critical in deciding how the signaling pathway is influenced. An excess of a particular type
of receptor may titrate out available PPARα or RXRα, preventing PPARα/RXRα
heterodimers from forming. Examples of this type of cross-talk have been identified for PPARα/
RXRα mediated signaling. Jow, L. and Mukherjee, R. 1995 demonstrated that PPARβ
(hNUC1) could repress peroxisome proliferator signaling mediated by hPPARα/RXRα
heterodimers. Increasing amounts of PPARβ titrated out RXRα, and formed PPARβ/ RXRα
heterodimer complexes bound to a PPRE. Miyamoto, T. et al 1997 demonstrated that high levels
of thyroid hormone receptor (TR) could repress PPARα/RXRα mediated signaling. The
inhibitory action of TR was lost when a mutation was introduced into the DNA binding domain
of TR, indicating that competition for DNA binding was involved. RXRα/ TR heterodimers
were shown to bind PPREs in electromobility shift assays. Thus it was concluded that RXRα/
TR competition for binding to PPRE was the mechanism of inhibitory cross-talk by TR. The
α isoform of TR (TRα) has been shown to bind to PPARα in solution without the presence of
DNA. TRα/PPARα heterodimers did not bind to a DR4 thyroid hormone response element
(TRE). TRβ a different isoform of TR was found to form heterodimeric complexes on a DR2
TRE with PPARα, and that TRβ/PPARα could induce the transcription of a reporter gene
under the control of a DR2 TRE (Bogazzi, F. et al 1994). Thus PPARα can cross-talk with
thyroid hormone receptor signaling in either a positive manner or negative manner depending
on the type of TR isoform expressed. COUP-TFII is another nuclear steroid hormone receptor
shown to repress induction of gene expression mediated by peroxisome proliferators and
PPARα/ RXRα heterodimers (Baes, M.et al 1995 and Marcus, S.L. et al 1996). PPARα/
RXRα heterodimers have been shown to bind to estrogen receptor response elements (EREs),
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and upregulate gene expression of a reporter gene under the control of the vitellogenin A2-ERE
(Nunez, S.B. et al 1997). The orphan nuclear steroid hormone receptor LXRα can cross-talk
with PPARα signaling. LXRα can bind to either PPARα or RXRα in solution, but not as a
heterodimer bound to a PPRE. The expression of LXRα in mammalian cell blocked
peroxisome proliferator signaling mediated by PPARα/RXRα heterodimers (Miyata, K.S. et al
1996).
Σεχτιον 1.3.3 Πηοσπηορψλατιον ρεγυλατεσ νυχλεαρ στεροιδ ηορmονε ρεχεπτορ φυνχτιον
Immunoprecipitation of endogenous PPARα from primary rat adipocytes pre-labelled with
[32P]-orthophosphate and treated with vanadate and okadaic acid demonstrated that PPARα is
a phosphoprotein. Insulin was shown to produce a time dependent increase in phosphorylation
of PPARα. The change in phosphorylation was paralled by an enhancement of transciptional
activation by PPARα (Shalev, A. et al 1996). In vivo [32P]-orthophosphate labelling experiments
have demonstrated that PPARγ is also a phosphoprotein. PPARγ can undergo epidermal growth
factor (EGF) -stimulated MEK/mitogen activated protein (MAP) kinase dependent
phosphorylation. Mutation of the Ser82 phosphorylation site in PPARγ to Ala82 inhibited
phosphorylation of PPARγ and inhibited growth factor mediated transcriptional repression
(Camp, H.S. and Tafuri, S.R. 1997). Phosphorylation of human thyroid receptor β (TRβ)
enhances the formation of TRβ/RXRβ heterodimers on thyroid hormone response elements
(TRE). Dephosphorylation led to the loss of ability to form heterodimers. Okadaic acid
inhibition of phosphatases 1A and 2A increased in vivo phosphorylation of TRβ and increased
reporter gene expression under the control of a TRE (Bhat, M.K. et al 1994).
Σεχτιον 1.3.4 DΝΑ βινδινγ δοmαινσ δε⇒νε σπεχι⇒χ DΝΑ ιντεραχτιονσ
The nuclear steroid hormone receptor superfamily is a well conserved group of receptors
(Laudet, V. et al 1992 and Motojima, K. 1993). The tertiary structures of glucocorticoid receptor
(GR), estrogen receptor (ER) and retinoid X receptor (RXR) have been solved by
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crystallography ( Luisi, B.F. et al 1991 and Schwabe, J.W. et al 1993) and by NMR studies
(Schwabe, J.W.R. et al 1990, Lee, M.S. et al  1993 and 1994). The DNA binding domain (DBD)
of this group of nuclear receptors contains two zinc finger structures making them distinct from
other groups of  DNA binding proteins. The Zn2+ ions are tetrahedrally co-ordinated by four
cysteines stabilising two peptide loops. This type of DBD differs from other eukaryotic zinc
finger containg receptors such as TFIIA, ADR-1 and Xfin. Zn2+ ions in these receptors are co-
ordinated by two histidines and two cysteines (Freedman, L.P. and Luisi, B.F. 1993).  The Zn2+
co-ordination site of the yeast transcription factor GAL-4 is different as it has two Zn2+ ions
sharing a cluster of six cysteines (Marmomstein, R. et al 1992). These structurally distinct zinc
finger containing domains share the general feature that Zn2+ fingers stabilize and orientate an
α-helix for interaction with the major groove of the DNA response element (Freedman, L.P.
and Luisi, B.F. 1993). Analysis of the tertiary structures of the GR and ER DBDs complexed
with their cognate response elements indicate that the P-box in the first zinc finger functions as
the recognition helix that is inserted into the major groove ( Luisi, B.F. et al 1991 and Schwabe,
J.W.R. et al 1990). A feature of PPARs that makes them a distinct sub-family from other steroid
hormone receptors is the size of the D-box in the second zinc finger. PPARs have three amino
acids, whereas all other receptors have 5 (Laudet, V. et al 1992 and Motojima, K. 1993). The
function of the D-box in PPARs has not been defined. The cloning and expression of PPARα
DBD would facilitate the possibility of detailed structural and functional analysis of PPARα
DBD. X-ray crystallographic studies, NMR studies and electromobility shift assays could be
performed on PPARα DBD to determine the structural and sequence specific features of
PPARα that make them distinct from other nuclear steroid hormone receptors. This information
will advance our understanding of the mechanism by which PPARα is controlled and how
specific gene regulation is mediated. It has been an aim of my work to clone, express and purify
soluble mPPARα-DBD protein and to determine if as a single domain it can retain its DNA
binding function.
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Σεχτιον 1.3.5 DΝΑ βινδινγ δοmαινσ χονταιν ιmπορταντ διmερισατιον σεθυενχεσ
Structural features of Retinoid X Receptor (RXR), Retinoic Acid Receptor (RAR), Thyroid
Hormone Receptor (TR), Hepatic Nuclear Factor-4 (HNF-4) and Vitamin-D Receptor (VDR)
which regulate their function have been characterised. Wild type and mutant forms of the DBD
of RXR, RAR, TR and HNF-4 have been produced as stable proteins and have been assayed
in DNA binding experiments. Both binding specificty to DNA response elements  and
heterodimerisation function have been located in the DBD of these receptors ( Mader, S et al
1993 and Zechel, C. et al 1994). The D-box of the C-terminal CII zinc finger of RXR forms a
surface specifically required for the formation of the heterodimerisation interface on direct
repeat-4 (DR4) and DR5 elements. RAR / RXR heterodimerisation on DR5 elements
requires the tip of the RAR CI zinc finger. TR / RXR heterodimers need a seven amino acid
sequence encompassing the the pre-finger region in the TR partner (Zechel, C. et al 1994). The
HNF-4 receptor like RXR has an important dimerisation region in the DBD called the T-box
( Jiang, G. et al 1997 and Wilson, T.E. et al 1992). The T-box of RXR forms an α-helix
immediately after the conserved Gly-Met boundary that signals the end of the zinc finger region.
The T-box  helix mediates both protein-protein and protein-DNA interactions required for co-
operative, dimeric binding of RXR-DBD to DNA ( Lee, M.S. et al 1994 ). The T-box is
conserved between HNF-4 and RXR but not PPARs. HNF-4 has an A-box region next to the
T-box which makes important protein-DNA contacts with nucleotides flanking the core
recognition sequence of the response element ( Jiang, G. et al 1997).
Σεχτιον 1.3.6 Λιγανδ βινδινγ δοmαινσ χονταιν ιmπορταντ διmερισατιον σεθυενχεσ
The ligand binding domains (LBDs) of RXR and TR contain important dimerisation sequences.
Mader, S. et al 1993 found that dimerisation function in the LBD stabilises but does not change
the receptors DNA binding specificty. Qi, J-S. et al 1995 used GAL-4.DBD-RXR.LBD and
GAL-4.DBD-TR.LBD fusion proteins to demonstrate that functional dimerisation could take
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place in the absence of DBDs in RXR or TR. Gal-4.DBD-RXR.LBD coexpression in a cell
line with full length PPARγ could induce transcriptional activation of a GAL-4 response element
containing reporter gene contruct in the presence of Wy-14,643. This result shows that there is
sufficient heterodimerisation interface in the LBD of RXR to allow functional interactions with
PPAR to take place (Qi, J-S. et al 1995). The crystal structure of RXR LBD homodiners found
that approximately 11% of each monomer solvent accessible surface contributes to the
dimerisation interface, typical of specific protein-protein interactions (Bourguet, W. et al 1995). 
Σεχτιον 1.3.7 ΛΒDσ ιντεραχτ ωιτη βασαλ τρανσχριπτιον mαχηινερψ
RXR-LBD makes specific and direct contacts with a conserved region of TATA-binding
protein, a protein of the cells basal transcription machinery. Mutations that reduced ligand
dependent transcription by RXR also reduced RXR-TATA binding protein interactions
(Schulman, I.G. et al 1995). Using a yeast two hybrid protein interaction assay MacDonald, P.N.
et al 1995 found that the LBD of TR forms specific protein contacts with the the basal
transcription factor TFIIB. This interaction was also demonstrated in an in vitro binding assay.
Similar regions in RXR or RAR did not bind TFIIB.
Σεχτιον 1.3.8 Νυχλεαρ στεροιδ ηορmονε ρεχεπτορσ χονταιν τωο τρανσχριπτιοναλ αχτιϖα−
τιον δοmαινσ
Regions involved in transcriptional activation (Activation Functions , AFs ) have been mapped
in PPARγ, RXRα, RXRβ and RARα. An N-terminal ligand independent transcriptional
activation domain corresponding to amino acids 31-99 in PPARγ has been characterised
(Werman, A. et al 1997). The AF domain of PPARγ2 exhibits 6-fold greater activity than the
AF domain of PPARγ1 isoform. Leng, X. et al 1995 demonstrated a separable AF domain within
the E-region, 21 amino acids long at the extreme C-terminal end of RXRβ. Deletion of this
AF domain resulted in a constitutive transcriptional silencer receptor. RXR and RAR contain
an AF1 domain in the N-terminal  A region, and an AF2 domain in the LBD. AF1 fused to a
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GAL-4 DBD functioned as a transcription activator in the absence of ligand, whereas AF2
functioned as a transcriptional activator only in the presence of ligand (Folkers, G.E. et al 1996).
The activity of AF1 displayed strong cell type specificity, with AF2 cell type specificity to a lesser
degree. These results implied cell specific co-activator molecules were required for maximal
transcriptional activity.
Σεχτιον 1.3.9 Νυχλεαρ ρεχεπτορσ ιντεραχτ ωιτη χο−αχτιϖατορ προτεινσ
Folkers, G.E. et al 1996 found that in some cell lines, the additional expression of adenoviral E1A
protein, a transcriptional co-activator, synergistically activated transcription of RAR and RXR.
In vitro transcription experiments by Conaway, R.C et al 1993 had already demonstrated that for
activated transcription by AF domains protein co-factors were required. Ligand dependent
transcription by RAR on DR5 elements requires the removal of nuclear receptor co-repressor
(N-CoR), and recruitment of co-activators P140 and P160. N-CoR associates with RAR/
RXR heterodimers on DR1 and DR5 response elements. RAR or RXR ligand causes the
dissociation of N-CoR from RAR/RXR heterodimers, but only on DR5 elements (Kurukawa,
S. et al 1995). N-CoR was shown to interact within the hinge region of RAR. This stretch of
amino acids was defined as the CoR-box. The AF2 domain of ER interacts with P140 and P160
in an estrogen dependent manner (Halachmi, S. et al 1994). BRL49653, a PPARγ agonist
stimulates the binding of P160 to PPARγ. P140 and P160 interact with RXRα homodimers and
RXRα / PPARγ heterodimers in the presence of  RXR ligand LG69 (Direnzo, J. et al 1997).
Cloning of the cDNA of P160 (Hong, H. et al 1996) revealed that it was an extended form of
co-activator SRC-1, originally cloned by Onate, S.A. et al 1995. SRC-1 is a protein that interacts
with multiple nuclear receptors in a ligand dependent manner, and functions as a co-activator of
transcription. The coactivator SRC-1 has been shown to bind PPARα in a ligand specific
dependent manner (Krey, G. et al 1997). A newly identified coactivator protein PPARγ-binding
protein (PBP) has been shown to bind to PPARα also in a ligand dependent manner (Zhu, Y.
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et al 1997). However, neither SRC-1 nor PBP have been tested to see if they can augment
peroxisome proliferator induced transcription mediated by PPARα. It is possible that the species
differences in response to peroxisome proliferators is due to differing expression of coactivator
proteins or differences in interactions of coactivator proteins with PPARα. The cloning of
coactivator proteins from responsive and non-responsive species and the characterisation of their
interaction and activity with PPARα needs to be determined. LG69 and BRL49653 can both
induce the interaction of SCR-1 with PPARγ/ RXRα heterodimers on an acyl-CoA oxidase
PPRE. Over expression of SRC-1 enhanced PPARγ ligand induced activation of a luciferase
reporter containing a PPRE. PPARγ LBD was fused to a GAL-4 DBD and tested for ligand
induced activation of a GAL-4 response element containing reporter, in the presence and absence
of SRC-1. The presence of SRC-1 markedly increased ligand induced reporter activity
(Direnzo, J. et al 1997). These experiments indicate that SRC-1 is a co-activator of PPARγ.
Direnzo, J. et al 1997 also examined N-CoR interactions with PPARγ. Using a GST-PPARγ
pull down assay no interaction of N-CoR with PPARγ was found. Human transcriptional
intermediary factor 2 (TIF-2) a 160 kDa protein with partial sequence homology to SRC-1
interacts in vitro with RXR, TR, ER, and  RAR in an agonist dependent manner. TIF-2
enhanced  AF2 and ligand dependent PR, ER and androgen receptor (AR)  transcriptional
activation in Cos-1 cells, but no significant enhancement of ligand induced transcriptional
activation was seen for RAR (Voegel, J.J. et al 1996). TIF-2 is therefore described as a
transcriptional co-activator for some nuclear steroid hormone receptors. Other co-activator
proteins like hTAFII30, RIP140, mSUG1 and TIF1 have been shown to interact with various
nuclear steroid hormone receptors in an agonist and AF2 domain dependent manner ( Jacq, X.
et al 1994, Cavailles, V. et al 1995 and vom Buar, E. et al 1996). 
Σεχτιον 1.3.10 Dιφφερεντιαλ προmοτερ υσαγε ανδ αλτερνατιϖε σπλιχινγ
PPARγ is expressed in adipose tissue in two distinct isoforms γ1 and γ2. Mouse PPARγ1 and
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PPARγ2 mRNAs result from transcription of different promoters within the PPARγ gene and
alternative splicing of the PPARγ transcript (Zhu, Y. et al 1995). mPPARγ2 has an additional 30
N-terminal amino acids and hPPARγ2 an additional 28 N-terminal amino acids (Zhu, Y. et al
1995 and Elbrecht, A. et al 1996). Both isoforms of human PPARγ bind thiazolidenedione
ligands with the same affinity and both were equal in their ability to transactivate a reporter gene
under the control of an AP2 gene regulatory response element (Elbrecht, A. et al 1996 and
Mukherjee, R. et al 1997). Though PPARγ1 and PPARγ2 are functionally similar, their
expression can be differentially modulated by nutrional control. In fasting mice the expression of
PPARγ2 is reduced to a much greater extent than PPARγ1 (Vidal Puig, A. et al 1996). This may
reflect distinct roles for each subtype of PPARγ receptor in vivo. The retinoic acid receptor
(RAR) family has three isoforms, α, β and γ , with each isoform having multiple subtypes. This
diversity is generated from differential promoter usage and alternative splicing. The resultant
receptors have differing domain structures and recognise different DNA response elements
(Blumberg, B. et al 1992, Kastner, P. et al 1990, Giguere, V. et al 1990, Zelent, A et al 1991,
Leroy, P et al 1991 and Nagpal, S et al 1992). The human glucocorticoid receptor (hGR) has two
isoforms α and β, produced as a result of alternative splicing of the last two exons (Hollenberg,
S.M. et al 1985 and Encio, I.J. et al 1991). hGRβ is unable to bind glucocorticoid hormones or
transactivate transcription ( Hurley, D.M. et al 1991, Chrousos, G.P. et al 1993 and Karl, M. et
al 1993). hGRβ has been shown to inhibit the effects of hormone hGRα on a glucocorticoid-
responsive reporter gene in a concentration dependent manner. hGRα and hGRβ have similar
patterns of tissue expression, therefore the ratio expression of these receptors will be critical in
regulating a target cells responsiveness to glucocorticoid hormones (Bamberger, C.M. et al 1995
and Oakley, R.H. et al 1997). A novel vitamin D receptor VDR1 has been cloned from rat. The
difference between VDR1 and VDR is generated during splicing of VDR mRNA. An intron is
retained within the mRNA producing a distinct receptor. VDR1 does not exhibit ligand binding
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of vitamin D but does exhibit DNA binding as a homodimer or heterodimer with VDR on
vitamin D response elements. VDR1 can act as a dominant negative repressor of VDR
transactivation, thus the levels of expression of VDR1 will be important for vitamin D signaling.
The expression levels of VDR1 were determined to be at least 15-fold less than VDR, indicating
that VDR1 activity in rat may not be significant (Ebihara, K. et al 1996). The Thyroid hormone
receptor α (TRα )isoform has three subtypes α1, α2 and α3, generated by alternative splicing of
TRα mRNA. The alternative splicing is believed to disrupt a putative dimerisation domain. In
DNA binding studies it was found that TRα1 could bind to a thyroid hormone response element
(TRE) as a monomer or homodimer. TRα2 and TRα3 could not bind to a TRE as a monomer
or homodimer but could form a heterodimeric complex with RXRα on a TRE. Thus as a result
of alternative splicing a complex pattern of response element binding by TR can be achieved
(Nagaya, T. et al 1996). Differential splicing of the estrogen receptor (ER) mRNA results in the
formation of many types of ER receptor being expressed. Alternative splicing resulting in
deletion of exons 3 and 7 has been found for ER in many breast tumours (Zhang, Q-X. et al
1996). The role of these splice variants in tumour development and resistance to drug therapies
targeted at the ER receptor is not known. A mutant ER receptor resulting from genomic DNA
rearrangement of exons has been identified in a human breast cancer cell line (Pink, J.J. et al
1996).
There has not been any evidence found to suggest that PPARα subtypes can be produced from
differential promoter usage or alternative splicing, as is found for PPARγ receptors. It is possible
that PPARα subtypes could exist in non-responsive species and that these subtypes could exert
a dominant negative effect over PPARα, resulting in the non-responsive phenotype to
peroxisome proliferators.
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Σεχτιον 1.4 Συmmαρψ
Peroxisome proliferating chemicals cause peroxisome proliferation and hepatocellular
carcinogenesis to varying degrees in rodent species. The peroxisome proliferation response has
been characterised in reponsive species such as rats and mice. A member of the nuclear steroid
hormone receptor superfamily, peroxisome proliferator activated receptor α (PPARα) has been
shown to mediate the action of peroxisome proliferators. This transcription factor is highly
expressed in the liver of responsive species and regulates gene expression through specific DNA
response elements called peroxisome proliferator response elements (PPREs). 
Humans which are believed to be non-responsive to peroxisome proliferators also have a
functional PPARα gene expressed in the liver, which can mediate peroxisome proliferator
induced transcriptional control of genes containing a PPRE. Humans therefore have some of the
molecular characteristics of the mechanism of peroxisome proliferation that is observed in
responsive species. This knowledge is insufficient though for determining the risk of humans
getting peroxisome proliferation or hepatocellular carcinogensis. It would be advantageous to be
able to model the human response to peroxisome proliferation in an appropriate non-responsive
species. Our current knowledge suggests that the guinea pig would be an appropriate laboratory
animal model for peroxisome proliferation in humans. But it is not known if guinea pigs have
similar charateristics to humans, such as an expressed functional PPARα receptor. It is therefore
very important for the validation of the guinea pig as a model species, that it be determined if
they have an expressed functional PPARα receptor. It is also important to understand the
detailed molecular functioning of the PPARα receptor. This can be achieved by cloning and
expressing functional PPARα receptor and PPARα receptor domains. This will then allow
experiments to be carried out which will determine what it is within the PPARα receptor that
defines and controls its regulation of gene expression.
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Σεχτιον 1.5 Εξπεριmενταλ οβϕεχτιϖεσ
1)Examine the expression of mouse liver PPARα receptor, relating functional receptor and
protein levels to the PPARα mediated physiological responses induced by peroxisome
proliferators.
2)Investigate the molecular basis of the inability of the guinea pig to respond to peroxisome
proliferators by cloning and characterising the guinea pig PPARα receptor.
3)Clone and express the DNA binding domain of mPPARα, allowing functional and structural
studies of this domain.
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Chapter 2 Methods
Σεχτιον 2.1 Λαβορατορψ ανιmαλσ 
Adult male Wistar Rats, adult (8-10 week) male C57 Bl/6 mice and Dukin-Hartley guinea pigs
(400g) were obtained from Harlan-Olac and fed standard laboratory chow ad lib. Animals were
kept in a standard 12 hour dark /light cycle. Mice were dosed i.p. with 100ml of 2mg/ml
Methylclofenopate in corn oil (10 mg /kg body weight), or 100ml corn oil for 3 days. Animals
were sacrificed by terminal exsanguination under anaesthesia. Livers were collected and weighed
before processing. For diurnal studies animals were sacrificed at 6.00 am, 12.00 noon, 6.00 pm
and 12.00 midnight.
Σεχτιον 2.2 Γενεραλ Μολεχυλαρ Βιολογψ Τεχηνιθυεσ.
Σεχτιον 2.2.1 Βαχτεριαλ γροωτη mεδια
Luria-Bertani Broth (LB); 10g Bactotryptone, 5g Bacto yeast extract, 10g NaCl, made up to 1
litre with Ultra High Pure (UHP) water and autoclaved. LB-Agar plates; 15g agar added to 1litre
of LB and then autoclaved. Media was melted, antibiotics added and poured into 10 cm petri
dishes. Antibiotics were used at the following final concentrations. Tetracycline at 50mg/ ml,
Ampicillin at 12.5mg / ml , Kanamycin at 12.5mg/ ml and Chloramphenicol at 34 mg/ ml. For
blue white selection 40 ml of a 20 mg / ml IPTG solution and 40ml of 20 mg / ml 5-bromo-4-
chloro-3-indolyl-b-D-galactoside (X-gal) soluition was added and spread evenly per plate.
Σεχτιον 2.2.2 Πρεπαρατιον οφ ΧαΧλ2 χοmπετεντ ΞΛ1 Βλυε Ε.χολι ανδ ΒΛ21 (DΕ3) πΛψσ 
Σ Ε.χολι
Components used:
LB-Tet / Amp
LB- Chl / Amp
0.1M CaCl2 (0.22mM filtered)
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0.1M CaCl2, 10% glycerol ( 0.22mM filtered)
Single colonies of XL1 Blue and BL21 (DE3)pLysS E.coli were innoculated in 10ml of LB-Tet/
Amp and LB-Chl / Amp media respectively. Cultures were grown in a shaking incubator
overnight at 37 C. 5 ml of each culture was used to seed 500 ml of LB- Tet / Amp and 500 ml
LB- Chl / Amp media. Large cultures were grown in a shaking incubator at 37 C until an OD
600nm = 0.6-0.8 was reached. The cultures were placed on ice for 10mins, then centrifuged in a
JA14 rotor at 7000rpm for 15minutes at 4 C. 10 ml of ice cold 0.1M CaCl2 was used to resuspend
cell pellets, 10 ml per 100 ml of spun culture was used. Cells were pelleted again by a
centrifugation at 7000 rpm in a JA14 rotor. Cells were resuspended in 2 ml of ice cold 0.1M
CaCl2, 10% glycerol per 50ml of original culture pelleted. Cells were put into 200 ml aliquots
and stored at -80 C.
Σεχτιον 2.2.3 Τρανσφορmατιον οφ DΝΑ ιντο ΧαΧλ2 χοmπετεντ Ε.χολι
Cells were aliquoted into 50 ml volumes and kept on ice. 25 ng of plasmid DNA or 5 ml of a
ligation reaction was added to the cells and allowed to incubate on ice for 10mins. The cells were
then heat shocked at 42 C for 90 seconds and then immediately placed on ice for 2 minutes. 1ml
of LB-glucose media (20 mM glucose) was added to the cells which were then cultured at 37 C
for 1 hour. 100 ml of cell was added per agar plate. Plates wer incubated overnight at 37 C.
Σεχτιον 2.2.4 Πρεπαρατιον οφ ελεχτρο−χοmπετεντ Ε.χολι
Components used:
LB-Tet / Amp
LB- Chl / Amp
sterile UHP water
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Single colonies of XL1 Blue and BL21 (DE3) pLysS E.coli were innoculated in 10ml of LB-Tet/
Amp and LB-Chl / Amp media respectively. Cultures were grown in a shaking incubator
overnight at 37 C. 5 ml of each culture was used to seed 500 ml of LB- Tet / Amp and 500 ml
LB- Chl / Amp media. Large cultures were grown with shaking at 37 C until an OD600nm =
0.6-0.8 was reached. The cultures were placed on ice for 10mins, then centrifuged in a JA14
rotor at 7000rpm. 10 ml of ice cold sterile UHP water was used to resuspend the cell pellets,
10ml was used per 100ml of spun bacterial culture.Cells were pelleted by centrifugation at 7000
rpm in a JA14 rotor at 4 C for 15 minutes. Cell resuspension and pelleting was repeated a further
five times with sterile UHP water. Cells were finally resuspended in 2ml of sterile UHP water ,
10% glycerol per 50 ml of original culture pelleted. Cells were put into 200ml aliquots and stored
at -80 C.
Σεχτιον 2.2.5 Τρανσφορmατιον οφ ελεχτρο− χοmπετεντ Ε.χολι
Electroporation cuvettes and cuvette holder were put on ice to cool. Frozen aliquots of cells were
thawed quickly using hand warmth and then immediately put onto ice. 50ml of cells was added
to 25ng of plasmid DNA . Ligation reaction DNA was  first ethanol / sodium acetate precipitated
and resuspended in 10 ml of UHP water. 5 ml of ligation DNA was added to 50ml of cells and
put on ice. Cells were electroporated at 1.8kV using a bio-rad electroporator. 1ml of LB-glucose
was immediately added and the cells allowed to recover at 37 C for 1 hour. 100ml of transformed
cells were spread per agar plate.
Σεχτιον 2.2.6 Πηενολ:Χηλοροφορm τρεατmεντ οφ νυχλειχ αχιδσ.
Components used:
phenol:chloroform (1v:1v)
2 volumes of phenol:chloroform was added to the sample of nucleic acid, and then vortexed
thoroughly. Organic and aqueous phases are separated by centrifugation at 15000 rpm for 5
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minutes in a benchtop mini-centrifuge. Contaminant proteins partition at the interface between
the organic and aqueous phases. The aqueous phase is carefully removed and kept as it contains
the nucleic acid.
Σεχτιον 2.2.7 Πρεχιπιτατιον οφ νυχλειχ αχιδσ υσινγ τηε ετηανολ / σοδιυm αχετατε προτο−
χολ.
Components used:
100 % Ethanol
70 % Ethanol (v/v)
3 M sodium acetate (pH=5.2), 0.22mM filtered
1/10th volume of sodium acetate was added to the nucleic acid sample. 2 volumes of ethanol are
added to this solution, mixed and placed on ice or at -20 C to precipitate the nucleic acid.
Nucleic acid pellets were washed in a minimum of 200ml of 70% Ethanol. The pellet was spun
to the bottom of the tube and the ethanol extracted by careful pippeting. Nucleic acid pellets
were air dried to remove traces of ethanol. DNA pellets were resolubilised in UHP water and
RNA pellets were resolubilised in DEPC treated water.
Σεχτιον 2.2.8 Πλασmιδ DΝΑ πυρι⇒χατιον βψ Αλκαλινε λψσισ mετηοδ
Components used:
Solution 1: 10mg / ml RNase A in 25 mM Tris (pH=8.0), 10 mM EDTA
Solution 2: 0.4 M NaOH, 1% SDS
Solution 3: 3M K-Acetate, 11.5% glacial acetic acid
phenol:chloroform (1v/1v)
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3M Na-Acetate (pH=5.2)
100 % ethanol
70% ethanol
UHP water
1.5ml of bacterial culture was pelleted by centrifugation at 15000 rpm for 5 mins, and the
supernatant discarded. A further 1.5ml of culture was pelleted in the same tube and the
supernatant discarded. 100 ml of solution 1 was used to resuspend the pellet. 200ml of soltion 2
was added and mixed by pipetting. The tubes were stood at room temperature for 5 mins. 150
ml of ice cold solution 3 was added and mixed by inverting the tube. The tube was put on ice
for 10 mins to precipitate proteins. Precipitate was pelleted by centrifugation at 15000 rpm for
10 mins.
The supernatant was transferred to fresh tubes and 900 ml of phenol:chloroform added. The tube
was vortexed thoroughly and then centrifuged at 15000 rpm for 5 minutes. The aqueous phase
was transferred to new tubes and 45ml of 3M Na-Acetate added. 1 ml of 100 % ethanol was then
added and the tube put on ice for 30 minutes. DNA was pelleted by centrifugation at 15000 rpm
for 30 mins. The DNA pellet was washed in 200 ml of 70% ethanol. The ethanol was pipetted
off and the pellets allowed to air dry. 20 ml of UHP water was used to rsolubilise the DNA pellet.
Purified plasmid DNA was stored at -20 C until required.
Σεχτιον 2.2.9 Πυρι⇒χατιον οφ πλασmιδ DΝΑ ον Θιαγεν Μινι−πρεπ ανδ Μαξι−πρεπ χολ−
υmνσ
Components used:
Buffer P1: 50 mM Tris-Cl (pH=8.0), 10 mM EDTA, 100 mg / ml RNase A
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Buffer P2: 200 mM NaOH, 1% SDS
Buffer P3: 3.0M Kac (pH=5.5)
Buffer QBT: 750 mM NaCl, 50 mM MOPS (pH=7.0), 15% v/v isopropanol, 0.15% v/v Triton
X-100
Buffer QC: 1 M NaCl, 50 mM MOPS (pH=7.0), 15% v/v isopropanol
Buffer QF: 1.25 M NaCL, 50 mM Tris-Cl (pH=8.5), 15 % v/v isopropanol
70% v/v Ethanol
Autoclaved UHP water
Qiagen tip columns contain diethylaminoethanol (DEAE) anion exchange resin. The negative
charge on the phosphate backbone of DNA cuases the DNA to bind to this resin , and is only
eluted from it at high salt concentrations. Impurities such as RNA, protein, carbohydrates and
small metabolites are washed from the resin in medium salt buffers.
Σεχτιον 2.2.9.1 Μινι−πρεπ mετηοδ
3ml of an 10 ml overnight culture was pelleted by centrifugation at 15000 rpm. The bacterial
pellet was resuspended in 0.3ml of buffer P1. 0.3 ml of buffer P2 was added and mixed
thoroughly, and incubated at room temperature for 5 minutes. 0.3 ml of chilled buffer P3 was
added and mixed by inversion of the sample tube. The sample was incubated on ice for 10
minutes. The sample was centrifuged at 15000 rpm for 15 minutes, then the supernatant was
promptly removed and stored on ice. A Qiagen-tip 20 was equilibrated with 1 ml of buffer QBT.
The supernatant was applied to the column and allowed to drain through, using gravity to pull
the solution through. The column was washed four times with 1 ml of buffer QC. DNA was
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eluted with 0.8 ml of buffer QF. DNA was precipitated by the addition of 0.56 ml of
isopropanol. The solution was centrifuged at 15000 rpm for 30 minutes. The DNA pellet was
washed with 1 ml of 70 % ethanol. 20 ml of autoclaved UHP water was used to resolubilise the
DNA. The concentration of DNA was determined by measuring the A260νm of a diluted sample.
DNA samples were stored at -20 C.
Σεχτιον 2.2.9.2 Μαξι−πρεπ mετηοδ
500 ml LB + antibiotics was seeded with 5ml of a 10 ml overnight culture. The 500 ml culture
was then grown overnight with shaking at 37 C. The 500 ml of culture was pelleted by
centrifugation at 15000 rpm. The bacterial pellet was resuspended in 10 ml of buffer P1. 10 ml
of buffer P2 was added and mixed thoroughly, and incubated at room temperature for 5 minutes.
10 ml of chilled buffer P3 was added and mixed by inversion of the sample tube. The sample was
incubated on ice for 20 minutes. The sample was centrifuged at 15000 rpm for 15 minutes, then
the supernatant was promptly removed and stored on ice. A Qiagen -tip 500 was equilibrated
with 1 ml of buffer QBT. The supernatant was applied to the column and allowed to drain
through, using gravity to pull the solution through. The column was washed twice with 30 ml
buffer QC. DNA was eluted with 10.5 ml of buffer QF. DNA was precipitated by the addition
of 15 ml of isopropanol. The solution was centrifuged at 15000 rpm for 30 minutes. The DNA
pellet was washed with 5 ml of 70 % ethanol. 300 ml of autoclaved UHP water was used to
resolubilise the DNA. The concentration of DNA was determined by measuring the A260νm of
a diluted sample. DNA samples were stored at -20 C.
Σεχτιον 2.2.10 Πυρι⇒χατιον οφ ΠΧΡ προδυχτσ
Components used:
PB buffer
PE wash buffer
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Qiaquick columns
Autoclaved UHP water
250 ml of PB buffer was added to each PCR reaction. The sample was placed in a qiaquick spin
column and centrifuged in a bench-top microcentrifuge at 14000 rpm for 60 seconds. The flow
through was discarded. 750ml of PE buffer was added to the spin column, and then certifuged at
14000rpm for 60 seconds. The flow trough was discarded and the column centrifuged again at
14000 rpm for 60 seconds to remove traces of residual PE wash buffer. 50 ml of water added to
the column, and centrifuged at 14000 rpm for 60 seconds to elute the bound DNA.
Σεχτιον 2.2.11 Ρεστριχτιον ενδονυχλεασε διγεστσ οφ DΝΑ σαmπλεσ
Components used:
NBL buffer 6: 50 mM Tris-HCl (pH=7.8), 100 mM NaCl, 10 mM MgCl2, 1 mM DTT
NBL buffer 4: 10 mM Tris-HCl (pH=8.3), 100 mM NaCl, 5 mM MgCl2, 1 mM 2-
Mercaptoethanol
Boehringer Mannheim buffer A: 33 mM Tris-Ac (pH=7.9), 10 mM MgOAc, 66 mM KOAc,
0.5 mM DTT
Boehringer Mannheim buffer B: 10 mM Tris-HCl (pH=8.0), 5 mM MgCl2, 100 mM NaCl, 1
mM 2-Mercaptoethanol
Boehringer Mannheim buffer H: 50 mM Tris-HCl (pH=7.5), 10 mM MgCl2, 100 mM NaCl,
1 mM Dithioerythritol
Stratagene Universal Buffer: 25 mM Tris-Ac (pH=7.6), 100 mM KOAc, 10 mM MgOAC, 0.5
mM 2-Mercaptoethanol, 10mg/ ml BSA
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The above restriction digest buffers were used with the appropriate manufacturers restriction
enzyme. Concentrations given are final assay concentrations. Assay volumes and amount of DNA
digested varied according to the purpose of the assay. Analytical digests were incubated at 37 C
for 1 hour. Restriction digests used for the purpose of cloning were carried out at 37 C for up
to 3 hours.
Σεχτιον 2.2.12 Σηριmπ Αλκαλινε Πηοσπηατασε (ΣΑΠ) τρεατmεντ οφ  ϖεχτορσ.
Components used:
10* SAP buffer: 200 mM Tris-HCl (pH=8.0), 100 mM MgCl2. (United States Biochemical-
USB)
Shrimp Alkaline Phosphatase Enzyme (SAP). (USB)
UHP water
Restriction enzyme cut plasmid vector was gelpurifed first using GeneClean II kit. Purified DNA
was added to SAP buffer (assay concentration = 1*) and SAP and made up to either 30ml or 50
ml final volume. The assay reaction was incubated at 37 C for 30 minutes and then heat
inactivated by incubation at 65 C for 15 minutes. DNA treated with SAP was then extracted
with 2 volumes of phenol:chlorofom (1v:1v) and then ethanol / sodium acetate precipitated.
Pelleted DNA was resolubilised in 5-10ml of UHP water.
Σεχτιον 2.2.13 Πυρι⇒χατιον οφ DΝΑ εξχισεδ φροm αν αγαροσε γελ,
Components used:
1* TAE Agarose gel
NaI solution
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Glassmilk silica matrix in UHP water 
New Wash Buffer
UHP water
DNA was first separated and resolved on a 1* TAE agarose gel. The gel is kept in its perspex
casting tray and is visualised on a UV transiluminator to minimise UV damage to the DNA.
Bands of interest were excised using a scapel and were weighed. Three gel slice volumes of NaI
was added to the gel slice. The gel slices were dissolved by heating the tube to 55 C. 5ml of
glassmilk was added to the DNA solution and vortexed thoroughly. The DNA binds to the
glassmilk by incubation at room temperature for a minimum of 5 minutes. The glassmilk was
pelleted by centrifugation at 15000 rpm for 5 seconds. The supernatant was extracted and
discarded. The glassmilk pellet was washed three times with 400 ml of ice cold New Wash Buffer.
The Glassmilk was pelleted again and then resuspended in 5-10ml of UHP water to elute the
DNA. The tube was heated to 55 C for 2 minutes and then centrifuged. The supernatant
containing the purified DNA was carefully extracted and stored at -20 C. A second DNA elution
was done by repeating the above elution step.
Σεχτιον 2.2.14 Νον δενατυρινγ ελεχτροπηορεσισ ιν αγαροσε γελσ.
Components used:
Agarose
0.5* TBE: 5.4g / l Tris, 2.75g /l Boric Acid, 2ml / l 0.5M EDTA (pH= 8.0)
1* TAE: 4.84g / l Tris, 1.142ml /l Glacial acetic acid, 2ml / l 0.5M EDTA (pH=8.0)
Ethidium Bromide: 10 mg / ml in UHP water
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10 * Load Buffer: 0.25% Bromophenol Blue, 0.25% Xylene Cyanol FF, 30% Glycerol
1 kb marker ladder: 75 bp -12kbp, 0.5 mg / mm width of lane (Gibco BRL)
Electrophoresis tank, casting gel, comb and electrophoresis power supply.
UV light transilluminator
Photographic equipment
For minigels 60 ml of 0.5* TBE or 1* TAE buffer was placed in a duran bottle. Agarose solid
was added to this solution to give a final percentage between 0.7-1.5% w/v. The solution was
heated in a microwave at full power in 20 second bursts until all the agarose was dissolved. The
agarose solution was allowed to cool to a hand hot temperature. The agarose was poured into a
cast, containing a comb and was allowed to set. The gel was placed in the electrophoresis tank
and covered with the same buffer as used to make the gel. DNA samples between 10 and 30 ml
volume were prepared in a 1 * load buffer solution. After loading of samples the gel was run at
constant voltage , 7-18v per cm gel. The gel was run for period of time that gave the desired
resololution. DNA bands were visualised by illuminationtion with UV light and photographed.
Σεχτιον 2.2.15 DΝΑ σεθυενχινγ mετηοδ
DNA sequencing was carried out by John Keyte in the Biomolecular Synthesis and Analysis unit,
Queens Medical Centre, Nottingham. Briefly the ABI prism dye terminator cycle sequencing
ready reaction kit (Perkin Elmer) was used for the PCR stage of the sequencing protocol. Only
qiagen purified DNA template was used for DNA sequencing. PCR sequencing reactions were
analysed on a 373A DNA sequencer (Perkin Elmer). Raw DNA sequence were inspected and
edited using GCG sequence analysis software. The software programs used were, TED, SEQED,
BESTFIT, GENASSEMBLE and MAP (Wisconsin Package Version 9.0). Protein sequence
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alignments and phylogenetic analysis was done using GCG, CLUSTALW 1.6 (Thompson, J.D.
et al 1994), SAGA (Notredame, C. and Higgins, D.G. 1996), Puzzle 4 (Strimmer, K. and von
Haeseler, A. 1996), Genedoc (Nicholas, K.B. and Nicholas J.B. 1997), and Treeview computer
programs.
Σεχτιον 2.2.16 Πυρι⇒χατιον οφ τοταλ ΡΝΑ 
Components used:
Lysis Buffer: 5M Guanidine thiocyanate, 10mM EDTA, 50 mM Tris-HCl and 8% (v/v)
2-mercaptoethanol
Precipitation Buffers: 4M LiCl and 3M LiCl
SDS-TE buffer: 0.1% SDS (w/v), 1 mM EDTA, 10mM Tris-HCl
Diethyl Pyrocarbonate (DEPC) treated water (0.1%)
RNA was extracted from liver tissue using the method of Cathala, G et al 1983. 1g of liver was
homogenised for 30 seconds in an RNase free vial containing 5ml of lysis buffer, using a
Silverston Homogeniser. 35 mL of ice cold precipitation buffer was added and mixed by tube
inversion. Precipitation was carried out at 4 C overnight. The sample was centrifuged at 11000g
for 90 minutes at 4 C in a JA20 rotor. The supernatant was discarded and the pellet resolubilised
in 5ml of ice cold 3M LiCl. This solution was centrifuged at 11000g for 60 minutes at 4 C in a
JA20 rotor. The supernatant was discarded and the pellet resolubilised in 5ml of SDS-TE. 5 mL
of phenol:chloroform (1v:1v) was added. The sample was put on ice, with 20sec long vortexing
every 5 minutes. The sample was then frozen at -80 C for 30 minutes. The sample was thawed
on ice and then centrifuged at 10000g for 15 minutes at 4 C in a JA20 rotor. The aqueous phase
was extracted and treated with phenol:chloroform as described above. The aqueous phase was
Alex R. Bell Section 2.2.17
Page 67
then ethanol/ sodium acetate precipitated at -20 C overnight. RNA was pelleted by
centrifugation at 10000g for 15 minutes at 4 C in a JA20 rotor. The pellet was first washed in
90% ethanol in DEPC water, and then resuspended in 1 ml DEPC treated water.
Quantification of amount of RNA produced was done by measuring the A260 nm of a diluted
sample of the RNA. The quality and integrity of the RNA was visualised by analysis of 2ml and
4 ml of RNA in a 0.8% agarose gel made with 1*TBE, 0.1% SDS run at 90v for 1 hour. The gel
was prestained with ethidium bromide. 
Σεχτιον 2.2.17 Πυρι⇒χατιον οφ πολψΑ+ ΡΝΑ
Components used:
5* Bind buffer: 2.5M NaCl , 50 mM Tris-HCl (pH=7.5) , 0.5% (v/v) Sarkosyl , 5 mM EDTA
(pH=8.0)
DEPC treated water
0.1M NaOH
Note: 1* Bind buffer was filtered through a 0.22mM filter.
0.08g of Oligo -dT resin (Pharmacia) was preswollen at 4 C for 1hour by the addition of 5ml of
DEPC treated water. Swollen resin was poured into a syringe barrel stuffed with glasswool at the
base, and allowed to settle. The packed bed volume was approximately 0.5ml. The resin was
washed first with 20 volumes of 0.1M NaOH , and then 30 volumes of DEPC treated water.
The resin was then washed with 10 volumes of 1* Bind buffer.
 1.25 mg of guinea pig total RNA was ethanol/ sodium acetate precipitated, then resuspended
in 2.5ml of 1* Bind buffer to give a final RNA concentration of 0.5 mg/ml. The RNA sample
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was heated to 65 C and loaded onto the column. The eluate was collected, heated to 65 C and
loaded onto the column again. This step was repeated once more. The column was washed with
5ml of 1* Bind buffer to remove unbound RNA. Ten 0.5ml DEPC treated water samples were
preheated to 65 C. Each 0.5 ml was loaded onto the column with individual 0.5ml eluate
fractions being collected. RNA in each eluate fraction was precipitated using the ethanol /
sodium acetate method, then resolubilised in 10ul of DEPC treated water. 2ml of each RNA
fraction was analysed on a 0.8% agarose gel , made with 1*TBE / 0.1% SDS. Fractions containing
intact poly A+ RNA were pooled. The amount of polyA+ RNA was quantitated by measuring
the A260nm of a diluted sample.
Σεχτιον 2.2.18 Ινχορπορατιον οφ [32Π]−λαβελλεδ νυχλεοτιδεσ
Components used:
0.5 M Na2 HPO4
DE 81 filters (whatmann)
100 % ethanol 
UHP water
Hi-Safe liquid scintillant
The synthesised probe was first diluted 10 fold using UHP water ( or DEPC treated water if an
RNA probe was being assayed). Six 1ml aliquots of diluted probe were spotted onto six DE 81
filters and allowed to dry. Three filters were then placed in a radiation shielded container. These
filters were labelled with a T to represent total counts. The other three filters were washed four
times in 10 ml of 0.5M Na2HPO4. Residual Na2HPO4 was removed by washing the filters in
two 10ml UHP water washes. Filters were then rinsed in 100% ethanol and allowed to air dry.
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3ml of liquid scintillant was put into a scitillation vial. Each dry filter was then put in its own
scintillation tube and counted on a [32P] program for 1 minute in a Packard 1900 TR liquid
scintillation analyser. The amount of incorporation was calculated as follows:
mean washed filter counts / mean total filter counts * 100 = % incorporated
Σεχτιον 2.3 Προτειν mετηοδολογιεσ
Σεχτιον 2.3.1 Πυρι⇒χατιον οφ λιϖερ νυχλεαρ προτεινσ.
Components used:
Hommogenisation buffer: 10 mM Hepes (pH=7.6), 25 mM KCl , 0.5 mM Spermine, 1 mM
EDTA 2M Sucrose, 10% Glycerol (v/v)
Protein extraction buffer 10 mM Hepes (pH=7.6) 100 mM KCl, 3 mM MgCl2, 0.1 mM EDTA,
1 mM DTT, 1 mM PMSF, 10 % Glycerol (v/v)
Dialysis buffer: 25 mM Hepes (pH=7.6), 40 mM KCl, 0.1 mM EDTA, 1 mM DTT
10 % Glycerol (v/v)
Fresh liver tissue was homogenised in 8ml ice cold Homogenisation Buffer (HB). Ten mini-
ultracentrifuge tubes were prepared with 400ml cushions of ice cold HB. 550ml of homogenate
was layered onto each cushion. Tubes were centrifuged in a TLA 120.2 rotor at 120000 rpm for
8 min, at 4 C. Supernatant was discarded and new HB cushions poured over the pelleted nuclei.
Remaining homogenate was layered over the cushions and the centrifugation step repeated. The
nuclei pellets were resuspended in 2ml of HB. This was layered over six 500ml cushions and
centrifuged at 120000rpm for 8 min at 4 C. Nuclei pellets were resuspended in 4ml of protein
extaction buffer and were incubated on ice for 30 min. 1/10th volume of 4M (NH4)2SO4 was
added and gently mixed. The solution was incubated on ice for 30 min. The solution was divided
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between four mini-ultracentrifuge tubes and was centrifuged at 120000rpm for 23min at 4 C.
The supernatant was collected , solid (NH4)2SO4 was added to a final concentration of 0.3g/ml
and dissolved slowly on ice. After 30min the solution was centrifuged at 120000 rpm for 23min
at 4 C to pellet precipitated proteins. The protein pellet was resuspended in 800 ml of dialysis
buffer and was dialysed for approximately for 18 hours against 2 litre of dialysis buffer. After
dialysis the protein solution was centrifuged in eppendorf tubes at 15000 rpm for 10 min.
Supernatant was collected , aliqouted out and stored at -20 C. Protein concentration was
determined by Bradford assay. The integrity of the protein in the samples was analysed using
SDS-polyacrlyamide gel electrophoresis (SDS-PAGE).
Σεχτιον 2.3.2 Βραδφορδ (Χοοmασσιε Βλυε) Προτειν Ασσαψ
Components used:
Bradford reagent: 100 mg Serva blue G dissolved in 100 ml of 85% phosphoric acid and 50 ml
of 95% ethanol. This solution is made up to 1 litre and filtred through whatman paper.
1 M NaOH
Bovine Serum Albumin: 2 mg / ml in UHP water
UHP water
30 ml of protein sample was added to 50ml of 1 M NaOH. To this 950 ml of Bradford reagent is
added. The assay solution was vortexed thoroughly. The assay solution was put into a cuvette
and the absorbance at 590nm was measured. BSA protein standard assays are done between the
range 0-40mg / ml. All assays are done in triplicate and the mean result determined. A plot of
BSA concentration against A590nm measurements produces a linear plot. Linear regression was
carried out on the data to produce the equation:
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Absorbance = Slope ( [ ] protein sample) + constant
Data from plots where R2 >0.95 were used. Unknown concentration of protein samples was
calculated from the above formula. 
Σεχτιον 2.3.3 Πολψαχρλψαmιδε γελ ελεχτροπηορεσισ οφ προτεινσ ( ΠΑΓΕ )
Components used:
5* SDS load buffer: 250 mM Tris-HCl (pH=6.8), 0.5M DTT, 10% SDS (w / v), 0.5%
bromophenol blue, 50% glycerol (v / v)
Denaturing running buffer: 25 mM Tris-HCl (pH=8.3), 250 mM glycine, 0.1% SDS (w / v)
Denaturing stacking gel acrylamide solution: 4% acrylamide/bis acrylamide (30%), 125 mM Tris-
HCl (pH=6.8), 0.1% SDS, 0.001% TEMED, 0.005% Ammonium persulphate (APS)
Denaturing separation gel acrylamide solution: 20% -6% acrylamide / bis acrylamide (30%), 375
mM Tris-HCl (pH=8.8), 0.1% SDS, 0.001% TEMED, 0.005% APS
Native running buffer: 0.25*TBE
Native separation gel acrylamide solution:20% -6% acrylamide / bis acrylamide (30%), 375 mM
Tris-HCl (pH=8.8), 0.001% TEMED, 0.005% APS
Protein markers: Low Molecular Weight Range, Sigma M3913 High Molecular Weight Range,
Sigma SDS-7B.
Coomassie Blue stain: 0.25g coomassis brilliant blue R250 in 90 ml methanol:water (1v/1v) +
10 ml glacial acetic acid.
Destain solution: 30% Methanol (v/v), 10% glacial acetic acid.
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UHP water
For denaturing polyacrylamide gel electrophoresis (SDS-PAGE) protein samples were made up
to between 30 and 60ml volumes with 5* SDS load buffer (final [ ]= 1*) and UHP water and
then boiled for three minutes. SDS-PAGE polyacrylamide gels for separating proteins were made
at a final percentage of between 6 and 20%, depending on the size resolution required. A mini-
protean gel gel system (Bio-Rad) was used to run the gels. After electrophoresis, the gels were
stained in coomassie blue stain for 30 minutes, and then destained to remove unbound dye with
several washes with destain solution. Gels were dried onto Whatman 3MM chromatography
paper using a heated flatbed dryer under vacuum. For native polyacrylamide gel electrophoresis
separation gels were made with native PAGE solutions, and did not have a stacking gel.
Reactions run on native gels such as electromobility shift assays were not boiled in denaturing
load buffer. Gels were dried onto whatman 3MM chromatography paper using a heated flatbed
dryer under vacumm
Σεχτιον 2.3.4 Ιmmυνοβλοττινγ αναλψσισ οφ λιϖερ νυχλεαρ προτειν εξτραχτσ
Components used:
SDS-PAGE: see denaturing polyacryamide gel electrophoresis section
Transfer buffer: 25 mM Tris-HCl, 192 mM glycine, 20% methanol (v/v), 0.1% SDS (w / v)
Methanol
PVDF membrane  ( Millipore Immobilon-P 0.45 mM pore size)
Whatman Paper
1* TBS: 20mM Tris-HCl (pH=7.6), 500 mM NaCl
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1* TTBS: 20mM Tris-HCl (pH=7.6), 500 mM NaCl, 
0.1% Tween 20 (polyoxyethylenesorbitan monolaurate )
Marvel dried milk powder
Primary antibody: Rabbit Anti-mouse PPARα polyclonal antibody
Secondary antibody: Goat Anti-rabbit IgG (H+L) horseradish peroxidase conjugate antibody
(Bio-Rad)
ECL western blotting detection kit (Amersham Life Science)
Hyperfilm (Amersham Life Science)
1* Developer solution (Ilford)
1* Fixing solution (Ilford)
UHP water
20 mg of liver nuclear protein was separated using denaturing SDS-page on 7.5% or 10% gels.
After electrophoresis the gel was soaked in transfer buffer for 10 minutes. A square of PVDF
membrane, large enough to cover the whole of the gel was presoaked in methanol for 2 minutes
and then soaked in transfer buffer for 10 minutes. The gel was placed onto two sheets of whatman
paper pre-wetted with transfer buffer. All air bubbles between the gel and paper were carefully
removed. The soaked PVDF membrane was overlaid on to the gel , carefully removing air
bubbles. Two more sheets of pre-wetted whatman paper were overlaid onto the PVDF
membrane. The sandwich gel was placed into a electro-transfer cassette , with the gel side nearest
to the cathode and membrane side nearest the anode electrode. Proteins were transferred to the
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PVDF membrane by electro-transfer in transfer buffer at 4 C, and at a constant 75mA. After
transfer , the membrane was blocked in 1*TBS, 10% Marvel skimmed milk overnight. The blot
was then incubated in 20 ml of 1*TTBS containing rabbit anit-mouse PPARα antibody at a
1:10000 dilution for 1 hour with rocking. The blot was then washed with four 100 ml 1*TTBS
washes. The blot was then incubated in 20ml of 1*TTBS containing goat anti-rabbit IgG-HRP
antibody at a 1:40000 dilution for 1hour with rocking. The blot was then washed with four 100
ml 1*TTBS washes and developed using the ECL kit according to the manufacturers
instructions. Blots were the exposed to hyperfilm for 1 hour. Films were soaked in 1* developer
for 2 mins, washed in water for 2 mins , fixed in 1* fixing solution for 2 mins and then allowed
to air dry.
Σεχτιον 2.4 χDΝΑ χλονινγ mετηοδολογιεσ
Σεχτιον 2.4.1 Σψντηεσισ οφ 1στ στρανδ χDΝΑ βψ ρεϖερσε τρανσχριπτιον
Components used:
Superscript II Rnase H- Reverse Transcriptase , 200u /ml (Gibco BRL ,Life Technologies)
5* First strand Buffer: 250 mM Tris-HCl (pH=8.3), 375 mM KCl, 15 mM MgCl2, 0.1 M
Dithiothreitol (DTT)
Σεχτιον 2.4.1.1 1στ στρανδ χDΝΑ σψτηεσισεδ υσινγ τοταλ ΡΝΑ ασ α τεmπλατε.
5, 2.5 and 1mg of total RNA was each added to 500ng of Oligo -dT (12-18) primer and the total
volume made up to 11 ml with DEPC treated water. Each reaction was heated to 70 C for 10
minutes and then chilled on ice immediately, then centrifuge. To each tube the follwing were
added. 4ml of 5* 1st strand buffer, 2ml 0.1M DTT , 1ml 10mM dATP,dGTP,dCTP and dTTP
mix . To one tube 1ml of [3H] dCTP (50 mM stock) was added. 1ml of DEPC treated water was
added to the other two tubes. All three tubes were heated to 42 C for 2 minutes, then 1ml of
Superscript II enzyme was added to each tube and mixed thoroughly. The tubes were incubated
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at 42 C for a further 50 minutes, then at 70 C for 15 minutes. The tubes were cooled on ice, and
2ml of Rnase H added to each. These were then incubated at 37 C for 20 minutes. A DE81 assay
was carried out on the reaction containing [ 3H]dCTP. This verified that 1st cDNA had been
made.
Σεχτιον 2.4.1.2 1στ στρανδ χDΝΑ σψντηεσισεδ υσινγ πολψ Α+ ΡΝΑ.
The method that was used to generate 1st strand cDNA from total RNA was used, except that
600ng and 300ng of poly A+RNA was used as template material.
Σεχτιον 2.4.2 ΠΧΡ Αmπλι⇒χατιον οφ γυινεα πιγ χDΝΑ∏σ. 
PCR primers were designed from regions of DNA sequence identity of mouse , human and
xenopus PPARa’s. Two sets of primers were used to generate 436bp and 1056bp DNA
fragments from reverse transcribed guinea pig total and poly A+ RNA. Guinea pig primer
(GPIGP) 2 and GPIGP3 were used to generate the 436bp fragment. GPIGP4 and GPIGP3 were
used to generate the 1056bp fragment.
Components used:
Primer name and DNA sequence
GPIGP2   5∏−ΓΑΤΓΑΑΧΑΑΑΓΑΧΓΓΓΑΤΓΧΤΓ−3∏
GPIGP3   5∏−ΧΤΧΑΓΤΑΧΑΤΓΤΧΧΧΤΓΤΑΓΑΤ−3∏
GPIGP4   5∏ ΤΑΧΓΓΑΓΤΤΧΑΧΓΧΑΤΓΤΓΑΑΓΓΧΤΓΧΑΑΓΓΓΧΤΤΧΤΤ−3∏
10 * KlenTaq PCR reaction buffer: 400 mM Tricine-KOH (pH 9.2 at 25 C), 150 mM KOAc,
35 mM Mg(OAc)2, 750 mg/ml Bovine Serum Albumine.
Klen Taq Polymerase Mix: Taq start antibody: Antibody dilution buffer: DNA polymerase in
the ratio 1:4:1 volumes
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dNTP mix : 10 mM dATP, dGTP, dCTP, dTTP (Pharmacia)
Autoclaved UHP water
The genearal PCR reaction contained 5 ml 10* Klen Taq PCR reaction buffer, 2ml 5’-Primer
(~70 pmol), 2ml 3’-Primer (~70 pmol), 1ml dNTP mix , 2ml cDNA or 25ng positive control
plasmid , 1ml Klen Taq polymerase mix and water to a final volume of 50 ml. 2 drops of mineral
oil was overlayed onto each reaction to prevent evaporation. A three step cycle was used for each
PCR reaction. A denaturation temperature of 94 C and extension temperature of 72 C were
used. The annealing temperature was dependant upon the sequence of the primers used. The
following formula was used to calculate appropriate annealing temperatures.
81.5 + 16.6(-log [salt +] ) + 0.41 (% GC) - (675/ number of nucleotides in primer) 
5ml of each PCR reactions was analysed on appropriate percentage agarose gels, made with 0.5*
TBE, prestained with ethidium bromide (final [ ] =0.166 mg/ml) and run at 100v for 1hour.
Σεχτιον 2.4.3 Λιγατιον οφ αmπλι⇒εδ πυτατιϖε γυινεα πιγ ΠΠΑΡα χDΝΑ φραγmεντσ.
Components used:
pGEM -T vector (50 ng / ul): pGEM-5Zf(+) digested with EcoRV and 3’ terminal thymidines
added (Promega)
10 * T4 DNA ligase buffer: 300mM Tris-HCl (pH=7.8), 100 mM MgCl2, 100 mM DTT, 5
mM ATP (Promega)
T4 DNA ligase in 10 mM Tris-HCl (pH=7.4), 50 mM KCl, 1 mM DTT, 0.1 mM EDTA, 50%
Glycerol (Promega)
Autoclaved UHP water
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The following ligation reactions were assembled. 1ml 10* T4 DNA ligase buffer, 1ml pGEM-T
vector, 1ml T4 DNA ligase, 1 or 5 ml Qiaquick spin purified PCR product, and water to a final
reaction volume of 10ml. The reactions were incubated at 4 C overnight. 5ml of each ligation
reaction was transformed into 50ml of CaCl2  competent XL1 Blue E.Coli. Blue/ white selection
was used to select for plasmids containing an insert 10 white colonies to 2 blues colonies were
cultured in 5ml of TET/AMP Lbroth. DNA was miniprepped from each culture using the
alkaline lysis method. 1ml of uncut DNA from each miniprep was analysed on 1% agarose gel.
Plasmid DNA without an insert has a lower molecular weight and migrates through the gel faster
than plasmid DNA with an insert. Therefore plasmids containing an insert are easily
distinguishable. Three plasmids positive for both cDNA inserts were purified using Qiagen
miniprep columns and DNA sequenced. The following primers were used for sequencing.
pUC/M13 forward primer 5∏−ΓΤΤΤΤΧΧΧΑΓΤΧΑΧΓΑΧ−3∏
pUC/M13 reverse primer 5∏−ΓΓΑΑΑΧΑΓΧΤΑΤΓΑΧΑΤΓ−3∏
GPIGP8 primer 5∏−ΓΧΓΓΑΤΧΤΑΧΓΑΓΓΧΧΤΑΧΧΤΓ−3∏
GPIGP9 primer 5∏−ΧΧΓΧΑΑΑΧΧΧΤΤΧΤΓΧΓΑΧΑΤΓ−3∏
GPIGP10 primer 5∏−ΓΧΧΓΓΓΧΧΓΑΤΧΤΧΧΓΧΑΓΧΑ−3∏
GPIGP11 primer 5∏−ΧΧΑΧΧΓΑΧΑΧΑΧΑΧΤΓΓΧΑΓΧ−3∏
GPIGP12 primer 5∏−ΧΤΓΤΧΧΧΓΓΤΧΑΧΑΓΓΤΓΑΓΓ−3∏
Σεχτιον 2.5 Αmπλι⇒χατιον οφ 5∏−χDΝΑ ενδσ υσινγ ΡΑΧΕ
Components used:
GPIGP6 primer: 5∏−ΓΧΧΧΤΤΤΓΧΑΓΧΧΤΤΧΑΧΑΤΓΧΓΤΓΑΑΧΤΧΧ−3∏ (35 pmol / ml)
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GPIGP7 primer 5∏−ΓΑΤΧΤΤΓΧΑΓΧΤΓΧΓΓΤΧΑΧΑΤΤΤΓΤΧΓ−3∏ (35 pmol /ml)
5’ RACE system for rapid amplification of cDNA ENDs (version 2, Gibco BRL.)
5’ RACE abridged anchor primer:
5∏−ΓΓΧΧΑΧΓΧΓΤΧΓΑΧΤΑΓΤΑΧΓΓΓΙΙΓΓΓΙΙΓΓΓΙΙΓ−3∏
Universal amplification primer:
5∏−ΧΥΑΧΥΑΧΥΑΧΥΑΓΓΧΧΑΧΓΧΓΤΧΓΑΧΤΑΓΤΑΧ−3∏
Guinea pig total RNA
Guinea pig polyA+ RNA
DEPC treated water
Synthesis of cDNA
Two reactions were setup as follows. 3.5 pmol of GPIGP7 primer was added to 1mg of polyA+
RNA and 1mg of total RNA in separate tubes. DEPC water was added to a final volume of
15.5ml. The tubes were heated to 70 C for 10 mins to denature secondary RNA structures. The
tubes were then chilled on ice and then centrifuged briefly. 2.5 ml of 10* PCR buffer, 2.5 ml of
25mM MgCl2, 1ml of 10mM dNTP mix and 2.5ml of 0.1 mM DTT were added to each tube.
The tubes were incubated at 42 C for 1 minute and then 1 ml of Superscript II reverse
transcriptase was added to each. The reactions were incubated for a further 50 mins at 42 C. Final
composition of the reaction was 20mM Tris-HCl (pH=8.4), 50 mM KCl, 2.5 mM MgCl2, 10
mM DTT, ≈ 1.4 ng GPIGP7 primer, 400 mM dATP,dCTP,dTTP,dGTP, 40ng/ml RNA and
200 units of reverse transcriptase. Reverse transcription was terminated by incubating the tubes
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at 70 C for 15 mins. The tubes were centrifuged and then 1ml of RNase mix was added to each
tube. The reactions were incubated at 37 C for 30 mins.
Σεχτιον 2.5.1 Πυρι⇒χατιον οφ χDΝΑ
 cDNA’s were purified using Glassmax DNA isolation spin cartridges. Briefly, 120ml of 6M NaI
was added to each tube of cDNA. The solution containing the cDNA’s was transfered to a spin
cartridge, which was then centrifuged for 20 seconds at maximum g. Four 350ml aliquots of wash
buffer and two aliquots of 70% ethanol was used to wash the bound cDNA. cDNA was eluted
from the spin cartridge by the addition of 50ml of water ( pre-heated to 65 C) and centrifugation
for 20 seconds. 
Σεχτιον 2.5.2 Ηοmοπολψmεριχ ταιλινγ οφ χDΝΑ
Purified cDNA was treated with Terminal deoxynucleotidyl transferase (TdT) to add a
homopolymeric tail of dCTP’s. The following reaction was setup for cDNA made from both
polyA+ RNA and total RNA. 6.5 ml of DEPC treated water, 5 ml of 5* tailing buffer, 2.5ml of
2mM dCTP was added to 10ml of cDNA. The tubes were incubated at 94 C for 2 minutes, and
then chilled on ice immediately , and then centrifuged. 1ml of TdT enzyme was added to each
tube and the reactions were incubated at 37 C for 10 mins. TdT was heat inactivated by
incubation at 65 C for 10 mins.
Σεχτιον 2.5.3 ΠΧΡ αmπλι⇒χατιον οφ δΧ−ταιλεδ χDΝΑ
cDNA produced from both polyA+ RNA and total RNA was amplified with (a) 5’RACE kit
reagents (reactions 1 and 2) and (b) Pharmacia Taq DNA polymerase reagents (reactions 3 and
4). The general reaction was as follows:
10* PCR Buffer 5ml
25 mM MgCl2 ( omitted from (b) reactions) 3ml
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GPIGP6 primer 1ml
5’ RACE primer 2ml
10 mM dNTP mix 1ml
dC-tailed cDNA 5ml
Water (made up to a vulume of 47ml )
Taq DNA polymerase mix 3ml
The reactions were amplified using the conditions [ 94 C ,1 min; 61 C, 1 min; 72 C ,1 min 30
secs ] for 35 cycles. 5ml of each reaction was analysed on a 1% agarose gel (0.5 * TBE). A negative
control reaction was done for each set of reagents. These reactions did not contain any cDNA
template. PCR products were identified on a 1% agarose gel. 1ml of each reaction was
reamplified, using GPIGP6 and universal anchor primers, using the above conditions for 20
cycles. The products of reactions 3 and 4 were diluted 20-fold and 100-fold respectively and
were reamplified using GPIGP6 and universal anchor primers.The products of the
reamplification step were analysed on a 1% agarose gel. DNA fragments were produced from
reactions 1, 3 and 4. These fragments were purified using Qiagen QIAquick PCR purification
spin columns (see general molecular biology methods section). Purified PCR product was
resuspended in 30ml of ultra high pure water.
Σεχτιον 2.5.4 Χλονινγ ανδ σεθυενχινγ οφ 5∏ χDΝΑ ενδσ.
Components used:
pGEM -T vector (50 ng / ml): pGEM-5Zf(+) digested with EcoRV and 3’ terminal thymidines
added (Promega)
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10 * T4 DNA ligase buffer: 300mM Tris-HCl (pH=7.8), 100 mM MgCl2, 100 mM DTT, 5
mM ATP (Promega)
T4 DNA ligase in 10 mM Tris-HCl (pH=7.4), 50 mM KCl, 1 mM DTT, 0.1 mM EDTA, 50%
Glycerol (Promega)
Autoclaved UHP water
The following ligation reactions were assembled. 1ml 10* T4 DNA ligase buffer, 1ml pGEM-T
vector, 1ml T4 DNA ligase, 5 ml Qiaquick spin purified PCR product, and water to a final
reaction volume of 10ml. The reactions were incubated at 4 C overnight. 5ml of each ligation
reaction was transformed into 50ml of CaCl2  competent XL1 Blue E.Coli. Blue/ white selection
was used to select for plasmids containing an insert. 10 white colonies and 2 blue colonies were
cultured in 5ml of TET/AMP LB-broth. DNA was miniprepped from each culture using the
alkaline lysis method. 1ml of uncut DNA from each miniprep was analysed on 1% agarose gel.
Clones for all of the purified PCR products were obtained. Five plasmid clones were purified
using qiagen mini prep columns and were sequenced with the following primers. The clones
were termed GP11, GP12, GP13, GP14 and GP15.
pUC/M13 forward primer 5∏−ΓΤΤΤΤΧΧΧΑΓΤΧΑΧΓΑΧ−3∏
pUC/M13 reverse primer 5∏−ΓΓΑΑΑΧΑΓΧΤΑΤΓΑΧΑΤΓ−3∏
GPIGP14 primer 5∏−ΧΤΤΓΓΑΓΓΧΧΓΑΓΓΑΧΧΤΓΓΑΓ−3∏
GPIGP15 primer 5∏−ΤΧΧΑΓΓΤΧΧΤΧΓΓΧΧΤΧΧΑΑΓΓ−3∏
Σεχτιον 2.6 Οϖερλαππινγ ΠΧΡ mετηοδ
The strategy used to generate full length cDNA involved PCR amplification of two overlapping
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PCR products. A 394 bp 5’ product was made by PCR amplification of 5’cDNA end clone
GP11 with GPIGP16 (5∏−ΓΓΑΧΤΓΓΧΤΧΧΤΧΧΧΧΓΧΓΓΑΧΑΤΓΓΤΓΓ−3∏) and GPIGP6 (5∏−
ΓΧΧΧΤΤΤΓΧΑΓΧΧΤΤΧΑΧΑΤΓΧΓΤΓΑΑΧΤΧΧ−3∏) primers. A 1056 bp was generated by PCR
amplification of clone GP1, using GPIGP4 and GPIGP3 primers. The general PCR reaction was
as follows.
2ml each primer
5ml 10* Taq polymerase buffer 
1ml 10 mM dNTP’s 
0.5 ml Template DNA (25 ng)
3.3ml Taq Polymerase Mix
36.2ml UHP water
The reaction was amplified under the following conditions, [ 94 C, 1 min; 56 C, 1 min; 72 C,
2 min ] for 25 cycles.The 394bp prodcut and 1056bp product were used in a two stage
amplification was used to generate the full length cDNA:
Reaction (A) 
5ml 10* Taq Polymerase buffer 
1 ml 10 mM dNTP’s
1ml 394bp product
1ml 1056bp product
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41.5 ml UHP water
The reaction was assembled and overlayed with 3 drops of mineral oil, then heated to 94 C for
1 min. 0.5ml of Taq polymerase was added to the reaction. DNA was then amplified under the
following conditions [ 94 C, 1 min; 57 C, 1 min; 72 C, 2 min ] for 10 cycles.
Reation (B):
5ml 10* Taq Polymerase Buffer 
1ml 10 mM dNTP’s 
2ml GPIGP16 primer 
2ml GPIGP3 primer 
1ml 10-fold diluted reaction (A) 
38.5ml UHP water
The reaction was assembled and overlayed with 3 drops of mineral oil, then heated to 94 C for
1 min. 0.5ml of Taq polymerase was added to the reaction. DNA was then amplified under the
following conditions [ 94 C, 1 min; 57 C, 1 min; 72 C, 2 min 30s ] for 25 cycles. 5ml of reaction
(B) was analysed on a 1% agarose gel. PCR produced was purified using a Qiagen QIAquick
PCR purification spin column (see general molecular biology methods section). A 1.4kb product
was produced and ligated into pGEM-T vector, and then transformed into XL1 Blue E.coli cells.
Putative clones termed α1-full-pGEM-T were mapped with the restriction enzymes Pst I, Sac
II, Not I and Eco 52I for verification of correct insert DNA.
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Σεχτιον 2.6.1 Χλονινγ οφ 1.4κβ χDΝΑ ιντο πΒΚ−ΧΜς
1.4kb cDNA was cloned into a mammalian expression vector, pBK-CMV. The 1.4kb cDNA
could not be cloned directly into pBK-CMV, and so was first cloned into pBluescript SK(+).
α1-full-pGEM-T and pBluescript SK (+) was cut with Sac II and Not I restriction enzymes.
Each restriction digest was run on a 0.8% agarose gel made with 1* TAE buffer. The 1.4kb insert
and linearised pBluescript SK(+) vector were gel excised and purified using the GeneClean II kit
( see general molecular biology techniques section) .The 1.4 kb insert and linearised pBluescript
SK(+) DNAs were ligated together and were transformed into XL1 Blue E.coli cells. Putative
α1-full-pBluescript clones were isolated. A Sac I / Not I double restriction enzyme digest was
performed to verify the presence of the the 1.4kb insert. α1-full-pBluscript DNA was then
purified using a Qiagen mini prep column. 
α1-full-pBluescript and pBK-CMV DNAs were digested with Sac I and Not I restriction
enzymes. Each restriction digest was run on a 0.8% agarose gel made with 1* TAE buffer. The
1.4kb insert and linearised pBK-CMV were gel excised and purified using GeneClean II kit. The
1.4kb insert and linearised pBK-CMV were ligated together and were transformed into XL1
Blue E.coli cells. Putative clones of full length cDNA-pBK-CMV ( gpigα-pBK-CMV) were
screened for the presence of an insert by restriction digest with a Sac I / Not I double digest.
gpigα-pBK-CMV DNA was purified using a quiagen mini-prep column. The 1.4kb insert in
gpigα-pBK-CMV was mapped with the following enzymes Xho I, Nar I, Eco 52I, Pst I, and
Bgl II for verification that the insert was was the correct product. gpigα-pBK-CMV DNA was
sequenced with the following primers in order to verify that the overlap between the 394bp and
1056 bp product had formed correctly and to also verify that the insert was correct.
GPIGP9: 5’-ΧΧΓΧΑΑΑΧΧΧΤΤΧΤΓΧΓΑΧΑΤΓ-3’
GPIGP12: 5’-ΧΤΓΤΧΧΧΓΓΤΧΑΧΑΓΓΤΓΑΓΓ-3’
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GPIGP16: 5∏−ΓΧΧΧΤΤΤΓΧΑΓΧΧΤΤΧΑΧΑΤΓΧΓΤΓΑΑΧΤΧΧ−3∏
gpigα-PBK-CMV plasmid DNA was maxi-preppeped using a Qiagen maxi prep column ( see
general molecular biology techniques section). The concentration of DNA was determined by
measuring the absorbance at 260 nm.
Σεχτιον 2.7 Ιν ϖιτρο τρανσχριπτιον ανδ τρανσλατιον
Promegas TNT Coupled Rabbit Reticulocyte Lysate System was used to produce PPARα and
RXRα receptors in vitro. The manufacturers protocol was followed.
DEPC treated water 6ml
TNT reaction buffer 2ml
RNase Inhibitor (Pharmacia) 1ml
Plasmid DNA ( 1mg) 1ml
RNA polymerase 1ml
Amino acid mixture (- Met) 1ml
TNT Rabbit Reticulocyte Lysate 25ml
[35S]-L-Methionine [ 1458Ci / mmol,12.25Ci / ml ] 3ml
Each reaction was incubated at 30 C for two hours, and then placed at 4 C until use. T3 RNA
polymerase and T7 RNA polymerase were used. gpigα-pBK-CMV, hPPARα-pBK-CMV and
pGEM-RXRα plasmid DNAs were all purified on Qiagen DNA puritication columns before
use. 10ml of each transcription / translation reaction was analysed on a 10 % SDS-PAGE gel. The
gels were dried and autoradiographed either on hyperfilm, or by using a BioRad G250 Phosphor
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Imaging system.
Σεχτιον 2.8 ΡΝΑ προτεχτιον ασσαψσ
Σεχτιον 2.8.1 Σψντηεσισ οφ ΡΝΑ προβεσ φορ ΡΝΑ προτεχτιον ασσαψ
General reaction:
5ml 5* TCS buffer
1 mg Linearised template plasmid DNA 
1ml 10 mM ATP, GTP, UTP 
1ml 0.75 mM DTT 
3 ml 12.5 mM [ α-32P ] CTP , specific activity 600 Ci/mmol 
3ml 10mM CTP 
1ml Sp6 or T7 RNA polymerase 
DEPC treated water to a final volume 25ml 
Components used:
DNase I
Phenol:chloroform (1v/1v)
3M sodium acetate (pH=5.2)
100% Ethanol 
Formamide solution
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The transcription assay was setup as listed above and incubated at 37 C for 1hour. 1ml of the assay
was diluted 10-fold with DEPC treated water. The diluted assay sample subjected to a DE81
assay to measure incorporation of labelled nucleotide into synthesised RNA. ( see DE81 assay
method) If incorporation of radiolabel greater that 10% was achieved 1 ml of DNase I was added
to the synthesis reaction to degrade template DNA. RNA probe was incubated with DNase I for
30 minutes at 37 C. The reaction was cleaned up by extraction with phenol:chloroform and by
precipitation by the sodium acetate/ethanol protocol. RNA was resolubilised in 20 ml of
formamide solution. RNA probe was stored for a maximum of 6 hours at -20 C until use in an
RNA protection assay.
Σεχτιον 2.8.2 Σψντηεσισ οφ [α−32Π]δΧΤΠ λαβελλεδ 100 βπ DΝΑ λαδδερ
Components used:
5ml 5* Labelling buffer: 50 mM Tris-HCl (pH=7.5), 250 mM NaCl, 50 mM MgCl2 
5ml 10mM dATP, dTTP, dGTP mix (Pharmacia)
5ml 100 bp DNA ladder [ ] = 1mg / ml
5ml [ α-32P ] dCTP ( 3.3 mM ) (Dupont ICN)
2ml Klenow (fragment of E.coli DNA polymerase) DNA polymeraes, 5U/ml (Nbl)
3ml UHP water
The above reaction was setup and incubated at room temperature for 2 hours. Incorporation of
radiolabelled nucleotide was measured by DE 81 assay.
Σεχτιον 2.8.3 Dετερmινατιον οφ γενε εξπρεσσιον λεϖελσ υσινγ αν ΡΝΑ προτεχτιον ασσαψ
Components used:
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Guinea pig total RNA
Yeast tRNA: 7 mg/ ul in DEPC water
32P-labelled RNA probe
Solution I: 80% formamide (v/v), 40 mM pipes (pH=6.7), 0.4 M NaCl, 1 mM EDTA
Solution II: 10 mM Tris-HCl (pH= 7.5), 0.35 M NaCl, 5 mM EDTA, 10 mg/ ml RNase A
100mg/ml Proteinase K
10% SDS (w/v)
Phenol:chlorofom (1v/1v)
3M sodium acetate (pH=5.2)
Denaturing load buffer: 80 % formamide (v/v), 10 mM EDTA (pH=8.0), 1 mg/ ml
Xylenecyanol FF, 1 mg/ ml bromophenol blue
1* TBE
6% denaturing urea-acrylamide gel:
Fixing solution
Hyperfilm
A bio-rad protean gel system was used. Sequagel concentrate and diluent was used to make 50ml
gels. The following formulae were used to determine the appropriate amounts of concentrate
and diluent to be used in oreder to make a certain fixed percentage gel.
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[ ( % acrylamide gel need) * ( volume of gel) ] / 25 = volume of concentrate needed
volume of gel - ( 1/10th volume of gel + volume of concentrate ) = volume of diluent
For a 6% gel 5ml of 10* TBE, 12 ml of concentrate and 33ml of diluent was mixed. 30ml of
TEMED and 500ml of 10% APS was added and mixed. The gel solution was pipetted in the gel
cast without introducing air bubbles. The comb was inserted into the gel and the gel was allowed
to set. After setting the gel was placed in the gel tank and 1* TBE was used to fill the anode and
cathode compartments. Unpolymerised acrylamide was washed out of each well using a syringe.
The gel was then heated to 55 C and pre-run at 50v for 1hour.
Σεχτιον 2.8.4 ΡΝασε προτεχτιον ασσαψ
30 mg of total RNA was precipitated by the ethanol / sodium acetate protocol. Two 30mg
aliqouts of tRNA were also precipitated. Pellets were stored at -20 C until use. 32P labelled RNA
probe was diluted 100 fold in solution I. 30ml of solution I was used to resolubilise each RNA
pellet. After resolubilisation of RNA tubes were heated to 85C for 3 minutes to denture RNA
secondary structure. Tubes were then switched to a 45 C waterbath and incubated overnight to
allow probe hybridisation. 350 ml of sultion II , minus RNase A was added to one tube
containing tRNA and probe. To the remaining tubes, 350 ml of solution II plus RNase A was
added. All tubes were incubated at 37 C for one hour. During this step all single strand RNA is
degraded. Duplex RNA is protected from degradation. 4ml of proteinase K and 20 ul of 10%
SDS was added to each tube, which were then incubated at 50 C for 45 minutes. Each protection
reaction was treated with 800 ml of phenol:chloroform. The aqueous phase was extracted and
ethanol / sodium acetate precipitated. Pellets were dissolved in 10ml of load buffer, heated to 85
C for 3 mins and then centrifuged. The sample was reheated to 85 C , centrifuged and then
loaded onto a 6% denaturing UREA- polyacrylamide gel. 1* TBE running buffer was stirred
throughout the electrophoresis. RNA samples were electrophoresed at 250v until the Xylene
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cyanol FF dye front had travelled at least 75% through the gel. The gel was fixed for 30 minutes
in fixing solution and then dried under vacuum. Dried gels were exposed to hyperfilm at -70 C
for between 1 and 3 days. Hyper film was developed according to the manufacturers instructions.
Σεχτιον 2.9 Τισσυε χυλτυρε προχεδυρεσ
Σεχτιον 2.9.1 Γροωτη ανδ Πασσαγε οφ Ηυmαν Εmβρψονιχ Κιδνεψ 293 χελλσ
293 cells are human embryonic kidney cells transformed with sheared human Ad5 DNA . A
frozen (-80 C) ampule of 293 cells was obtained from the European collection of animal cell
cultures.
Components used:
DFPS medium: 90% v/v DMEM-glutamax I ( -sodium pyruvate, + pyridoxine, + L-alanyl-L
glutamine), 10% foetal calf serum, 26mg / ml penecillin G, 8.2 mg / ml streptomycin.(0.22mM
filtered), pre-warmed to 37 C before use.
1* PBS: 0.21g/l KH2PO4, 9g/l NaCl, 0.726 g/l Na2HPO4.7H2O (pH= 7.2)
25cm2 Falcon flasks
trypan blue dye
37 C incubator with 5% CO2 and humidification
Σεχτιον 2.9.2 Ρεσυρρεχτιον οφ φροζεν 293 χελλσ
Cells were thawed at room temperature for 1 minute, then warmed to 37 C until fully thawed.
10 ml DFPS media was added to the cells, which were then pelleted by centrifugation at 100 g
for 5 minutes. The supernatant was extracted and the cells resuspended in 5 ml of DFPS media,
and then put into a single culture flask and incubated for 1 week. At the 1st passage the culture
media was removed from the flask and the confluent cell layer was detached by washing with 5
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ml of 1*PBS. Cells were pelleted by centrifugation at 100g for 5 mins. The supernatant was
discarded and the cells were resuspended in 5 ml of DFPS medium. 0.5ml of cells was seeded
into 4.5ml of DFPS medium in new culture flasks and incubated for1 week. Flasks with confluent
cell layers were chosen for further passage and experimentation.
Σεχτιον 2.9.3 Πασσαγε οφ 293 χελλσ
Medium from flasks containing confluent cell layers was removed and the cells detached by
washing with 5 mL 1* PBS + 0.5mM EDTA for 5 mins at 37 C. 293 cells were pelleted by
centrifugation at 100g for 5 minutes and then resuspended in 1 ml of DFPS medium. Total cell
number and cell viability were determined by the following procedure. 100ml of resuspended
cells were added to 20 ml of trypan blue dye. 20 ml of these cells were placed onto a
haemocytometer. The total number of cells per square and the total number of blue cells per
square were counted for five squares. Viable cells do not take up the blue dye as their membrane
is still intact. The percentage of viable cells was calculated from the following equation:
[ (total number of cells counted- total number of blue cells)/100 ] * 100
The total number of cells resuspended is calculated from the following equation:
mean number of cells per square * 400000 (number of squares in 1 ml) * 0.83 (dilution factor of
dye assay)
The total number of viable cells can be got from multiplying the percent of viable cells by the
total number of cell in 1 ml. 0.5 * 106 viable cells were seeded into DFPS medium (total volume
= 5 ml) for cell propagation flasks and for transfection experiments. All flasks were incubated at
37 C, with humidification.
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Σεχτιον 2.9.4 Σψντηεσισ οφ χατιονιχ λιποσοmε τρανσφεχτιον ρεαγεντ
Components used:
Dope: 10 mg / mL L-a-phosphatidylethanolamine, dioleoyl ( C18:1, [cis]-9 ), dissolved in 1ml
chloroform.(Sigma)
Dotma: 10 mg (N-[I-(2,3-dioleyloxy)propyl]-N,N,N-triethylammonium) (generous gift from
C.Elcombe , Zeneca CTL)
Nitrogen Gas
Sterile UHP water
10 mg Dotma was dissolved in 1 mL of Dope, and dryed at room temperature under nitrogen
gas and in the dark. The dried dotma/dope mix was dissolved in 2ml of sterile UHP water and
then sonicated in a 50-60Hz, 80watts Polaron Sonibath for 5 minutes. An opaque particulate
solution was formed and stored at 4 C. Final concentration of dotma / dope mix was 5mg /ml.
Σεχτιον 2.9.5 Σψντηεσισ οφ (ΑΧΟ−ΠΠΡΕ)2.πΓΛ3−Λυχ ρεπορτερ ϖεχτορ
Components used:
pGL3-Luc promoter vector (Promega)
Long (ACO-PPRE)2 primer A: 5∏−ΧΧΧΓΑΑΧΓΤΓΑΧΧΤΤΤΓΤΧΧΤΓΓΤΧ
ΧΧΧΤΧΧΓΑΑΧΓΤΓΑΧΧΤΤΤΓΤΧΧΤΓΓΤΧΧΧΧΤΤΑ−3∏
Long (ACO-PPRE)2 primer B: 5∏−ΓΑΤΧΤΑΑΓΓΓΓΑΧΧΑΓΓΑΧΑΑΑΓΓΤΧΑ
ΧΓΤΤΧΓΓΑΑΓΓΓΓΑΧΧΑΓΓΑΧΑΑΑΓΓΤΧΑΧΓΤΤΧΓΓΓΑΓΧΤ−3∏
1mg pGL3-Luc promoter vector was cut with Sac I and Bgl II restriction enzymes. The linearised
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plasmid was run on a 0.7% agarose gel run in 1* TAE. The cut plasmid was gel excised and
purified by Gene Clean II kit. The cut pGL3-Luc vector was resolubilised in 12 ml of UHP
water. The following ligation reaction was setup and incubated at 4 C overnight.
1ml 10* T4 DNA ligase buffer: 300mM Tris-HCl (pH=7.8), 100 mM MgCl2, 100 mM DTT,
5 mM ATP
1ml Sac I / Bgl II cut pGL3-Luc vector
3ml Long (ACO-PPRE)2 primer A
3ml Long (ACO-PPRE2) primer B
1ml T4 DNA ligase in 10 mM Tris-HCl (pH=7.4), 50 mM KCl, 1 mM DTT, 0.1 mM EDTA,
50% Glycerol
1ml UHP water
5 ml of ligation reaction was transformed into CaCl2  competent XL1 blue E.coli. Putative (ACO-
PPRE)2.pGL3-Luc clones were screened for the loss of the Mlu I polylinker restriction site.
Positive clones which had lost the Mlu I site were sequenced with RV3 primer (5’-
ΧΤΑΓΧΑΑΑΑΤΑΓΓΧΤΓΤΧΧΧ-3’). (ACO-PPRE)2.pGL3-Luc vector was Quiagen Maxi-
prepped.
Σεχτιον 2.9.6 293 χελλ τρανσφεχτιον προτοχολ
Components used:
Dotma / Dope cationic liposome mixture
DMEM medium
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Qiagen pure plasmid DNA ( maxiprepped DNA)
Solution A: (5-12 mg DNA + 300 ul DMEM ) * number of flasks to be transformed
Solution B: (5ml dotma / dope mix + 300 ul DMEM) * number of flasks to transformed
Soltion A and B were made up in the class II cabinet and left to stand at room temperature for
40 mins. A and B were then mixed and left to stand for a minimum of 15 mins to form solution
C. Whilst A and B were being incubated together, medium from the flasks to be transformed
was removed. The attached cells were washed with no agittation in 1* PBS for 20 seconds. The
PBS was removed and 2.4 ml of DMEM added to each flask. When solution C had completed
its minimum incubation period, 600 ml of this solution was added to each flask. The flasks were
incubated at 37 C with 5% CO2 and humidification for 4 hours. After 4 hours the transfection
medium was removed and replaced with 5 ml of DMEM medium. Flasks were then cultured for
2 days .
Σεχτιον 2.9.7 β−γαλαχτοσιδασε ηιστοχηεmιστρψ (Σανεσ, ϑ.Ρ. ετ αλ 1986)
Components used:
1* PBS: 150 mM NaCl, 15 mM Na2H2PO4 (pH=7.3)
Fixing solution: 2% Formaldehyde (v/v), 0.2% glutaraldehyde (v/v) in 1* PBS 
Developing reagent: 5 mM Ferricyanide, 5 mM Ferrocyanide, 2 mM MgCl2 in 1* PBS ( stored
in the dark at 4 C.)
5-bromo-4-chloro-3-indolyl-β-D-galactoside (X-Gal): 40 mg/ml in DMSO (stored at 20 C)
Culture media from transfected flasks was removed. 3ml of fixing solution was added to each
flask, which were then icubated at 4 C for 5 minutes. The fixing solution was removed and flasks
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were washed with 3ml of 1* PBS. 3ml developer reagent was added to each flask , along with
75 ml of X-gal. Flasks were incubated at 37 C overnight. Transformed cells develop a blue
cytoplasm and can be easily distinguished from non-transformed cells.
Σεχτιον 2.9.8 Χελλ εξτραχτ ηαρϖεστινγ φορ ρεπορτερ ασσαψσ
Components used:
1* PBS : 150 mM NaCl, 15 mM Na2H2PO4 (pH=7.3)
1* Reporter lysis buffer (Promega)
1* Passive lysis buffer (Promega)
Medium from transfected flasks was removed and the cell layer was washed without agitation
with 5 ml 1* PBS. For extracts for CATand Firefly luciferase assays the 1* PBS was removed and
900 ml of 1* reporter lysis buffer was added to each flask. Flasks were rocked for 5 mins and then
scraped with a tissue culture cell scraper. Cell extract was pipetted into a microfuge tube. Extracts
to be assayed for CAT activity and Firefly luciferase activity were snap frozen in liquid nitrogen,
and then immediately thawed at room temperature, vortexed and then centrifuged at 15000 rpm
for 15 seconds. The supernatant was transferred to fresh tubes and stored at -70 C until required
for assaying. For extracts for dual luciferase assays, the 1* PBS was removed from each flask and
900ml of 1* passive lysis buffer was added. Flasks were rocked for 5 mins and then scraped with
a tissue culture cell scraper. Cell extract was pipetted into a microfuge tube and placed on ice
until use.
Σεχτιον 2.9.9 Χηλοραmπηενιχολ αχετψλτρανσφερασε ασσαψ
Components used:
[ D-threo-[dichloroacetyl-1-14C] Chloramphenicol, 54 miCi / mmol (Amersham)
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1M Tris (pH =8.0)
25 mM n-butyryl-Coenzyme A
1.208 mg /ml Chloramphenicol in 2% Ethanol
UHP water
Transfected cell extract
5 ml Polystyrene tubes (Sarstedt cat. no. 55-476)
Xylene:2,6,10,14-Tetramethyl-pentadecane (1v:2v)
Hi-Safe Scintillation liquid
20 ml of cell extract was mixed with 30 ml of UHP water and was incubated at 65 C for 15
minutes. The tube was spun and then 10 ml Tris (pH= 8.0), 10 ml n-butyryl-CoA, 5ml [14C]-
Chloramphenicol and 25ml of Chloramphenicol were added. Reactions were incubated
overnight at 37 C. 200ml of Xylene:TMPD was added to each reaction, which were then
vortexed thoroughly, and then centrifuged for 5 min in a benchtop centrifuge at maximum rpm.
The xylene phase was pipetted into 3ml of scintillation fluid. Reactions were counted for 1
minute on a 14C program in a Packard 1900 TR Liquid scintillation analyser.
Σεχτιον 2.9.10 Φιρε⇓ψ λυχιφερασε ασσαψ
Components used:
Luciferase assay system (Promega)
Cell extract
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Cell extracts were prepared using 1* reporter lysis buffer. 20ml of cell extract was mixed with
100 ml of Luciferase assay reagent (Promega) in a tube, and placed in a Packard (PICO-LITE)
luminometer analyser. Luminesence was measured for ten, 10 s periods. The average
luminesence over this period was used as the final measurement.
Σεχτιον 2.9.11 Dυαλ λυχιφερσε ασσαψ
Components used:
Luciferase assay reagent II (Promega)
Stop & Glo reagent (Promega)
Cell extracts were prepared using 1* passive lysis buffer. 20 ml of cell extract was added to 100
ml luciferase assay reagent II. The luminesence of the Firefly luciferase reaction was taken over
four 10s intervals in a Packard (PICO-LITE) luminomter. 100ml of Stop & Glo reagent was then
added to the tube and the luminesence of the Renilla luciferase reaction was taken over four 10s
intervals. The average luminesence for each luciferase assay was used as the final measurement.
Σεχτιον 2.10 Χλονινγ οφ ΠΠΑΡα DΝΑ βινδινγ δοmαιν
A 335bp cDNA fragment corresponding to amino acids 95G -198S of mPPARα DNA binding
domain was amplified by PCR from the full length mPPARα cDNA. Two mismatch
oligonucleotide primers were designed, such that a Pst I restriction endonuclease site was
engineered at the 5’ end of the PCR fragment , and that a translation stop codon was engineered
at the 3’ end of the PCR fragment. The DBD DNA fragment was subcloned into pRSETA, a
prokaryotic expression vector that contains an in-frame N-terminal His*6 tag and enterokinase
cleavage site. The pRSETA-mPPARα-DBD vector was transformed into the BL21 (DE3) pLys
S strain of E.coli, specially designed for high level protein expression. Fusion protein expression
is driven by the addition of IPTG to the culture media. BL21 (DE3) cells contain bacteriophage
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DE3, a lambda derivative that carries a DNA fragment containing the lacI gene, lacUV5
promoter, the beginning of the lacZ gene and the gene for T7 RNA polymerase. T7 RNA
polymerase transcription is inducible by IPTG. The T7 RNA polymerase can then transcribe the
mPPARα-DBD fusion protein from the T7 promoter present in the pRSETA vector. BL21
(DE3) pLys S cells carry a plasmid which expresses low levels of T7 lysozyme, an inhibitor of T7
RNA polymerase. The low level expression of T7 lysozyme inhibits any basal expresion of fusion
protein which may be cytotoxic to the cell. The low level of T7 lysozyme does not interfere with
induced expression as large amounts of T7 RNA polymerase are produced. It may however cause
a lag in the production of target protein.. The presence of pLys S has a secondary advantage. T7
is a bifunctional protein and also has the ability to cut specific bonds within the peptidoglycan
layer of the E.coli cell wall. This aids lysis of the cells after a freeze thaw cycle (Mierendorf, R. et
al 1994 and Tabor, S. 1990).
Components used:
1ml Taq DNA polymerase (in 50 % glycerol, 50 mM Tris-HCl (pH=8.0), 100 mM NaCl, 0.1
mM EDTA, 5 mM DTT, 1% Triton X-100. Promega) 
5ml 10 * Polymerase buffer: 500 mM KCl, 100 mM Tris-HCl (pH=9.0), 1% Triton X-100
0.5ml 20 mM dATP, dGTP, dCTP, dTTP mix
2.5ml 25 mM MgCl2 
0.5ml upstream primer : 5∏−ΓΑΓΤΧΧΧΧΧΤΓΧΑΓΤΓΧΧΧΤΓ−3∏ ( 35 pmol /ml )
0.5ml downstream primer : 5∏−ΓΑΓΓΤΧΤΓΧΑΓΤΤΤΑΧΓΑΑΤΧ−3∏ ( 35 pmol / ml )
2ml pGEM-7 -mPPARα plasmid ( 1.3 mg / ml ) 
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40 ml UHP water
1.5% Agarose (1* TBE ) gel
The above PCR reaction was assembled minus the Taq DNA polymerase, along with a negative
control reaction lacking template DNA and minus polymerase. Two drops of mineral oil were
overlaid onto each reaction. Reactions were heated to 94 C and then the Taq DNA polymerase
added. The following cycle conditions were used, [ 94 C 1min, 50 C 1min, 72 C 1min ] for 15
cycles. 5ml of each reaction were analysed on a 1.5% agarose gel. The 335bp fragment was gel
purified with Geneclean II kit and restriction digested with Pst I. The bacterial vector pRSET A
was resticted with Pst I and then treated with Shrimp Alkaline Phosphatase I. The digested
mPPARα-DBD fragment and pRSET A were ligated and transformed into electrocompetent
XL1 Blue E.coli cells. Cells were plated on Tet/Amp plates and grown for 24 hour. Individual
colonies were cultured and DNA purified by the alkaline lysis method. DNA preps with putative
inserts were digested with Kpn I enzyme. Plasmids containing an insert in the correct orientation
produced a 274 bp fragment. pRSETA-mPPARα-DBD positives were purifed with Qiagen
Plasmid purification kit. pRSETA-mPPARα-DBD DNA was transformed into
BL21(DE3)pLysS E.coli cells using a CaCl2 protocol and plated onto Chl / Amp plates.
Σεχτιον 2.11 Χλονινγ οφ τηιορεδοξιν−mΠΠΑΡα φυσιον 
Pst I cut pThio-His.A was run on a 1% TAE gel at a constant 100v for 1hour 30 min. The
linearised plasmid band was gel excised and purified using Geneclean II Kit (see general
molecular biology techniques section). Purified Pst I cut pThio-His.A was ligated with Pst I cut
mPPARα-DBD PCR fragment at 4 C for 2 days. The ligation mix was transformed into CaCl2
competent XL-1 blue E.coli. 12 colonies were picked and grown overnight in 5ml cultures.
DNA was purified by the alkaline lysis method, and then digested with Pst I and Bgl II restriction
enzymes for verification of the presence and orientation of the DNA insert. pThio-His.A-
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mPPARα-DBD DNA was transformed into BL21 (DE3) pLys S E.coli.
Σεχτιον 2.12 Εξπρεσσιον οφ DΒD φυσιον προτεινσ ιν Ε.χολι
Σεχτιον 2.12.1 Σmαλλ σχαλε χυλτυρεσ
Components used:
pRSETA-mPPARα-DBD BL21 (DE3) pLys S E.coli
LB-Chl / Amp media
IPTG
15% SDS-PAGE gel
Several colonies of pRSETA-mPPARα-DBD BL21 (DE3) pLys S E.coli were cultured at 37 C
with shaking in 10 ml of LB-Chl / Amp media. Cultures were grown until on OD600nm of 0.6-
0.8 had been reached. 2ml of uninduced culture was saved and put onto ice. IPTG was added to
each culture at a final concentration of 0.5 mM. A control culture of BL21 (DE3) pLys cells was
grown and induced with IPTG as well. After three hours induction at 37 C with shaking, 2 ml
of each culture was centrifuged to pellet the cells. 100 ml of 2*SDS-load buffer was used to
resuspend the cells, which were then boiled for 5 minutes. 10ml from each boiled sample was
analysed on a 15% SDS-page gel.
Σεχτιον 2.12.2 Λαργε σχαλε χυλτυρε
Components used:
pRSETA-mPPARα-DBD BL21 (DE3) pLys S E.coli or pThio-His.A-mPPARα-DBD BL21
(DE3) pLys S E.coli
LB-Chl / Amp media
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IPTG
Talon bind buffer: 50 mM NaH2PO4, 10 mM Tris-HCl (pH=8.0), 100 mM NaCl, 200mM
ZnSO4, 5% Glycerol
Denaturing Talon bind buffer: 50mM NaH2PO4, 10 mM Tris-HCL (pH=8.0), 6M
Guanidinium HCl, 100 mM NaCl, 5% Glycerol 
Invitrogen ProBond Binding Buffer:20mM Sodium Phosphate, 500 mM NaCl, pH=7.8
15% & 20% SDS-PAGE gels
A colony of pRSETA-mPPARα-DBD BL21 (DE3) pLys S E.coli or pThio-His.A-mPPARα-
DBD BL21 (DE3) pLys S E.coli was cultured at 37 C with shaking in 10 ml of LB-Chl / Amp
media. Four 2.5ml aliquots of this culture was used to seed four 500ml aliquots of LB-Chl / Amp
media. Each 500 ml culture was grown at 37 C with shaking to an OD600nm = 0.6-0.8 and then
induced to express mPPARα-DBD fusion protein by the addition of IPTG to a final
concentration of 0.5mM. Culturing was continued for a further 3 hours. Cells were harvested
by centrifugation in a JA14 rotor at 7000rpm, 4 C for 15mins. Cell pellets were resuspended in
Talon bind buffer or ProBond Binding buffer, 2ml per 25ml of centrifuged culture. Cells were
freeze thawed once and then sonicated in six, 15 second bursts to lyse the cells. Soluble and
insoluble material was separated by ultra-centrifugation in a TLX optima centrifuge and
TLA120.2 rotor at 100000 rpm for 8 minutes at 4 C. Soluble proteins were stored at -20 C until
required. Insoluble material was solublised in 20 ml of denaturing talon buffer, and stored at -20
C until needed. The protein concentration of the soluble and insoluble fractions was determined
by bradford assay. 12.5mg of each protein sample was analysed on a 15% SDS-PAGE gel.
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Σεχτιον 2.13 Πυρι⇒χατιον οφ DΒD φυσιον προτεινσ
Σεχτιον 2.13.1 Χλοντεχη Ταλον αφ⇒νιτψ ρεσιν 
Components used:
Talon Metal Affinity resin 
Wash buffer: 50 mM NaH2PO4, 10 mM Tris-HCl (pH=8.0), 100 mM NaCl, 5% Glycerol
Elution buffer: 50 mM NaH2PO4, 10 mM Tris-HCl (pH=6.2), 100 mM NaCl, 5% Glycerol
Denaturing Talon wash buffer: 50mM NaH2PO4, 10 mM Tris-HCL (pH=8.0), 6M
Guanidinium HCl, 100 mM NaCl, 5% Glycerol 
Denaturing Talon elution buffer: 50mM NaH2PO4, 10 mM Tris-HCL (pH=6.2), 6M
Guanidinium HCl, 100 mM NaCl, 5% Glycerol 
Dialysis buffer: 25 mM Hepes (pH=7.6), 100mM NaCl, 400mM ZnSO4
Native and denatured protein samples were incubated with talon affinity resin to purify His*6
tagged proteins. 3ml of Talon affinity resin (packed volume) was aliquoted into a 50ml falcon
tube. The tube was spun at 700g for 5mins then the supernatant was extracted and discarded.
The resin was resuspended in 15ml talon bind buffer, and centrifuged again at 700g for 5mins.
The supernatant was discarded. This wash step was repeated one more time, then 10ml of the
native protein sample was applied to the resin.The protein solution and resin was mixed slowly
at room temperature for 20mins, and then centrifuged at 700g for 5mins. The supernatant was
collected and stored at -20 C. 30 ml of Talon wash buffer was used to resuspend the resin. The
tube was agititated gently for 5mins at room temperature. The resin was pelleted by
centrifugation at 700g for 5mins. The wash solution was discarded. The resin was washed twice
more by the same procedure. 3ml of elution buffer was used to resuspend the talon resin
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pellet.The elution buffer and resin were mixed at room temperture for five minutes, and then
centrifuged at 700g for 5mins. The supernatant was collected and stored at -20 C. Two more
elution steps were carried out. The native protein sample, unbound protein sample and each
elution sample were analysed on a 15% SDS-PAGE gel. Talon resin was recycled as instructed
by the manufacturer. His*6 tagged proteins were purified from the denatured protein sample
using the same method as used for native proteins, except that denaturing buffers were used.
Elutions 1 and 2 were dialysed against 5* 600ml of dialysis buffer over a 2 hour period at room
temperature. Dialysed protein samples were analysed on a 20 % SDS-PAGE gel.
Σεχτιον 2.13.2 Ινϖιτρογεν ΠροΒονδ Ρεσιν
Components used:
Invitrogen prepacked ProBond resin column
Binding buffer: 20mM Sodium Phosphate, 500 mM NaCl, pH=7.8
Wash buffer: 20mM Sodium Phosphate, 500 mM NaCl, pH=6.0
Imidazole elution buffers:20mM Sodium Phosphate, 500 mM NaCl, pH=6.0 plus 50, 200, 350
or 500 mM imidazole.
ProBond resin was equilibrated with binding buffer prior to addition of soluble protein extract,
acording to the instruction manual. The resin in the prequilibrated ProBond column was
resuspended in 5 ml of soluble protein extract (see large scale culturing of fusion proteins). The
column was capped and gently rocked for 10 minutes. The resin was pelleted by low speed
centrifugation (< 800g), the supernatant removed , and then stored on ice. A further 5 ml of
soluble protein extract was bound to the resin using the same procedure. The column resin was
washed twice with three 4 ml aliquots of wash buffer, by resuspending the resin and rocking for
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two minutes, and then centrifugation at low speed to pellet the resin. The supernatant was
removed from each wash and stored on ice. Proteins were eluted from the resin by sequential
addition of 5 ml of each imidazole elution buffer. The resin was incubated in each elution buffer
for 5 minutes with gentle rocking, then pelleted by centrifugation. The supernatant from each
elution was collected and analysed for proteins by SDS-PAGE. The ProBond rsein was recharged
according to instructions in the ProBond resin manual.
Σεχτιον 2.14 Ιν ϖιτρο χουπλεδ τρανσχριπτιον/τρανσλατιον
Components used:
6ml DEPC treated water 
2ml TNT reaction buffer (Promega)
1ml RNase Inhibitor (Pharmacia) 
1ml Plasmid DNA ( 1mg) 
1ml RNA polymerase (Promega)
1ml Amino acid mixture (- Met) (Promega)
25ml TNT Rabbit Reticulocyte Lysate (Promega)
3ml [ 35S]-L-Methionine [ 1458Ci / mmol,12.25Ci / ml ] (Dupont ICN)
Each reaction was incubated at 30 C for two hours, and then placed at 4 C until use. T3 RNA
polymerase and T7 RNA polymerase were used. Qiagen purified pRSETA-mPPARα-DBD,
pGEM-mRXRα and pT7-7.mPPARα DNAs were used. 10ml of each transcription /
translation reaction was analysed on a 15 % SDS-PAGE gel. The gels were dried and
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autoradiographed on hyperfilm. 
Σεχτιον 2.15 Ελεχτροmοβιλιτψ σηιφτ ασσαψ mετηοδολογιεσ
Synthesis of [ α-32P ] dCTP labelled con-4A6z-PPRE probes
Components used:
3ml 5* Labelling buffer: 50 mM Tris-HCl (pH=7.5), 250 mM NaCl ,50 mM MgCl2 
5ml 10mM dATP, dTTP, dGTP mix (Pharmacia)
2ml PPRE primer oligonucleotide (35 pmol /ml ) 5∏−ΧΧΧΤΓΑΧΧ−3∏
1ml PPRE oligonucleotide (35 pmol / ml) 5∏−ΧΑΑΑΑΧΤΑΓΓΤΧΑΑΑΓΓΤΧΑΓΓΓ−3∏
5ml [ α-32P ] dCTP ( 3.3 mM )
1ml Klenow DNA polymerase (fragment of E.coli DNA polymerase), 5U/ml (NBL)
5ml UHP water
The labelling assay was setup with the appropriate PPRE primers and oligonucleotides and was
incubated at room temperature after the addition of Klenow polymerase for 2 hours. Synthesis
of labelled probe was measured by DE 81 assay. Single mutant and double mutant ACO-PPRE
probes were synthesised by the same method, using appropriate mutant oligonucleotides 
Σεχτιον 2.15.1 Ελεχτροmοβιλιτψ σηιφτ ασσαψσ
Components used:
Native polyacrylamide gels
0.25* TBE
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Liver nuclear protein extracts
In vitro translated proteins
32P-labelled PPRE probes
p(dI-dC.dI-dC) (Pharmacia)
1* Hepes EMSA buffer: 10mM Hepes (pH=7.9), 125 mM NaCl, 0.1mM EDTA, 7% v/v BSA,
1 mM DTT, 150mM PMSF
Incubation reactions of liver nuclear proteins or in vitro translated proteins with PPRE probes
were setup, in the presence or absence of non-specific competitor DNA. The incubation
reactions were either carried out at room temperature or on ice, then electrophoresed on an
appropriate percentage native polyacrylamide gel in 0.25* TBE running buffer. Gels were dried
and autoradiographed either on hyperfilm or by phosphoimaging on a Bio-Rad GS250
Molecular imager.
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Chapter 3 Results
Σεχτιον 3.1 Ρατ λιϖερ νυχλεαρ προτειν βινδσ σπεχι⇒χαλλψ το α ΠΠΡΕ
It has previously been shown that rat liver nuclear proteins (rLNP) bind to the rat acyl-CoA
oxidase gene PPRE (Osumi, T. et al 1993). To investigate PPARα binding to its cognate
response element, nuclear receptors were isolated from liver tissue samples, allowing functionally
active PPARα receptors to be assayed. Using in vivo protein samples, the effects of dosing rodents
with peroxisome proliferators, on the levels of PPARα can be investigated. rLNP were isolated
and tested for binding to peroxisome proliferator response elements using electromobility shift
assays. The acyl-CoA oxidase PPRE was synthesised as an oligonucleotide containing the
sequence 5∏−ΤΓΑΧΧΤ Τ ΤΓΤΧΧΤ−3∏, and labelled with [α-32P] dCTP, by using Klenow
DNA polymerase. Incorporation of labelled nucleotide ranged from 45% to 90%. Non-[32P]
labelled probes were made using unlabelled dCTP and [3H] dCTP, for use in competition
binding assays, to demonstrate that binding to the 32P labelled probe to LNP samples was
saturable. Figure 3.1shows that the binding of rat LNP to ACO-PPRE was not competed out
by an excess of  non-specific competitor DNA. Figure 3.2 demonstrates that an excess of
-LNP
p(dI-dC.dI-dC)
-p(dI-dC.
dI-dC)
1 2 3 4 5 6 7 8
Shifted
Complex
Unbound
probe
Figure 3.1 Rat liver nuclear protein binds specifically to an acyl-CoA oxidase gene PPRE. 0.165
pmol [32P]-labelled ACO-PPRE probe was incubated with 11mg rat LNP at room temperature for 30 min in 1*Hepes
EMSA buffer (10mM Hepes (pH=7.9), 125 mM NaCl, 1mM EDTA, 7% v/v BSA, 1 mM DTT, 150mM PMSF). Protein-
DNA complexes were resolved on a 10% native polyacrylamide gel in 0.25*TBE, at 4 C. Lane 1 has no non-specific
competitor DNA, lanes 2 to 7 have increasing amounts of poly (dI-dC.dI-dC) competitor DNA, 64ng, 128ng, 384ng,
800ng, and 1440ng respectively. Lane 8 contains no LNP. Radioactivity was visualised by phosphor-imaging on a
Bio-Rad GS250 Molecular imager.
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unlabelled ACO-PPRE can specifically compete out rLNP binding to [32P] labelled ACO-
PPRE. These two results demonstrate that the shifted complex formed between rLNP and
ACO-PPRE is specific and is saturable. The binding of the receptors to DNA probes in an in
vitro assay may be less stable at room temperature. Experiments were carried out to see if this
was occuring. Figure 3.3, lanes denoted B shows that rLNP and ACO-PPRE can form a specific
complex at both room temperature and on ice. There was no observable difference in the
amount, or pattern of receptor binding when the incubation step was carried out at room
temperature or on ice.
The non-specific competitor DNA used in the EMSA assays was a synthetic DNA molecule
containing nucleotide, deoxyinosine, not found in cellular DNA. It is possible that this synthetic
DNA is inappropriate for demondstrating that the binding of nuclear receptors to the PPRE is
sequence specific. Therefore the binding of rLNP was assayed with PPREs containing a single
nucleotide change. If an excess of these mutant PPREs could compete for binding to rLNP it
would show that the observed shifted complex was formed from a non-specific binding
- [3H]-ACO
PPRE
[3H]-ACO-PPRE
- LNP
1 2 3 4 5 6 7 8
Shifted
complex
Figure 3.2 Rat LNP binding to ACO-PPRE is saturable. 41 fmol [32P]-labelled ACO-PPRE probe was incu-
bated with 11mg rat LNP and 625 ng p(dI-dC.dI-dC) at room temperature for 30 min in 1*Hepes EMSA buffer (10mM
Hepes (pH=7.9), 125 mM NaCl, 1mM EDTA, 7% v/v BSA, 1 mM DTT, 150mM PMSF). Protein-DNA complexes were
resolved on a 10% native polyacrylamide gel in 0.25*TBE, at 4 C. Binding was assayed with increasing amounts of
[3H] ACO-PPRE, lanes 2 (1.6 pmol), 3( 3.3 pmol),4(5 pmol),5 (13.2 pmol), 6 (33.2 pmol) and 7 (66.4 pmol), the
absence of [3H] ACO-PPRE lane 1 and in the absence of LNP, lane 8. Radioactivity was visualised using a Bio-Rad
GS250 Molecular Imager.
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interaction. [32P]dCTP and [3H]dCTP labelled ACO-PPRE probe containing a single mutation
at position 3 in the PPRE (5∏−ΤΓΓΧΧΤ Τ ΤΓΤΧΧΤ−3∏) was synthesised. The single mutant
ACO-PPRE (mACO-PPRE) was a very poor competitor substrate in binding assays containing
rLNP and ACO-PPRE. Figure 3.4A, lane 3 shows that [ 3H]-mACO-PPRE failed to
completely compete out the binding of rLNP to ACO-PPRE at greater than 10000 fold molar
excess. When [32P] labelled mACO-PPRE is used as a binding substrate with an excess of non-
Shifted
complex
Unbound 
probe
Incubation
on ice
Incubation at
room temperature-r LNP
A B C A B C
Figure 3.3  Effect of incubation temperature on ACO-PPRE EMSA. 0.165 pmol [32P]-labelled ACO-PPRE
probe was incubated with 11mg rat LNP and with either A-no p(dI-dC.dI-dC), B- 625ng p(dI-dC.dI-dC) or C- an excess
of unlabelled ACO-PPRE( 33.2 pmol) for 30 min at the indicated temperature in 1*Hepes EMSA buffer (10mM Hepes
(pH=7.9), 125 mM NaCl, 1mM EDTA, 7% v/v BSA, 1 mM DTT, 150mM PMSF). Protein-DNA complexes were resolved
on a 7.5% native polyacrylamide gel in 0.25*TBE, at 4 C. Radioactivity was visualised using a Bio-Rad GS250 Mo-
lecular Imager.
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Figure 3.4 Rat LNP does not bind efficiently to a mutant ACO-PPRE. 1.8 fmol [32P]-labelled ACO-PPRE
probe (A) or 4.7 fmol [32P]-labelled mACO-PPRE probe (B) was incubated with 11mg rat LNP (lanes 1-4 and 6-9)at
room temperature for 30 min in 1*Hepes EMSA buffer (10mM Hepes (pH=7.9), 125 mM NaCl, 1mM EDTA, 7% v/v
BSA, 1 mM DTT, 150mM PMSF). Lanes 1 and 6 had the additiion of 1mg p(dI-dC.dI-dC), lanes 2 and 7 had the addition
of 13.2 pmol [3H]-ACO-PPRE, plus1mg p(dI-dC.dI-dC), lanes 3 and 8 had the addition of 20 pmol [3H]-mACO-PPRE
plus1mg p(dI-dC.dI-dC),lanes 4 and 9 no p(dI-dC.dI-dC) and lanes 5 and 10 no LNP was added. Protein-DNA complex-
es were resolved on a 7.5% native polyacrylamide gel in 0.25*TBE, at 4 C. Free probe was run off the gel. Radiation
was visualised by phosphor-imaging on a Bio-Rad GS250 Molecular Imager.
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specific competitor DNA no specific shifted complex is observed, see figure 3.4B. These results
demonstrate that rLNP binding to ACO-PPRE is highly sequence specific.
A double mutant ACO-PPRE (dmACO-PPRE) containing two mutations at position 2 and 3
in the PPRE (5’-TTGCCT T TGTCCT-3’) was synthesised and labelled with [32P] dCTP. This
dmACO-PPRE was assessed for binding to rLNP in an electromobility shift assay. Figure 3.5,
lane 2 demonstrates that rLNP does not bind to dmACO-PPRE in the presence of an excess of
non-specific competitor DNA. 
Σεχτιον 3.1.1 Μουσε λιϖερ νυχλεαρ προτεινσ βινδ σπεχι⇒χαλλψ το α ΠΠΡΕ
Purified mouse liver nuclear proteins (mLNP) were assessed for binding to rat acyl-CoA oxidase
PPRE using an electromobility shift assay. Figure 3.6 demonstrates that a specific protein-DNA
complex is formed between mLNP an ACO-PPRE containing the sequence 5∏−ΤΓΑΧΧΤ Τ
ΤΓΤΧΧΤ−3∏. An excess of non-specific competitor DNA did not abolish mLNP-ACO-PPRE
complex formation. Increasing amounts of mLNP incubated with ACO-PPRE results in an
1 2 3 4
Specific
complex
Unbound
probe
Figure 3.5 rLNP does not bind to a double mutant ACO-PPRE. 0.113 pmol [32P]-labelled ACO-PPRE
probe was incubated with 11mg rat LNP at room temperature for 30 min in 1*Hepes EMSA buffer (10mM Hepes
(pH=7.9), 125 mM NaCl, 1mM EDTA, 7% v/v BSA, 1 mM DTT, 150mM PMSF), in the presence (lane 1) and ab-
sence (lane 3) of 1mg p(dI-dC.dI-dC). 0.13 pmol [32P]-labelled double mutant ACO-PPRE probe was incubated with
11mg rat LNP at room temperature for 30 min in 1*Hepes EMSA buffer (10mM Hepes (pH=7.9), 125 mM NaCl,
1mM EDTA, 7% v/v BSA, 1 mM DTT, 150mM PMSF), in the presence (lane 2) and absence (lane 4) of 1mg p(dI-
dC.dI-dC). Protein-DNA complexes were resolved on a 7.5% native polyacrylamide gel in 0.25*TBE, at 4 C. Radio-
activity was visualised by phosphor-imaging on a Bio-Rad GS250 Molecular Imager.
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increasing amount of shifted complex formed. 
C57 Bl/6 mice were intraperotineally injected with 100ml of either 10mg/Kg of
methylclofenapate in corn oil or corn oil alone at 9.00 am for three consecutive days. The animals
were sacrified at 9.00 AM on day four of the experiment.. The livers of corn oil treated (control)
or methylclofenapate (MCP) treated mice were weighed before being processed for liver nuclear
-mLNP
mLNP mg
Specific
Shifted Complex
Free Probe
1 2 3 4 5
Figure 3.6 Binding of mouse LNP to rat acyl-CoA oxidase PPRE probe. 0.011pmol [32P]-ACO-PPRE was
incubated with increasing amounts of mLNP (lane 1, 5.1 mg; lane 2, 10.2 mg; lane 3, 15.3 mg ; lane 4, 25.5 mg and
lane 5 no mLNP) at room temperature in 1* Hepes EMSA buffer (10 mM Hepes, 1 mM EDTA, 7% v/v Glycerol, 5mg/
ml BSA, 1 mM DTT, 150 mM PMSF and 100 mM NaCl), in the presence of 0.75mg p(dI-dC.dI-dC). Protein-DNA com-
plexes were resolved on a 7.5% native acrylamide gel run at 200 v for 1hour in 0.25* TBE. Shifted complexes were
visualised by phosphor-imaging on a Bio-Rad GS250 Molecular Imager.
-LNPC D C D-LNP
 ACO-PPRE dm ACO-PPRE
Figure 3.7 mLNP from mice dosed with MCP does not bind a double mutant PPRE. 0.011pmol
[32P] ACO-PPRE or 0.013 pmol [32P] dm ACO-PPRE was incubated with 20 mg Control mLNP (C) or 20 mg dosed
mLNP (D) at room temperature in 1* Hepes EMSA buffer (10 mM Hepes, 1 mM EDTA, 7% v/v Glycerol, 5mg/ml
BSA, 1 mM DTT, 150 mM PMSF and 100 mM NaCl), in the presence of 0.75mg p(dI-dC.dI-dC). Protein-DNA com-
plexes were resolved on a 7.5% native acrylamide gel run at 200 v for 1hour in 0.25* TBE. Radioactivity was vi-
sualised by phosphor-imaging on a Bio-Rad GS250 Molecular Imager
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proteins.The liver:body weight ratio of MCP treated mice was 35% larger (p<0.001) compared
to the liver:body weight ratio of control mice (Table 3.1). This shows that the livers of MCP
treated mice had peroxisome proliferator induced hepatomegaly.
 mLNP purified from mice dosed with (MCP) and mLNP from control mice dosed were assayed
for binding to ACO-PPRE and dm ACO-PPRE. Figure 3.7 demonstrates that mLNP from
control mice and from MCP treated mice do not bind to dmACO-PPRE DNA.
Σεχτιον 3.1.2 Βινδινγ οφ mΛΝΠ φροm ΜΧΠ−τρεατεδ mιχε το α ΠΠΡΕ
The total amount of mLNP-DNA complex formed from control and dosed mLNP binding to
an excess of ACO-PPRE was determined. Figure 3.8 shows triplicate EMSA assays for each of
two independently isolated batches of mLNP from control treated mice and two independently
isolated batches of mLNP from MCP dosed mice. The mean total amount of control mLNP-
PPRE complex formed, as measured by phospho-imaging was not significantly different to the
mean total amount of dosed mLNP-PPRE complex formed. Statistical calculations were
performed using students T-Test.
Σεχτιον 3.1.3 Ισολατιον οφ λιϖερ νυχλεαρ προτεινσ
Rat, mouse and guinea pig liver nuclear proteins (LNP) were purified using a modified version
of protocol by Gorski, K. et al 1986. For diurnal studies mouse and guinea pig livers were isolated
Control 
mice liver 
weight (g)
Control 
mice body 
weight (g)
Liver:Body 
weight ratio
MCP 
treated 
mice liver 
weight (g)
MCP 
treated 
mice body 
weight (g)
Liver:Body 
weight ratio
1.15 23.2 0.0496 1.54 23.4 0.0658
1.24 23.1 0.0537 1.44 22.9 0.0629
1.09 21.9 0.0498 1.61 23.9 0.0674
1.21 24.5 0.0494 1.77 24.0 0.0738
Table 3.1 Methylclofenapate induced liver enlargement in C57 Bl / 6 mice. Male ten-week old 
mice were dosed i.p. with 10mg of MCP per kg per day for three days, or corn oil vehicle. Animals were killed and 
liver and body weights determined for each of 4 mice per group.
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at 6.00 AM, 12.00 Noon, 6.00 PM and 12.00 Midnight. Figure 3.9 shows that mouse LNP
proteins isolated from livers taken at each time point are similar and are intact. There are small
differences in the banding patterns between some of the samples isolated from livers taken at each
time point. The banding pattern and amount of high molecular weight protein in region A of
Control
mLNP (1)
Control
mLNP (2)
MCP
mLNP (1)
MCP
mLNP (2)
-mLNP
mLNP-DNA
complex
Figure 3.8 ACO-PPRE EMSA with mLNP from control and MCP treated mice. 0.005 pmol [32P] ACO-
PPRE was incubated with 10 mg of mLNP at room temperature in 1* Hepes EMSA buffer (10 mM Hepes, 1 mM
EDTA, 7% v/v Glycerol, 5mg/ml BSA, 1 mM DTT, 150 mM PMSF and 100 mM NaCl), in the presence of 0.75mg p(dI-
dC.dI-dC). mLNP(1) and mLNP(2) refer to two indepedent batch purifcations of liver nuclear proteins. Protein-DNA
complexes were resolved on a 7.5% native acrylamide gel run at 200 v for 1hour in 0.25* TBE. Radioactivity was
visualised by phosphor-imaging on a Bio-Rad GS250 Molecular Imager. Free probe was run off the gel.
205
116
97
66
45
kDa
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A
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C
Figure 3.9 SDS-Page analysis of mouse liver nuclear proteins . 20mg of mouse liver nuclear protein (mL-
NP) was run in each lane on a 7.5% SDS-polyacrylamide gel. Lanes 1 and 2 shows mLNP isolated from livers taken
at 6.00 AM, 3 and 4 mLNP from livers taken at 12.00 Noon, 5 and 6 mLNP from livers isolated at 6.00 PM and 7
and 8 mLNP from 12.00 Midnight. Lane denoted Ma contains marker proteins. Proteins were visualised by Coo-
massie blue staining. A, B and C denotes regions containing differences in banding patterns.
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LNP isolated from livers taken at 6.00 PM (lanes 5 and 6) and 12 Midnight (lanes 7 and 8) are
different to LNP samples from livers taken at 6.00 AM(lanes 1 and 2) and 12 Noon (lanes 3 and
4). At region B a protein of approximate molecular weight 97 kDa increases in amount, from
6.00 AM to 12 Midnight. At region C proteins of approximate molecular weight 50 kDa are
higher in amount at 12.00 Noon and 12 Midnight. Figure 3.10 shows guinea pig nuclear proteins
analysed by SDS-PAGE. An individual sample of nuclear extract isolated at each time point is
shown. There are small differences in the banding paterns between some of the samples isolated
from livers taken at each time point. The banding pattern and amount of proteins of approximate
molecular weight 50 kDa in region A of LNP isolated from livers taken at 6.00 AM (lanes 3 and
4) and 12.00 Noon (lanes 5 and 6) are different from LNP samples isolated from livers taken at
12.00 Midnight (lanes 1 and 2) and 6.00 PM (lanes 7 and 8).
Σεχτιον 3.1.4 Ιmmυνοβλοττινγ αναλψσισ οφ mουσε ΛΝΠ
Sera containing anti-mouse PPARα antibody were previously prepared in our laboratory and
demonstrated to be specific for the mPPARα isoform (Savory, R. 1997. PhD thesis). Specifically
no cross reactivity was observed with PPARβ and PPARγ isoforms (Savory, R. 1997. PhD
kDa
97
66
45
29
1Ma 2 3 4 5 6 7 8
A
Figure 3.10 SDS-Page analysis of guinea pig liver nuclear proteins. 20mg of guinea pig liver nuclear pro-
teins (LNP) were analysed on a 10 % SDS-polyacrylamide gel. Each lane shows a sample of LNP purified from livers
taken at 12 midnight (lane 1 & 2), 6.00 AM (lane 3 & 4), 12 Noon (lane 5 & 6) and 6.00 PM (lane 7 & 8). Lane
denoted Ma contains marker proteins. The region marked by arrow A shows variation in the banding pattern of a
proteins, approximately 50 kDa in size. Protein was visualised by Coomassie blue staining.
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thesis). Figure 3.11 shows that anti-mouse PPARα antibody detected levels of immunoblotted
recombinant mPPARα protein ranging from 20ng antigen to 140 ng antigen.
Anti-mPPARα antibody was used to detected the expression of mPPARα protein in protein
extracts of mouse liver nuclear proteins (mLNP) by immunoblotting. Figure 3.12 demonstrates
that a protein of approximate molecular weight 52 kDa is detected in equivalent amounts in
mouse liver nuclear protein samples purified from livers isolated at 6.00 AM, 12.00 Noon, 6.00
PM and 12.00 Midnight. The protein detected by anti-mPPARα antibody in mLNP co-
migrates with purified recombinant mPPARα protein. This strongly suggests that the protein
20 40 60 80 100 120 140 ng
recombinant mPPARα
Figure 3.11 Western blot analysis of purified recombinant mouse PPARα protein. Increasing amounts
of purified mPPARα protein were run on a 10% SDS-polyacrylamide gel. Protein was transferred by electroblotting
onto PVDF membrane as described in the methods. PPARα protein was detected by incubation of the blot in anti-
mPPARα (1:10000 dilution) for 1 hour, then with goat anti-rabbit-IgG-Horseradish Peroxidase antibody (1:40000) for
1 hour. PPARα bands were visualised using ECL chemiluminesence kit and exposure to hyperfilm.
Ma 1 2 3 4 mPPARα
Figure 3.12 Western blot analysis of mLNP with anti-mPPARα antibody. 10 mg mouse liver nuclear pro-
tein (LNP) and 40 ng purified recombinant mPPARα protein were run on a 10 % SDS-polyacrylamide gel and blotted
on to PVDF membrane. Detection of PPARα was as described in the methods. The band detected in the lane denoted
Ma is Fumarase,a 48.5 kDa protein marker. The secondary antibody alone was found to detect this pre-stained
marker protein. Four livers were pooled and homogenised to produce mLNP samples. Lanes 1-4 contain mLNP sam-
ples purified from livers of animals killed at 6.00 AM, 12 Noon, 6.00 PM and 12 Midnight respectively. The lane
containing purified recombinant mPPARα is denoted mPPARα. The results of three separate western blot experi-
ments are shown.
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detected in mLNP samples was mPPARα protein. The results in figure 3.12 show that mPPARα
protein expression does not vary in a diurnal manner in C57 Bl / 6 mice.
Σεχτιον 3.1.5 Εξπρεσσιον οφ mΠΠΑΡα προτειν ιν γυινεα ανδ mουσε
Nuclear protein extracts were isolated from the livers of mice sacrificed at 12.00 Midnight and
from liver of guinea pigs sacrificed at 06.00 AM. Western blotting of these nuclear protein
extracts with anti-mPPARα antibody revealed the presence of a band of ~52 kDa in mouse liver,
and also revealed the presence of a band of similar mobility in guinea pig liver which was less
intense (Figure 3.13). The mobility of the detected mPPARα in liver nuclear extracts and
putative guinea pig PPARα was the same as purified recombinant mPPARα. 
mPPARαmLNP gpLNP
Figure 3.13 Western blot analysis of mouse and guinea pig liver nuclear proteins. 20 ng of recombinat
mPPARα protein , and 10 mg of mouse (mLNP) and guinea pig liver nuclear protein (gpLNP) purified from each liver
isolated at 12.00 midnight and 06.00 AM respectiviely were run in triplicate on a 10% SDS-polyacrylamide gel, and
then probed by western blotting with rabbit anti-mPPARα antibody (1:10000 dilution) and anti-rabbit-IgG-HRP anti-
body (1:40000) as described in the methods section. Development of the blot was carried out using ECL detection
kit.
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Σεχτιον 3.1.6  Εξπρεσσιον οφ ΠΠΑΡα ιmmυνο−ρεαχτιϖε προτειν ιν γυινεα πιγ ΛΝΠ
Guinea pig liver nuclear protein samples (gpLNP) were analysed by immunoblotting with  the
same rabbit anti-mPPARα antibody that was used to probe mLNP samples. Figure 3.14
demonstrates a protein of approximate molecular weight 52 kDa was detected in gpLNP samples
purified from livers isolated at 6.00 AM, 12.00 Noon, 6.00 PM and 12.00 Midnight. These
results provide strong evidence to suggest that guinea pigs have a PPARα receptor, and that it is
expressed in a similar manner to mPPARα. There was no significant difference in the expression
of this 52 kDa protein accross a 24 hour period.
Σεχτιον 3.2 Χλονινγ οφ γυινεα πιγ ΠΠΑΡα χDΝΑ
Σεχτιον 3.2.1 Πυρι⇒χατιον οφ γυινεα πιγ ΡΝΑ
Total RNA was purified from guinea pig liver using the method of Cathala et al . Figure 3.15
shows total RNA analysed by electrophoresis in an agarose gel. The approximate yield of total
RNA was 0.5 mg per 2 g of liver tissue processed. 
1 2 1 2 1 2 1 2
6.00 AM
12.00
Noon 6.00 PM
12.00
Midnight
48.5 kDa
58.0 kDa
Ma
Figure 3.14 Western blot analysis of guinea pig liver nuclear protein. gpLNP was isolated from  individu-
al livers of two guinea pigs sacrificed at each time point. Both gpLNP samples from each timepoint were analysed
in three separate western blot experiments. 20 mg of gpLNP was run on a 10% SDS-polyacrylamide gel, and then
probed by western blotting with rabbit anti-mPPARα antibody (1:10000 dilution) and anti-rabbit-IgG-HRP antibody
(1:40000) as described in the methods section. Development of the blot was carried out using ECL detection kit.
Protein markers (Ma) Pyruvate Kinase and Fumarase were detected by the secondary antibody.
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Σεχτιον 3.2.2 ΠΧΡ αmπλι⇒χατιον οφ γυινεα πιγ 1στ στρανδ χDΝΑ 
Primers GPIGP2, GPIGP3 and GPIGP4 were designed from the DNA sequences of three
regions of identity in human, mouse and xenopus PPARα. Figure 3.16 shows the amino acid
alignment of the regions of the PPARα receptor used to design the PCR primers. GPIGP2
corresponds to 325-MNKDGML-331, GPIGP3 corresponds to 463-IYRDMY-468-XX (X=
3’non-coding triplet) and GPIGP4 corresponds to 114-YGVHACEGCKGFF-126.1st strand
cDNA was synthesised from total and poly A+ purified guinea pig liver RNA. Figure 3.17, lanes
1 to 3 demonstrates that a 436 bp fragment was amplified from guinea pig liver cDNA using
GPIGP2 and GPIGP3 primers. Lanes 6 and 7 contain a 436 bp amplified fragment from pSG5-
mPPARα and hPPARα-pBK-CMV plasmid DNAs. The PCR product of lane 4 was
reamplified using the same primers and was then purified by qiagen PCR Qiaspin-quick
columns. The purified DNA was cloned into pGEM-T vector. Three independent clones
containg the 436 bp insert were purified and sequenced. Each 436bp clone was sequenced only
once on each strand. Double stranded sequence was analysised for homology to known PPARα
cDNA sequences. DNA sequence analysis of the cloned 436 bp guinea pig PCR products
28s rRNA
18s rRNA
A B C D
Figure 3.15 Analysis of guinea pig liver RNA by agarose gel elecrophoresis. RNA samples were analsy-
sed on a 0.8 % agarose gel (1*TBE, 0.1% SDS) run at a constant 90v for 1 hour. Lanes A and B contain 4 and 8 mg
of RNA from liver RNA prep 1, and lanes C and D contain 6.6 and 13.2 mg of RNA from liver prep 2.
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demonstrated that they showed sequence similarity, but not identity to mouse , human, rat and
xenopus PPARα cDNA sequences. GPIGP3 and GPIGP2 primers amplified a partial guinea pig
PPARα cDNA fragment. Figure 3.18, lanes 1 to 3 demonstrates that a 1056 bp fragment was
amplified from guinea pig liver cDNA using GPIGP3 and GPIGP4 primers. Lanes 10 and 11
contain a 1056 bp amplified fragment from pSG5-mPPARα and pBK-CMV-hPPARα plasmid
DNAs. The PCR products of lanes 1-4 were reamplified using the same primers. The products
of these reactions are shown in in figure 3.18, lanes 5-8. The PCR product of lane 7 was purified
GPIGP4 Primer
hPPARα
mPPARα
xPPARα
GPIGP2 Primer
ηΠΠΑΡα
mPPARα
ξΠΠΑΡα
ηΠΠΑΡα
mPPARα
ξΠΠΑΡα
ΓΠΙΓΠ3 Πριmερ
(Α)
(Β)
(Χ)
Figure 3.16 Alignment of human, mouse and xenopus PPARα amino acid sequences. The amino acid
sequences of hPPARα (y07619), mPPARα (x57638) and xPPARα (m84161) were aligned using the pileup tool within
GCG sequence analysis program, and dispalyed using GeneDoc program. The numbers above the sequence align-
ment correspond to the position of the amino acid in the xenopus receptor. Identical amino acids in all three PPAR
sequences are shaded in grey. Amino acids identical in two of the three sequences are shaded in black. (A) shows
the amino acid alignment in the DNA binding domain, (B) the ligand binding domain, and (C) the C-terminal end of
the PPARα receptors. The regions of amino acid identity used to design PCR primers GPIGP2, GPIGP3 and GPIGP4
are underlined.
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by qiagen PCR Qiaspin-quick columns, and was cloned into pGEM-T vector. Three
independent clones containg the 1056bp insert were purified and sequenced in full on both
strands of DNA. DNA sequence analysis of the cloned 1056 bp guinea pig PCR products
demonstrated that they showed sequence similarity, but not identity to mouse , human, rat and
xenopus PPARα cDNA sequences.
bp
506
394
344
1 2 3 4 5 6 7
Figure 3.17 Amplification of guinea pig cDNA with GPIGP2 and GPIGP3 primers. 5 ml of each PCR reac-
tion was analysed on a 1.5 % agarose gel (1* TAE) run at a constant 100v for 1hour. Lanes 1-3 contains PCR prod-
ucts from the amplification of 1st strand cDNA produced from total RNA. Lane 4 contains products from the
amplification of 1 st strand cDNA produced from poly A+ RNA. Lane 5 is a negative control in which no template DNA
was added. Lanes 6 and 7 contain the products of amplification of pSG5-mPPARα plasmid DNA and pBK-CMV-hP-
PARα plasmid DNA respectively. Primers GPIGP2 and GPIGP3 were used in all PCR reactions
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Σεχτιον 3.2.3 5∏ΡΑΧΕ οφ γυινεα πιγ ΡΝΑ
A 5’- rapid amplification of cDNA ends’ (RACE) kit (Gibco BRL) was used to clone the
remainder of the gPPARα CDNA containing the N-terminal coding region. Using the
completed DNA sequence of the 1056 bp clones two primer GPIGP6 and GPIGP7 were
designed and used for cloning the 5’ gPPARα cDNA end. GPIGP7 corresponds to amino acids
DKCDRSCKI of the 1056 bp gPPARα clone and was used to synthesise 1st strand cDNA from
kb
0.5
1.0
1.5
2.0
1 2 3 4 5 6 7 8 9 10 11
Figure 3.18 Analysis of the PCR amplification of guinea pig liver cDNA. 5 ml of each PCR reaction was
analysed on a 1 % agarose gel (1* TAE) run at a constant 100v for 1hour. Lanes 1-3 contains PCR products from
the amplification of 1st strand cDNA produced from total RNA. Lane 4 contains products from the amplification of
1 st strand cDNA produced from poly A+ RNA. Lanes 5-8 contains products of the reamplification of reactions 1-4.
Lane 9 is a negative control in which no template DNA was added. Lanes 10 and 11 contain the products of ampli-
fication of pSG5-mPPARα plasmid DNA and pBK-CMV-hPPARα plasmid DNA respectively. Primers GPIGP3 and
GPIGP4 were used in all PCR reactions.
kb
1.0
0.5
0.4
-ve 1 2 3 4 5 6 7 8
Figure 3.19 5’RACE of gPPARα cDNA ends. 5 ml of each 5’RACE PCR reaction was anlaysed on a 1% agar-
ose gel (0.5* TBE) run at a constant 100 v for 1hour. Lanes 1, 3, 5 and 6 contain PCR products from the reampli-
fication of cDNA ends produced from 1st strand cDNA derived from poly A+ RNA. Lanes 2, 4, 7 and 8 contains PCR
products from the reamplification of cDNA ends produced from 1st strand cDNA derived from total guinea pig liver
RNA. 5’ RACE kit DNA polymerase reagents were used for reactions in lanes 1 and 2. Pharmacia Taq DNA poly-
merase reagents were used for all other reactions. Lane denoted -ve refers to the control amplification of no tem-
plate DNA. GPIGP6 and Universal Amplification Primer were used in all reactions.
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purified poly A+ RNA and total RNA. This 1st cDNA was dC-tailed using Terminal
deoxynucleotidyl transferase and then purified. Putative gPPARα 5’ cDNA clones were
amplified using GPIGP6 primer ( corresponding to amino acids GVHACEGCKG of the 1056
bp gPPARα clone ) and 5’RACE anchor primer. Analysis of the amplified 5’cDNA found that
very low levels of product were produced from amplification of 1st strand cDNA derived from
poly A+ and total RNA. The products of the first round of amplification were reamplified using
GPIGP6 and Universal Amplification Primer. Figure 3.19 shows putative amplified gPPARα
5’cDNA products. The PCR products of reactions 1 and 3 were purified by Qiagen Qiaspin
quick columns, and cloned into pGEM-T vector. Seven independent clones were purified and
sequenced. Five clones of the PCR products from reactions 1 and 3 showed high identity to
PPARα, and were termed GP11, GP12, GP13, GP14 and GP15. The sequence of the last 10
amino acids of the 3’ end of the 5’ cDNA clones was derived from the consensus GPIGP4
primer, not from actual guinea pig cDNA sequence. To obtain the cDNA sequence of these 10
amino acids, PCR cloning of a fragment which overlaps the 1056bp and 5’ cDNA end clones
was underway, but not completed. Clones GP11 to GP15 were sequenced in full on both strands
of DNA. GP13, GP14 and GP15 contained cDNA fragments of length 302 bp. GP12 contained
an insert of size 582 bp and GP11, an insert of 467 bp in size.
GP1, 2 & 3
GP12
GP11
GP13, 14 & 15
1610 bp
gPPARα cDNA
Met 1
Figure 3.20 Diagram showing assembly of guinea pig cDNA clones. cDNA clones GP1, 2, 3, 11, 12, 13,
14 and 15 was aligned using GELMERGE and GELASSEMBLE tools within the GCG sequence analysis program. Solid
black lines denote over lapping identical sequence. Hashed lines indicate sequence derived from a single cDNA
clone. The first translational methionine start site is indicated as Met 1.
Alex R. Bell Section 3.2.4
Page 123
Σεχτιον 3.2.4 Σεθυενχε αναλψσισ οφ γυινεα πιγ χDΝΑσ
Guinea pig cDNA clone DNA sequences were analysed using the TED, BESTFIT, SEQED, and
TRANSLATE sequence tools within GCG sequence analysis program. Guinea pig cDNA
clones were assembled into a contiguous single cDNA sequence using GELMERGE and
GELASSEMBLE tools within GCG sequence analysis program. All double strand gPPARα
cDNA sequences were aligned and assembled into a single contiguous DNA sequence 1610 bp
long, see figure 3.20. The DNA sequence of the assembled cDNA is shown in figure 3.21.
1     ΤΓΧΑΑΤΤΤΓΑ ΤΤΧΤΧΧΧΧΤΑ ΑΑΑΧΧΤΧΓΧΤ ΓΓΧΧΓΑΤΓΓΧ ΧΧΧΑΧΧΓΑΓΓ 
51    ΓΤΧΑΓΧΑΧΧΑ ΓΧΑΓΧΧΤΓΑΑ ΑΓΓΓΧΤΓΓΑΤ ΓΓΓΧΑΧΓΧΓΓ ΓΓΧΑΧΤΓΤΓΧ 
101   ΧΧΧΤΧΑΓΧΧΤ ΓΧΧΓΓΑΤΓΓΓ ΓΧΧΓΤΓΑΧΧΤ ΓΤΓΧΓΧΑΓΓΓ ΧΤΓΓΑΑΓΓΧΓ 
151   ΤΧΤΧΧΤΤΧΑΓ ΧΑΤΤΤΧΧΑΑΓ ΓΤΧΑΧΑΓΧΤΧ ΑΓΤΓΓΧΑΓΓΑ ΧΤΓΓΧΤΧΧΤΧ 
201   ΧΧΧΓΧΧΓΑΧΑ ΤΓΓΤΓΓΑΧΑΤ ΓΓΑΓΑΓΧΧΧΧ ΧΤΓΤΓΤΧΧΓΧ ΤΓΤΧΧΧΧΧΤΤ 
251   ΓΓΑΓΓΧΧΓΑΓ ΓΑΧΧΤΓΓΑΓΑ ΓΧΧΧΑΧΤΓΤΧ ΧΓΑΓΤΑΧΤΤΧ ΧΤΧΧΑΓΓΑΑΑ 
301   ΤΓΓΓΓΑΧΧΑΤ ΧΧΑΓΓΑΧΑΤΧ ΤΧΓΑΓΓΤΧΧΧ ΤΧΓΓΤΓΑΑΓΑ ΧΑΓΧΤΧΧΓΓΓ 
351   ΑΓΧΤΤΧΓΓΧΤ ΤΧΧΧΤΓΑΓΤΑ ΧΧΑΓΤΑΤΧΤΓ ΓΓΧΑΓΧΓΓΧΧ ΧΧΓΓΧΤΧΓΓΑ 
401   ΧΓΓΑΤΧΓΓΤΧ ΑΤΧΑΧΑΓΑΤΑ ΧΧΧΤΓΤΧΧΧΧ ΓΓΧΤΤΧΧΑΓΧ ΧΧΧΤΧΧΤΧΧΓ 
451   ΤΧΑΓΧΤΑΧΧΧ ΧΓΑΓΓΤΧΧΧΧ ΤΓΤΓΓΧΓΤΓΓ ΑΤΓΑΓΧΧΓΧΧ ΧΑΓΧΑΓΧΓΧΧ 
501   ΧΤΓΑΑΧΑΤΧΓ ΑΓΤΓΧΑΓΓΑΤ ΧΤΓΧΓΓΓΓΑΧ ΑΑΓΓΧΧΤΧΑΓ ΓΧΤΑΧΧΑΧΤΑ 
551   ΧΓΓΑΓΤΤΧΑΧ ΓΧΑΤΓΤΓΑΑΓ ΓΧΤΓΧΑΑΓΓΓ ΧΤΤΧΤΤΧΧΓΑ ΑΓΓΑΧΧΑΤΧΧ 
601   ΓΓΧΤΓΑΑΓΧΤ ΓΓΤΓΤΑΧΓΑΧ ΑΑΑΤΓΤΓΑΧΧ ΓΧΑΓΧΤΓΧΑΑ ΓΑΤΧΧΑΓΑΑΑ 
651   ΑΑΓΑΑΧΧΓΧΑ ΑΧΑΑΓΤΓΧΧΑ ΓΤΑΧΤΓΧΧΓΧ ΤΤΧΧΑΧΑΑΓΤ ΓΧΧΤΓΤΧΑΓΤ 
701   ΧΓΓΓΑΤΓΤΧΧ ΧΑΧΑΑΧΓΧΧΑ ΤΤΧΓΧΤΤΧΓΓ ΑΧΓΓΑΤΓΧΧΓ ΑΓΓΤΧΤΓΑΓΑ 
751   ΑΑΓΧΑΑΑΑΧΤ ΑΑΑΑΓΧΧΓΑΑ ΓΤΧΧΤΧΑΧΧΤ ΓΤΓΑΧΧΓΓΓΑ ΧΑΓΧΓΑΓΓΓΧ 
801   ΓΧΧΓΑΓΑΧΧΓ ΧΧΓΑΧΧΤΧΑΑ ΓΤΧΧΧΤΓΓΧΧ ΑΑΓΧΓΓΑΤΧΤ ΑΧΓΑΓΓΧΧΤΑ 
851   ΧΧΤΓΑΑΓΑΑΧ ΤΤΧΧΑΧΑΤΓΑ ΑΑΧΑΑΓΓΤΧΑ ΓΓΧΧΧΓΧΑΤΧ ΑΤΧΧΤΓΓΧΧΓ 
901   ΓΓΑΑΓΑΧΧΑΓ ΧΑΓΧΧΑΤΧΧΓ ΧΤΤΤΤΧΓΤΧΑ ΤΧΧΑΧΓΑΧΑΤ ΓΓΑΓΑΧΓΧΤΓ 
951   ΤΓΧΑΧΓΓΧΧΓ ΑΓΑΑΓΑΧΓΧΤ ΓΑΤΓΓΧΧΑΑΓ ΓΤΓΓΤΓΤΧΧΓ ΑΧΓΓΧΑΤΧΧΓ 
1001  ΧΓΑΧΑΑΓΓΑΓ ΓΧΧΓΑΓΓΤΧΧ ΓΧΑΤΧΤΤΧΧΑ ΧΤΓΧΤΓΧΧΑΓ ΤΓΤΓΤΓΤΧΓΓ 
1051  ΤΓΓΑΓΑΧΧΓΤ ΧΑΧΧΑΑΧΧΤΧ ΑΧΓΓΑΓΤΤΧΓ ΧΧΑΑΓΓΧΧΑΤ ΧΧΧΓΓΓΤΤΤΧ 
1101  ΓΧΧΑΓΧΧΤΓΓ ΑΧΧΤΓΑΑΧΓΑ ΧΧΑΓΓΤΧΑΧΧ ΧΤΓΧΤΓΑΑΓΤ ΑΧΓΓΧΓΤΓΤΑ 
1151  ΧΓΑΑΓΧΧΑΤΧ ΤΤΧΑΧΧΑΤΓΧ ΤΓΤΧΧΤΧΧΑΧ ΧΑΤΓΑΑΧΑΑΓ ΓΑΧΓΓΓΑΤΓΧ 
1201  ΤΓΓΤΓΓΧΧΤΑ ΧΓΓΑΧΑΧΓΓΧ ΤΤΧΑΤΧΑΧΧΧ ΓΧΓΑΓΤΤΧΧΤ ΧΑΑΑΑΑΧΧΤΧ 
1251  ΧΓΧΑΑΑΧΧΧΤ ΤΧΤΓΧΓΑΧΑΤ ΓΑΤΓΓΑΑΧΧΧ ΑΑΓΤΤΧΑΑΤΤ ΤΤΓΧΧΑΤΓΑΑ 
1301  ΓΤΤΧΑΑΧΓΧΧ ΧΤΓΓΑΓΧΤΓΓ ΑΧΓΑΧΑΓΧΓΑ ΧΑΤΧΤΧΓΧΤΓ ΤΤΧΓΤΓΓΧΧΓ 
1351  ΧΧΑΤΧΑΤΤΤΓ ΧΤΓΧΓΓΑΓΑΤ ΧΓΓΧΧΧΓΓΧΧ ΤΧΧΤΑΑΑΤΑΤ ΧΓΑΧΧΑΧΑΤΧ 
1401  ΓΑΓΑΑΑΑΤΓΧ ΑΓΓΑΓΓΧΤΑΤ ΧΓΤΓΧΑΧΓΤΓ ΧΤΧΑΑΑΧΤΧΧ ΑΧΧΤΓΧΑΑΑΓ 
1451  ΧΑΑΧΧΑΧΧΧΧ ΓΑΧΓΑΧΑΧΧΤ ΤΧΧΤΧΤΤΧΧΧ ΧΑΑΑΧΤΓΧΤΧ ΧΑΓΑΑΓΧΤΓΓ 
1501  ΧΓΓΑΧΧΤΓΧΓ ΓΧΑΓΧΤΓΓΤΓ ΑΧΓΓΑΓΧΑΤΓ ΧΧΧΑΓΧΤΧΓΤ ΓΧΑΓΓΤΧΑΤΧ 
1551  ΑΑΓΑΧΓΓΑΓΤ ΧΑΓΑΧΓΧΧΓΧ ΓΧΤΓΧΑΧΧΧΓ ΧΤΓΧΤΓΧΑΓΓ ΑΓΑΤΧΤΑΧΑΓ 
1601  ΓΓΑΧΑΤΓΤΑΧ 
Figure 3.21 cDNA sequence of gPPARα . cDNA clones GP1, 2, 3, 11, 12, 13, 14 and 15 were aligned and as-
semble into a single cDNA sequence using GELMERGE and GELASSEMBLE tools within the GCG sequence analysis
program. The open reading frame from the putative methionine start site Met 1 is highlighted in bold. This open read-
ing frame encodes for a 467 amino acid protein.
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Analysis of the contiguous guinea pig cDNA sequence identified a putative methionine start site
in an open reading frame encoding a 467 amino acid protein of predicted molecular weight 52
290 Da. Comparison of the predicted protein sequence of the cloned guinea pig cDNA with
known PPARα receptors demonstrated that the cDNA encodes a PPARα protein .The amino
acid sequence of the putative guinea pig PPARα (gPPARα) is shown in figure 3.22. The
gPPARα protein sequence is 1 amino acid shorter than the known mammalian PPARα’s. A
deletion of a Lysine (K) residue at position 447 has occured. The coding region of gPPARα
cDNA is 1401 bp long. The open reading frame contains two putative methionine start sites,
Met 1 closely followed by Met 2, highlighted in bold on figure 3.22. The DNA sequence of Met
1 shows the highest conservation (4 nucleotides out of 6) to the Kozak Methionine start sequence
motif (Kozak, M. 1994 and 1995). A third methione start site (Met 3) is present in the 200 bp of
cDNA 5’ to Met 1. Met 3 has poor similarity to the consensus Kozak sequence, only 2 out of six
nucleotides are conserved. 
       1  ΜςDΜΕΣΠΛΧΠ ΛΣΠΛΕΑΕDΛΕ ΣΠΛΣΕΨΦΛΘΕ ΜΓΤΙΘDΙΣΡΣ ΛΓΕDΣΣΓΣΦΓ 
      51  ΦΠΕΨΘΨΛΓΣΓ ΠΓΣDΓΣςΙΤD ΤΛΣΠΑΣΣΠΣΣ ςΣΨΠΕςΠΧΓς DΕΠΠΣΣΑΛΝΙ 
     101  ΕΧΡΙΧΓDΚΑΣ ΓΨΗΨΓςΗΑΧΕ ΓΧΚΓΦΦΡΡΤΙ ΡΛΚΛςΨDΚΧD ΡΣΧΚΙΘΚΚΝΡ 
     151  ΝΚΧΘΨΧΡΦΗΚ ΧΛΣςΓΜΣΗΝΑ ΙΡΦΓΡΜΠΡΣΕ ΚΑΚΛΚΑΕςΛΤ ΧDΡDΣΕΓΑΕΤ 
     201  ΑDΛΚΣΛΑΚΡΙ ΨΕΑΨΛΚΝΦΝΜ ΝΚςΚΑΡΙΙΛΑ ΓΚΤΣΣΗΠΛΦς ΙΗDΜΕΤΛΧΤΑ 
     251  ΕΚΤΛΜΑΚςςΣ DΓΙΡDΚΕΑΕς ΡΙΦΗΧΧΘΧςΣ ςΕΤςΤΝΛΤΕΦ ΑΚΑΙΠΓΦΑΣΛ 
     301  DΛΝDΘςΤΛΛΚ ΨΓςΨΕΑΙΦΤΜ ΛΣΣΤΜΝΚDΓΜ ΛςΑΨΓΗΓΦΙΤ ΡΕΦΛΚΝΛΡΚΠ 
     351  ΦΧDΜΜΕΠΚΦΝ ΦΑΜΚΦΝΑΛΕΛ DDΣDΙΣΛΦςΑ ΑΙΙΧΧΓDΡΠΓ ΛΛΝΙDΗΙΕΚΜ 
     401  ΘΕΑΙςΗςΛΚΛ ΗΛΘΣΝΗΠDDΤ ΦΛΦΠΚΛΛΘΚΛ ΑDΛΡΘΛςΤΕΗ ΑΘΛςΘςΙΚΤΕ 
     451  ΣDΑΑΛΗΠΛΛΘ ΕΙΨΡDΜΨ
Met 1 Met 2
Figure 3.22 Amino acid sequence of gPPARα. The guinea pig cDNA sequence was translated using the
TRANSLATE tool within GCG sequnce analysis program. An open reading frame of 467 amino acids from Methionine
translational start site 1 (Met 1) is shown. The predicited amino acid sequence was compared to known PPARα ami-
no acid sequences and was found to have high similarity, indicating that it encodes a PPARα receptor. A second
putative methionine translational start site (Met 2 ) is indicated.
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Σεχτιον 3.2.5 Μυλτιπλε σεθυενχε ανλαψσισ οφ ΠΠΑΡα αmινο αχιδ σεθυενχεσ.
A comparison between the amino acid squence of gPPARα and other known PPARα’s was
done using the BESTFIT tool within GCG sequence analysis program. Guinea pig PPARα has
88% amino acid identity to human, mouse and rat PPARαs, but only 71% and 72% amino acid
identity to mPPARγ and rPPARδ. Table 3.2 gives a breakdown of the percent amino acid
indentity between individual protein domains of gPPARα and other known PPAR isoforms.
The DNA binding domain of gPPARα is identical to mouse and human PPARα. The ligand
binding domain shows highest identity to the PPARα isform. The largest amount of variation
between sequences occurs in the putative A/B transactivation domain and putative hinge region. 
The amino acid sequences of gPPARα, hPPARα (y07619), mPPARα (x57638), rPPARα
(m88582) and xPPARα (m84161) have been aligned for comparison using the PILEUP tool
within GCG sequence analysis package. Figure 3.23 shows the differences in the amino acid
sequence of gPPARα to the aligned sequences.There are 22 amino acid positions which are
identical in rPPARα and mPPARα but are different in gPPARα and hPPARα. Of these 22
changes, 14 are conserved between gPPARα and hPPARα, with the remaining eight being
Dοmαιν
(αα ρεγιον)
Α/Β
(1−101)
DΒD
(102−166)
Ηινγε
(167−280)
ΛΒD
(281−467)
ηΠΠΑΡα 85 100 81 91
mΠΠΑΡα 78 100 80 93
ρΠΠΑΡα 79 98 80 93
ξΠΠΑΡα 51 87 78 87
ρΠΠΑΡδ 44(30) 86 52 70
mΠΠΑΡγ 60(10) 83 46 66
Table 3.2 Amino acid sequence identity between gPPARα and other PPARs.  The amino
acid sequences of guinea pig, human (y07619), mouse (x57638), rat (m88582) and xenopus (m84161)
PPARαs, and rat PPARδ (u40064) and mouse PPARγ (u01664) have been compared using the BESTFIT
tool within GCG sequence analysis program. The amino acid (aa) position of the domains of PPARα are
given in brackets below the domain name. A/B denotes putative transactivation domain, DBD denotes
DNA binding domain and LBD denotes the ligand binding domain. The figures in brackets next to the per-
cent identities are the length of amino acid stretch over which the idenity was matched. The 10 amino
acids derived from the consensus primer were included in the DBD BESTFIT analyses.
Alex R. Bell Section 3.2.5
Page 126
non-conserved. A comparison of the charge properties of the 22 differences reveals that at four
positions, a change in the charge property of the amino acid has occurred. At position 83 in
gPPARα and hPPARα a tyrosine residue is found, compared to a cysteine in mPPARα and
rPPARα. Position 196 in gPPARα and hPPARα is a negatively charged glutamate residue. In
rat and mouse PPARα the amino acid at 196 is a positively charged lysine residue. At position
211 in gPPARα and hPPARα an aromatic tyrosine residue is replaced by a positively charged
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histidine residue in mPPARα and rPPARα. At position 264 in gPPARα, an arginine residue
(positively charged), and 264 in hPPARα, a glutamine residue (polar uncharged) is changed to
a glutamate (negatively charged) residue in rat and mouse PPARα’s.
Figure 3.23 Amino acid sequence alignment of mammalian and Xenopus PPARα’s. The amino acid se-
quences of gPPARα, hPPARα (y07619), mPPARα (x57638), rPPARα (m88582) and xPPARα (m84161) have been
aligned for comparison using the PILEUP toolwithin GCG sequence analysis package. The dots (.) denote identical
amino acids and hyphens (-) indicate absent amino acids. 80% conservation of amino acids in all five sequences
are highlighted with grey shading and 60% conservation of amino acids between all five sequences are shaded in
black. The alignments were visualised with the GENEDOC program.
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Σεχτιον 3.2.6  Πηψλογενετιχ αναλψσισ οφ ΠΠΑΡα γενεσ
The tree shown in figure 3.24 is a typical output from Puzzle 4 with a Jones,Taylor and Thornton
(JTT) amino acid substitution matrix (Jones, D.T. et al 1992), with all branches strongly
supported (P>0.89). The length of the gPPARα branch compared to human, mouse and rat is
much longer, indicating that the gPPARα gene is evolving more rapidly than the PPARα gene
in these other species. The most likely tree places the guinea pig between the human and rodent
orders, with a bootstrap probability of approximately 0.93. The most likely remaining trees with
a combined bootstrap probability of approximately 0.07 excluded a monophyletic association of
guinea pig with mouse and rat.
Σεχτιον 3.2.7 γΠΠΑΡα χDΝΑ χονταινσ αν εξτενδεδ 5∏ ΟΡΦ
Initial DNA sequence analysis indicated a stop codon upstream of Met 1 ATG start site. Final
Figure 3.24 Phylogenetic analysis of PPARα genes. The deduced protein sequence of guinea pig PPARα
was initially aligned with the mouse (x57638), rat (m88592), human (s74349) and xenopus (m84161) PPARα pro-
tein sequences, and the mouse PPARβ (u10375) and mouse PPARγ (u10374) with CLUSTALW 1.6, then refined
with SAGA. The mouse PPARβ and γ sequences are added as outgroups to the analysis. Maximum likelihood anal-
ysis of the aligned peptide sequences utilised ProtML and Puzzle 4, compiled to run on OS/2 using the gnu C com-
piler. The branch lengths are proportional to the evolutionary rate of the gene. The tree output was visualised with
treeview. The branches are defined as gppar = guinea pig PPARα, mppar = mouse PPARα, hppar = human PPARα,
rppar = rat PPARα, xppar = xenopus PPARα, pparb = mouse PPARβ and pparg = mouse PPARγ. The scale indicates
a Ks = 0.1
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detailed analysis of the assembled 5’ cDNA sequence of clones, GP11 and GP12 demonstrated
that a continuous open reading frame 5’ to the putative methionine start site Met 1 was
present.The extended open reading frame contains a putative methionine translational start site,
indicated by Met 3 in figure 3.25. Translation of gPPARα mRNA from Met 3 would add an
additional 58 amino acids to the gPPARα protein.The gPPARα protein sequence containing
the N-terminal extended open reading frame was compared with sequences in the databank
Genembl. This sequence similarity search revealed that a gPPARα sequence (accession number
AJ000222) had been submitted to the databank. A comparison of the N-terminal ends of each
gPPARα is shown in figure 3.25. Figure 3.25 demonstrates that the amino acid sequences are
identical over a 13 amino amino stretch immediately N-terminal to Met 1, with the remaining
N-terminal sequence being different. 
The 5’ nucleotide sequence of gPPARα cDNA was compared to the exon DNA sequences
encoding the N-terminal region of mPPARα. The cDNA sequence of the N-terminal end of
gPPARα shown in bold in figure 3.26, aligns with start of mouse exon 3 (x75289) DNA
sequence (figure 3.26). The region of N-terminal identity between gPPARα and AJ000222 also
starts at this 5’ intron-exon junction. The difference in the N-terminal sequence of gPPARα and
AJ000222 could result from alternative splicing of gPPARα mRNA.
γππαρα   ∼∼∼∼∼∼∼∼∼∼ ∼ΘΦDΣΠΛΚΠΡ WΠ....ΜΑΠΠ ΡςΣΤΣΣΛΚΓΛ DΓΗΑΓΗΧΑΠΘ 
Αϑ000222 ΕΦΓΤΣΚΤΚΘΠ ΓΗΠDςΠΛΠΓΡ WΡΤΕΕΙΘΡΠΝ ΡΛΠΛΛΗΛΠΡΠ ΡΛΕΛΘΑΧΛΠΡ 
γππαρα   ΠΑΓWΓΡDΛΧΑ ΓΛΕΓςΣΦΣΙΣ ΚςΤΑΘWΘDWΛ ΛΠΑDΜ 
Αϑ000222 ΕΣΧ∗ΠςΕςΛΛ ΠΑΕΚ...WWΠ ΘςΤΑΘWΘDWΛ ΛΠΑDΜ 
Met 1
(Α)
Met 3
Figure 3.25 Alignment of cloned gPPARα protein with AJ000222. Alignment of gPPARα amino acid se-
quence with the amino acid translation of AJ000222 cDNA using BESTFIT tool of GCG sequence analysis program.
Identical sequence between gPPARα cDNA and AJ000222 cDNA, N-terminal of the Met 1 translational start site is
given in bold type. A putative methionine translational start site Met 3 is indicated in the upstream reading frame
of gPPARα. The gPPARα cDNA sequence region highlighted as (A) was derived from clones GP11 and GP12 and were
identical over this stretch. All gPPARα cDNA sequence upstream of region A was derived from one 5’ cDNA clone,
GP12.
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Σεχτιον 3.2.8 Α 436 βπ γΠΠΑΡα χλονε (ΓΠ4) ισ διφφερεντιαλλψ σπλιχεδ 
     −−−−ΑΓΓΤΧΑΧΑΓΧΤΧΑΓΤΓΓΧΑΓΓΑΧΤΓΓΧΤΧΧΤΧΧΧΧΓΧΓΓΑΧΑΤΓΓΤΓΓΑΧ−−
         || | |  |||| |||||  | |||||  |  ||  |  |||||||||||
     −−−−ΑΓΧΤΤΑΓΧΓΧΤΧΤΓΤΓΓΧΧΤΓΧΧΤΓΓΧΧΑΧΑΤΧΧΑΤΧΧΑΑΧΑΤΓΓΤΓΓΑΧ−−
Intron-Exon junction
gPPARα
mPPARα
exon3
218
589
169
Met 1
Figure 3.26 Comparison of gPPARα cDNA sequence with mPPARα exon3. gPPARα and mouse PPARα
exon 3 (x75289) were compaired using the BESTFIT tool with GCG sequence analysis program. The mPPARα exon 3
sequence starts at position 11 and is highlighted in bold type. DNA sequence 5’ and 3’ to that shown is denoted by
hyphens (-).
      2  ΑΤΓΑΑΧΑΑΑΓΑΧΓΓΓΑΤΓΧΤΓΓΤΓΓΧΧΤΑΧΓΓΑΧΑΧΓΓΧΤΤΧΑΤΧΑΧΧΧΓ 51
         |||||||| |||||||||||||||||||||||||||||||||||||||||
     973 ΑΤΓΑΑΧΑΑΓΓΑΧΓΓΓΑΤΓΧΤΓΓΤΓΓΧΧΤΑΧΓΓΑΧΑΧΓΓΧΤΤΧΑΤΧΑΧΧΧΓ 1022
                  .         .         .         .         .
     52  ΧΓΑΓΤΤΧΧΤΧΑΑΑΑΑΧΧΤΧΧΓΧΑΑΑΧΧΧΤΤΧΤΓΧΓΑΧΑΤΓΑΤΓΓΑΑΧΧΧΑ 101
         ||||||||||||||||||||||||||||||||||||||||||||||||||
    1023 ΧΓΑΓΤΤΧΧΤΧΑΑΑΑΑΧΧΤΧΧΓΧΑΑΑΧΧΧΤΤΧΤΓΧΓΑΧΑΤΓΑΤΓΓΑΑΧΧΧΑ 1072
                  .         .         .         .         .
     10  ΑΓΤΤΧΑΑΤΤΤΤΓΧΧΑΤΓΑΑΓΤΤΧΑΑΧΓΧΧΧΤΓΓΑΓΧΤΓΓΑΧΓΑΧΑΓΧΓΑΧ 151
         ||||||||||||||||||||||||||||||||||||||||||||||||||
    1073 ΑΓΤΤΧΑΑΤΤΤΤΓΧΧΑΤΓΑΑΓΤΤΧΑΑΧΓΧΧΧΤΓΓΑΓΧΤΓΓΑΧΓΑΧΑΓΧΓΑΧ 1122
                  .         .         .         .         .
    152  ΑΤΧΤΧΓΧΤΓΤΤΧΓΤΓΓΧΧΓΧΧΑΤΧΑΤΤΤΓΧΤΓΧΓΓΑΓΓΑΧΑΓΑΤΧΓΓΧΧΧ 201
         |||||||||||||||||||||||||||||||||||     ||||||||||
    1123 ΑΤΧΤΧΓΧΤΓΤΤΧΓΤΓΓΧΧΓΧΧΑΤΧΑΤΤΤΓΧΤΓΧΓΓ.....ΑΓΑΤΧΓΓΧΧΧ 1167
                  .         .         .         .         .
    202  ΓΓΧΧΤΧΧΤΑΑΑΤΑΤΧΓΑΧΧΑΧΑΤΧΓΑΓΑΑΑΑΤΓΧΑΓΓΑΓΓΧΤΑΤΧΓΤΓΧΑ 251
         ||||||||||||||||||||||||||||||||||||||||||||||||||
    1168 ΓΓΧΧΤΧΧΤΑΑΑΤΑΤΧΓΑΧΧΑΧΑΤΧΓΑΓΑΑΑΑΤΓΧΑΓΓΑΓΓΧΤΑΤΧΓΤΓΧΑ 1217
                  .         .         .         .         .
    252  ΧΓΤΓΧΤΧΑΑΑΧΤΧΧΑΧΧΤΓΧΑΑΑΓΧΑΑΧΧΑΧΧΧΧΓΑΧΓΑΧΑΧΧΤΤΧΧΤΧΤ 301
         ||||||||||||||||||||||||||||||||||||||||||||||||||
    1218 ΧΓΤΓΧΤΧΑΑΑΧΤΧΧΑΧΧΤΓΧΑΑΑΓΧΑΑΧΧΑΧΧΧΧΓΑΧΓΑΧΑΧΧΤΤΧΧΤΧΤ 1267
                  .         .         .         .         .
    302  ΤΧΧΧΧΑΑΑΧΤΓΧΤΧΧΑΓΑΑΓΧΤΓΓΧΓΓΓΑΧΧΤΓΧΓΓΧΑΓΧΤΓΓΤΓΑΧΓΓΑ 351
         ||||||||||||||||||||||||| ||||||||||||||||||||||||
    1268 ΤΧΧΧΧΑΑΑΧΤΓΧΤΧΧΑΓΑΑΓΧΤΓΓΧ.ΓΓΑΧΧΤΓΧΓΓΧΑΓΧΤΓΓΤΓΑΧΓΓΑ 1316
                  .         .         .         .         .
    352  ΓΧΑΤΓΧΧΧΑΓΧΤΧΓΤΓΧΑΓΓΤΧΑΤΧΑΑΓΑΧΓΓΑΓΤΧΑΓΑΧΓΧΧΓΧΓΧΤΓΧ 401
         ||||||||||||||||||||||||||||||||||||||||||||||||||
    1317 ΓΧΑΤΓΧΧΧΑΓΧΤΧΓΤΓΧΑΓΓΤΧΑΤΧΑΑΓΑΧΓΓΑΓΤΧΑΓΑΧΓΧΧΓΧΓΧΤΓΧ 1366
                  .         .         .    
    402  ΑχΧΧΓΧΤΓΧΤΓΧΑΓΓΑΓΑΤΧΤΑΧΑΓΓΓΑΧΑΤΓΤΑ 435
         ||||||||||||||||||||||||||||||||||
   1367  ΑΧΧΧΓΧΤΓΧΤΓΧΑΓΓΑΓΑΤΧΤΑΧΑΓΓΓΑΧΑΤΓΤΑ 1400
Figure 3.27 DNA alignment of  GP4 clone with gPPARα cDNA. The cDNA sequence of clone GP4 and gPPA-
Rα were compared using the BESTFIT tool with GCG sequence analysis program. The upper sequence of the align-
ment is GP4 cDNA sequence, and the lower sequence is gPPARα cDNA sequence. The five nucleotide insert is at
position 1157 in gPPARα cDNA.
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Sequence analysis of gPPARα GP4 clone revealed that this gPPARα clone contained a 5
nucleotide insert in the ligand binding domain region. This 5 nucleotide insert can be seen in
figure 3.27. The 5 nucleotide insert causes a frame shift in the open reading frame, leading to
incorrect sequence and a premature stop codon. Figure 3.27 shows the DNA sequence alignment
of the the GP4 clone and gPPARα cDNA . The regions shown were compared to the DNA
sequences of mouse PPARα exons 7 and 8. The 5 nucleotide insert aligns at the position of the
junction between exons 7 and 8. The donor GT- site of the intron between exon 7 and 8 forms
a lariat structure with an AG- acceptor site at the end of the intron.  In the mRNA that the GP4
cDNA was derived the donor site of the intron between exons 7 and 8 has differentially spliced
with another AG- acceptor site four nucleotides 5’ to the correct AG- acceptor site. This results
in intron sequence being left in the normal coding region. Figure 3.28 shows a cartoon of the
mechanism of differential splicing that would give rise to a 5 nucleotide insert.
Figure 3.28 gPPARα GP4 clone contains differentially spliced exons. The DNA sequence of the GP4
cDNA clone was compaired to the DNA sequence of gPPARα cDNA and to mPPARα exons 7 (x75293) and 8
(x75294) using BESTFIT tool within GCG sequence analysis program. The regions of high similarity between GP4
cDNA and mPPARα exons 7 and 8 are highlighted by bold lines. The five nucleotide insert lies between the re-
gions of similarity to exons 7 and 8. A cartoon of the mRNA lariat formation on the incorrect acceptor site is
shown below the sequence alignment.
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Σεχτιον 3.3 Χλονινγ οφ φυλλ λενγτη γΠΠΑΡα χDΝΑ
Full length gPPARα cDNA was generated by an overlapping PCR strategy. The cDNA inserts
of clones GP1 and GP11 were amplified using GPIGP6 and GPIGP16 for GP11 , and GPIGP4
and GPIGP3 for GP1. These amplifications gave rise to a 414 bp fragment encoding
DWLLPADMVD to GVHACEGCKG and a 1056 bp fragment encoding
YHYGVHACEGCKGFF to IYRDMY. These overlapping fragments were amplified for 10
cycles using the annealed overlap region as primer sites. This PCR reaction was then amplified
414 bp cDNA
1056 bp cDNA
GPIGP3
GPIGP16
Amplified full length
(1.4 kb) gPPARα
cDNA
(10 cycles)
(25 cycles)
Overlapping PCR
Standard PCR
Figure 3.29 Cartoon of two stage overlapping PCR strategy. 
kb
1.4
1.1
0.8
0.1kbp Ladder
Figure 3.30 PCR amplification of full length gPPARα cDNA. 5 ml of PCR reaction was analysed on a 1%
agarose gel (0.5*TBE) run at a constant 100v for 1.5 hours. The 414bp and 1056 bp DNA fragments were amplified
for 10 cycles in the following conditions [ 94 C, 1 min; 57 C, 1 min; 72 C, 2.5 min]. 0.1ml of the overlapping PCR
reaction was amplified with GPIGP16 and GPIGP3 for 25 cycles in the following conditions [ 94 C, 1 min; 57 C, 1
min, 72 C, 2.5 min ]. The PCR product was sized using a 100 bp DNA ladder.
Alex R. Bell Section 3.2.8
Page 133
using GPIGP16 and GPIGP3 to generate a 1423 bp gPPARα cDNA. Figure 3.29 shows a
cartoon of the strategy used to produce the amplified 1.4 kb gPPARα cDNA, and figure 3.30
shows the final product of the PCR startegy analysed by gel electrophoresis.
The 1.4kb gPPARα cDNA was purified and cloned into pGEM-T vector, producing the clone
α1-fullpGEM-T. The 1.4 kb insert was cut out of α1-fullpGEM-T using Sac II and Not I
restriction enzymes and cloned into Sac II / Not I cut pBluescript SK (+) vector, to produce α1-
full-pBluescript. The 1.4 kb insert was then cut out of α1-full-pBluescript using Sac I and Not
I restriction enzymes and cloned into Sac I / Not I cut pBK-CMV vector. A cartoon of the
cloning strategy is given in figure 3.31. gPPARα-pBK-CMV vector was verifed by DNA
sequencing using primers GPIGP9, GPIGP12 and GPIGP16. The DNA sequence of gPPARα-
pBK-CMV verfied that the overlapping PCR strategy worked correctly. gPPARα-pBK-CMV
was mapped using the Xho I, Nar I, Eco 52I, Pst I and Bgl II restriction enzymes. The results of
these digests also confirmed that full length gPPARα cDNA had been produced and cloned
correctly. 
Figure 3.31 Cartoon of the cloning of full length gPPARα cDNA . 
pBluescript SK (+)
pGEM-T
pBK-CMV
Sac I / Not I
Sac II / Not I
Eco RV cut + T-tailed
double digest
double digest
pGEM-5Zf(+)
Purified 1.4kb
gPPARα cDNA
(1)
(2)
(3)
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Σεχτιον 3.3.1 Ιν ϖιτρο σψντηεσισ οφ γΠΠΑΡα προτειν 
gPPARα-pBK-CMV plasmid was transcribed and translated in vitro, producing gPPARα
protein. Promega’s TNT rabbit reticulocyte lysate system was used to produce [35S] labelled
gPPARα, hPPARα and mRXRα proteins. Figure 3.32 shows SDS-PAGE analysis of in vitro
translated proteins produce using this system. In vitro transcription and translation of gPPARα-
pBK-CMV vector yielded a protein of approximate molecular weight 52 kDa. This result
confirms that a full length open reading frame of gPPARα was cloned and that the protein
produced from this open reading frame corresponded to the predicted molecular weight.
Σεχτιον 3.4 Φυνχτιοναλ χηαραχτερισατιον οφ γΠΠΑΡα
Σεχτιον 3.4.1 Οπτιmισατιον οφ τρανσφεχτιον.
Human embryonic kindey 293 cells were cultured in 25 cm2 falcon flasks. Briefly confluent
monolayers of 293 cells were separated into individual unattached cells by incubation in 1* PBS,
0.5 mM EDTA for 5 minutes at 37 C. Cells were pelleted by centrifugation at approximately
100g for 5 minutes. 293 cell pellets were resuspended in culture medium and assessed for viability
1 2 3 4
kDa
87
69
56
38
Figure 3.32 SDS-PAGE analysis of in vitro translated gPPARα, hPPARα and mRXRα. SDS-PAGE analy-
sis of proteins produced by in vitro transcription and translation of gPPARα-pBK-CMV vector (lane 1), hPPARα-pBK-
CMV (lane 2), mRXRα-pGEM5 (lane 3) and control, no vector DNA (lane 4). 10 ml of each transcription/ translation
reaction was analysed on a 10 % SDS-PAGE gel run in 1* Laemmli buffer. The gel was fixed and dried and exposed
for 4.5 hours on a high intensity [35S] screen.[ 35S] labelled protein bands were visualized using a Bio-Rad Molecular
Imager.
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by Trypan Blue Dye exclusion assay. Cell preparations which had a viability of 70-90% were used
for propagation of the cell line. 0.5 * 10 6 viable cells were seeded in 5 ml of culture medium
and allowed to attach over 3 days of incubation. Flasks with attached cells were either used for
continued propagation of the cell or used in transfection experiments.
A protocol for transfecting primary cultures of rat hepatocytes was established in our laboratory.
This protocol was used as the starting point for optimisation of transfection of 293 cells with
plasmid DNA. pRSV-βGAL vector, a eukaryotic expression vector for β-galactosidase was used
as the test plasmid for optimisation. The amount of transfected plasmid and amount of L-α-
phosohatidylethanolamine,dioleoyl (C18:1,[cis]-9) / N-[I-(2,3-dioleoyloxy)proyl]-N,N,N-
triethylammonium (Dotma/Dope 1:1 mix) cationic liposome transfection reagent (Felgner, D.L.
et al 1987) was varied to elucidate optimal transfection conditions. Transfection efficiency was
measured as the percentage of 293 cells per flask that stained a positive blue after X-gal
chromogenic assay (Sanes, J.R. et al 1986). Tables 3.3 and 3.4 show the results of optimising the
amounts of DNA and Dotma / Dope (DD) cationic liposome transfection reagent. The optimal
conditions for transfection of 293 cells were found to be 8-12 mg of DNA and 5mg of DD
reagent. Under these conditions 1-3% of cells were transfected successfully with DNA.
Transfections using amounts of DD higher than 5 mg led to cytotoxic effects, as measured by the
ammount of cell detachment.
Αmουντ οφ 
DΝΑ mγ
περ ⇓ασκ
4 8 12
% οφ χελλσ 
τρανσφεχτεδ
 1% 1−3% 2−3%
Table 3.3 Effect of amount of plasmid DNA on transfection efficiency . The 
amount of Dotma /Dope transfection reagent was kept constant at 5 mg per flask of 293 cells. 
The % of cells transfected was determined by counting the number of cell stained blue by the 
X-gal chromogenic assay in at least six microscope fields and by representing this number as a 
fraction of the total number of cells in the fields observed. (see methods)
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Σεχτιον 3.4.2 Χονστρυχτιον οφ (ΑΧΟ−ΠΠΡΕ) ρεπορτερ πλασmιδ.
The rat acyl-CoA oxidase gene PPRE were cloned into promega’s pGL3-Luc promoter vector
as a tandem repeat. Two complementary long oligonucleotides containing two tandem copies of
the PPRE were annealed to give Sac I and Bgl II overhangs. pGL3 -Luc vector was cut with Sac
I and Bgl II restriction enzymes and ligated to the PPRE DNA fragment. Positives for the insert
were screened by Mlu I digestion of positive clones. The Sac I/ Bgl II digest of pGL3-Luc
removed the polylinker Mlu I site. Clones positive for a PPRE did not cut with Mlu I enzyme.
A (ACO-PPRE)2-pGL3-Luc positive was sequenced accross the insert site to DNA confirm the
presence and sequence of the tandem PPREs.
Σεχτιον 3.4.3 Οπτιmιστατιον οφ τρανσφεχτιον νορmαλισατιον
Initial transfection assay conditions used 2 mg pCAT-control transfection normalisation vector
with 3 mg hPPARα-pBK-CMV vector and 6 mg (ACO-PPRE)2-pGL3-Luc vector, transfected
into 293 cells. Cells were dosed with peroxisome proliferator or vehicle and incubated for 48
hours. Cell extracts were harvested according to the instructions given in promega’s firefly
luciferase assay kit. The luciferase activity of each cell extract was done according to the
manufacturers instructions. Transfection of pCAT-control into mammalian cells results in strong
expression of CAT enzyme. Detection of CAT enzyme activity was performed by using [14C]
labelled chloramphenicol and n-butyryl co-enzyme A as subtrates. CAT transfers the n-butyryl
Αmουντ οφ 
DD mγ 
περ ⇓ασκ
5 10 15 20
% οφ χελλσ 
τρανσφεχτεδ
1−3% < 1% χψτοτοξιχ χψτοτοξιχ
Table 3.4 Effect of amount of Dotma/Dope (DD) on transfection efficiency.  The amount of 
DNA transfected into each flask was kept constant at 8 mg per flask of 293 cells. The % of cells transfected 
was determined by counting the number of cell stained blue by the X-gal chromogenic assay in at least six 
microscope fields and by representing this number as a fraction of the total number of cells in the fields 
observed.(see methods). Cytotoxicity was characterised by detachment of cells
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moiety of the co-factor to chloramphenicol. n-butyryl-[14C]-chloramphenicol products can be
isolated form unreacted [14C]-chloramphenicol using a xylene extraction process (Seed , B and
Sheen, J.Y. 1988). The amount of [14C]-chloramphenicol turned over was measured by liquid
scintillation counting and was directly proprotional to the amount of CAT enzyme produced in
transfected cells.
hPPARα-pBK-CMV, (ACO-PPRE)2.pGL3-Luc and pCAT-control vectors were transfected
into 293 cells in varying ratios. Extracts from flasks transfected with all three vectors together
were were assayed for Firefly luciferase activity and CAT activity. Table 3.5 summarises the
detection of each type of reporter gene activity at various ratios of transfected plasmid. 
CAT activity was measured in cell extracts to normalise the transfection efficiency of the
Luciferase reporter vector. The CAT activity measured for each cell extract was not above
background levels, except for cell extracts derived from flasks that had been only transfected with
pCAT-control vector. The presence of hPPARα-pBK-CMV and (ACO-PPRE)2.pGL3-Luc
vectors caused CAT expression from pCAT-control to be suppressed completely. 293 cell
extracts from cells only transfected with 6 mg or 12 mg of pCAT-control gave CAT activity values
4-fold and 12-fold above control respectively. Firefly luciferase activity measured in different
Αmουντ οφ ϖεχτορ οφ
ηΠΠΑΡα: Λυχιφερασε: ΧΑΤ
(mγ / ⇓ασκ)
Φιρε⇓ψ λυχιφερασε 
αχτιϖιτψ
ΧΑΤ αχτιϖιτψ
3 : 6 : 2 100−7000 φολδ 
αβοϖε βαχκγρουνδ
Νονε δετεχτεδ
3 : 3 : 6 100−7000 φολδ 
αβοϖε βαχκγρουνδ
Νονε δετεχτεδ
0 : 0 : 6 Νοτ ασσαψεδ 4−φολδ αβοϖε 
βαχκγρουνδ
0 : 0 : 12 Νοτ ασσαψεδ 12−φολδ αβοϖε 
βαχκγρουνδ
Table 3.5 Summary of  CAT and Luc reporter gene activity. 
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extracts from flasks transfected with (ACO-PPRE)2.pGL3-Luc varied between 100-fold to
7000-fold above background Luciferase activity.
It is possible that these results are due to interaction of the CMV promoter based plasmids with
the pCAT-control transfection normalisation plasmid, or due to toxicity resulting from high
levels of CMV promoter based plasmids.Therefore the transfection normalisation vector was
changed to pRL-CMV and the amounts of CMV promoter based plasmids was reduced. The
plasmid pRL-CMV (promega) contains the Renilla Luciferase gene (Sea Pansy luciferase gene)
under the control of cytomegalovirus (CMV) enhancer and immediate promoter. 293 cells co-
transfected with pRL-CMV and hPPARα-pBK-CMV (or gPPARα-pBK-CMV) and (ACO-
PPRE)2.pGL3-Luc produced extracts which when assayed for Renilla luciferase acitivity gave
measurements 20-7000 fold above background values. 293 cells transfected with between 0.1 -
6 mg of (ACO-PPRE)2-pGL3-Luc vector produced cell extracts which when assayed for firefly
luciferase activity gave measurements between 60 and 7000-fold above background
measurements. 
Figure 3.33 Induction  of luciferase requires a PPRE. 293 cells were transfected with 0.3 mg of hPPARα-
pBK-CMV expression vector, 1mg pRL-CMV, 1mg of either (ACO-PPRE)2-pGL3-Luc or 1 mg pGL3-Luc.pRSET-B was add-
ed to each flask make the final DNA amount per flask 5 mg. Flasks were either dosed with 100 mM Wy-14,643 or
DMSO vehicle control and incubated for 48 hours. Cell extracts were harvested and assayed for Firefly luciferase
activity and Renilla luciferase activity. Firefly luciferase activity was normalised with Renilla luciferase activity. The
mean of duplicate assays is plotted. R denotes PPARα receptor and PP denotes the peroxisome proliferator Wy-
14,643. *- Reporter activity in the presence of PPRE is significantly higher than in the absence of PPRE (p= 0.05,
df=2). Data points were analysed by Student’s T-test
*
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Σεχτιον 3.4.4 Ινδυχτιον οφ λυχιφερασε βψ ΠΠΑΡα ανδ περοξισοmε προλιφερατορσ
The induction of firefly luciferase reporter gene in (ACO-PPRE)2-pGL3-Luc by hPPARα and
the peroxisome proliferator Wy-14,643 was dependent on the presence of the PPRE. pGL3-Luc
control vector which does not contain either regulatory response elements or enhancer elements
was not induced by the expression of PPARα and presence of peroxisome proliferator in 293
cells, see figure 3.33. (ACO-PPRE)2.pGL3-Luc was not induced in the absence of both
hPPARα and peroxisome proliferator. 
The amount of (ACO-PPRE)2-pGL3-Luc vector was increased to 6mg per flask to see if a larger
peroxiosome proliferator induced response could be obtained. The amount of hPPARα-pBK-
CMV vector per flask was varied from 0 to 0.3 mg per flask in the presence of high amounts of
ACO-PPRE reporter vector. Figure 3.34 demonstrates that as the amount of hPPARα
expression vector is increases the total amount of normalised firefly luciferase activity decreases.
MCP
DMSO
Figure 3.34 Effect of plasmid quantity on luciferase expression. 293 cells were transfected with 0, 0.01,
0.05 and 0.3 mg of hPPARα-pBK-CMV expression vector, with equivalent amounts of pRL-CMV (except for flasks with
0mg of PPARα which had 0.3mg of pRL-CMV co-transfected), 6 mg of either (2*ACO-PPRE)pGL3-Luc. pRSET-B was
added to each flask make the final DNA amount per flask 9 mg. Triplicate flasks were either dosed with 50 mM me-
thylclofenopate (MCP) or DMSO and incubated for 48 hours. Cell extracts were harvested and assayed for Firefly
luciferase activity and Renilla luciferase activity. Firefly reporter gene activity was normalised with Renilla luciferase
activity. The mean of triplicate assays is plotted.
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Under these assay conditions 50 mM MCP was not able to augment reporter gene activity in the
presence of PPARα receptor. Substantial peroxisome proliferator independent activation of
reporter gene activity was observed, but in the absence of PPARα receptor activation of the
PPRE containing reporter vector was not observed.
A comparison of peroxisome proliferator induced activation of (ACO-PPRE)2-pGL3-Luc
reporter vector was tested at moderate (1mg) and low (0.1mg) levels of PPRE containing reporter
vector per flask. These two levels of (ACO-PPRE)2-pGL3-Luc vector were assayed at 0, 0.05
and 0.1 mg of gPPARα-pBK-CMV per flask in the presence or absence of 100 mM Wy-14,643.
Figure 3.35 shows that reducing the amount of PPRE containing reporter gene 10-fold, causes
a 10-fold reduction in reporter gene activity at all levels of gPPARα expression vector tested,
and in a peroxisome proliferator independent manner. Figure 3.35 also shows that Wy-14,643
0.1 mg per flask
(ACO-PPRE)2.
pGL3-Luc
1.0 mg per flask
(ACO-PPRE)2.
pGL3-Luc
Figure 3.35 Optimisation of quantity of transfected DNAs. . 293 cells were transfected with 0, 0.01, and
0.05 mg of gPPARα-pBK-CMV expression vector, 0.01mg pRL-CMV, and 1 mg of either (ACO-PPRE)2-pGL3-Luc. pRSET-
B was added to each flask to make the final DNA amount per flask 5 mg. Duplicate flasks were either dosed with
100 mM Wy-14,643 or DMSO and incubated for 48 hours. Cell extracts were harvested and assayed for Firefly lu-
ciferase activity and Renilla luciferase activity. Firefly reporter gene activity was normalised with Renilla luciferase
activity. * Wy-14,643 induced transcriptional activation of reporter gene 3.4 fold (df=2, p=0.02) over DMSO control
and ** Wy-14,643 induced transcriptional activation of reporter gene 1.7 fold (df=2, p=0.05) over DMSO control.
The mean of duplicate assays is plotted. Data points were analysed by Student’s T-test.
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could activate a PPRE containing reporter gene construct 3.4 fold (p=0.05, df=2) in flasks
containing 0.1 mg of (ACO-PPRE)2-pGL3-Luc and 0.05 mg of gPPARα-pBK-CMV vectors.
A smaller , 1.7-fold (p=0.02, df=2) induction of reporter gene activity was observed in flasks
containing 1mg of (ACO-PPRE)2.pGL3-Luc and 0.05mg gPPARα-pBK-CMV , dosed with
100 mM Wy14,643. The degrees of freedom used to calculate the statistical significance of these
results was low due to the low number of replicate flasks. Therefore the experimental conditions
which gave rise to a 3.4-fold induction of reporter gene activity were examined using more flasks
to give a higher degree of statistical accuracy. Figure 3.36 demonstrates that Wy-14,634 induced
(ACO-PPRE)2-pGL3-Luc reporter vector 2.3-fold (p=0.001, df=6) in the presence of
exogenously expressed gPPARα receptor.
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Figure 3.36 Wy-14,643 induces gPPARα transcriptional activation. 293 cells were transfected with
0.05 mg of gPPARα-pBK-CMV expression vector or 0.05 mg pBK-CMV vector, 10 ng pRL-CMV, 0.1mg of (ACO-PPRE)2-
pGL3-Luc. pRSET-β plasmid DNA was added to each flask make the final DNA amount per flask 5 mg. Flasks were
dosed with either 100 mM Wy-14,643 or DMSO and incubated for 24 hours. Cell extracts were harvested and as-
sayed for Firefly luciferase activity and Renilla luciferase activity. Firefly reporter gene activity was normalised with
Renilla luciferase activity. The mean of quadruplictate assays is plotted. **- Reporter activity in the presence of
Wy-14,643 is significantly higher than in the presence of DMSO (p= 0.001, df=6). The error bars shown represent
the standard deviation from the mean. Data points were analysed by Student’s T-test
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Σεχτιον 3.5 Εξπρεσσιον οφ γΠΠΑΡα ανδ mΠΠΑΡα mΡΝΑ
RNAse protection assays were used to examine the expression of mPPARα and gPPARα
mRNA in liver. Anti-sense ribo-probes corresponding to the C-terminal end of the coding
sequence were generated and hybridised to purified total liver RNA. Hybridisation of ribo-probe
to PPARα mRNA results in an RNA duplex structure which is resistant to digestion with
Ribonuclease A. The protected RNA fragments are run on a denaturing acrylamide gel and can
be visualised by autoradiography. Figure 3.37 (A) demonstrates that mPPARα is highly expressed
Ma
mouse
 RNA
tRNA
+ +-
Probe
RNase A
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RNase A
guinea pig
 RNA
tRNA
+ +-
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Protected
fragment
Protected
fragment
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100bp
200 bp
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(B)
Figure 3.37 Expression of gPPARα and mPPARα mRNA in liver. Determination of expression of mouse
PPARα (A) mRNA and guinea pig PPARα mRNA (B) by RNase protection assay. 30 mg of   RNA was hybridised with
each ribo-probe. Anti-sense mPPARα probe was made by transcribing Ase I cut pT7-7-anti sense mPPARα plasmid
with T7 RNA polymerase. Full length mPPARα probe was 282 bp and protected fragment length was 193 bp long.
30 mg tRNA hybridised with mPPARα probe was treated with and without RNase A to determine if non-specific mRNA
species were being protected. RNase protection assays were run on a 6% denaturing acrylamide gel in 1* TBE at
300 v. Anti-sense gPPARα probe was made by transcribing Pvu II cut gPPARα-pBK-CMV plasmid with T7 RNA poly-
merase. Full length gPPARα probe was 170bp . RNase protection assays were run on a 8% denaturing acrylamide
gel run in 1* TBE at 300 v. Gels were fixed, dried and exposed to the same piece of hyperfilm at -70 C for 2 days.
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in the liver, and figure 3.37 (B) demonstrates that gPPARα is also expressed in the liver. The
negative control (marked tRNA - ) shows that the riboprobe synthesised is full length and in
excess of the protected fragments. The addition of  RNase A  to yeast tRNA (figure 3.37 (A)
tRNA +) results in near complete digestion of  probe: therefore the protected fragments
observed in the guinea pig and mouse liver result from specific hybridisation. The mPPARα and
gPPARα anti-sense probes were  synthesised in tandem using the same reagents, and thus had
the same specific activity. The protected mPPARα fragment was 193 bp long and the gPPARα
signal  was 170 bp long. Thus equimolar amounts of  the mPPARα and gPPARα fragments in
figure 3.37 would produce a signal ratio of 1.14: 1. Figure 3.37 shows that the amount of mouse
PPARα RNA is much greater than the amount of guinea pig PPARα RNA: however, this data
is an autoradiogram, and is not suitable for quantitative analysis. Subsequent analysis of these
RNA samples by phosphor imaging showed that mPPARα mRNA expression was at least 10-
fold greater than gPPARα mRNA expression (D. Brady, personal communication). The
Full length
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Figure 3.38 Expression of gPPARα mRNA across a 24 hour period.  Anti-sense gPPARα probe was made
by transcribing Pvu II cut gPPARα-pBK-CMV plasmid with T7 RNA polymerase. Full length gPPARα probe was 170bp
and protected fragment length was 97 bp. The size of the protected fragment in 1 was the same as the full length
probe due to lack of RNase A digestion of the single strand RNA over hang in the probe / mRNA hybrid duplex. Pro-
tected fragment 2 is the probe / mRNA hybrid that has had single strand over hang (corresponding to transcribed
vector DNA) completely digested by RNase A, leaving only protected gPPARα mRNA. RNase protection assays were
run on a 8% denaturing acrylamide gel run in 1* TBE at 300 v. Gels were fixed, dried and exposed to hyperfilm at -
70 C for 2 days.
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expression of gPPARα mRNA was determined in liver of animals killed at 6.00 AM, 12.00
Noon, 6.00 PM and 12.00 Midnight. Figure 3.38 shows that gPPARα mRNA expression in
liver does not vary across a 24 hour period.
Σεχτιον 3.6 Εξπρεσσιον οφ mΠΠΑΡα DΝΑ βινδινγ δοmαιν
A 336 bp DNA fragment spanning the mPPARα DNA binding domain (mPPARα-DBD) was
amplified from pSG5-mPPARα DNA using primers mPPARα-P1 and mPPARα-P2. A Pst I
site was engineered into the 5’ end of the fragment by using a single nucleotide mismatch in
mPPARα-P1. The nucleotide change results in a Glycine to Cysteine amino acid transition. A
3’ translational stop codon was engineered by a nucleotide mismatch in primer mPPARα-P2.
The translational stop site occurs at position 199. The 336 bp amplified fragment spans from
amino acids 92 E to 203 L. Figure 3.39 shows an amplifed DNA fragment corresponding to the
predicted size.
mPPARα-DBD DNA was purified using Qiagen Qiaquick spin columns and was cloned into
pRSET-A prokaryotic expression vector. The mPPARα-DBD was cloned inframe to an N-
506 bp
394 bp
344 bp
298 bp
-ve
pSG-mPPARα
mPPARα-DBD
Figure 3.39 PCR amplification of mPPARα-DBD DNA. 5 ml of PCR reaction was analysed on a 1.5% agarose
gel, run in 0.5* TBE at 100v for 2 hours . DNA bands were visualised by ethidium bromide staining. mPPARα-DBD
DNA was amplified using pSG5-mPPARα template DNA and primers mPPARα-P1 and mPPARα-P2. The lane marked
negative contains products from a PCR with no template DNA. PCR reactions were amplified for 25 cycles at [94 C,
1 min; 50 C, 1min; 72 C, 1 min].
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terminal 41 amino acid tag. The N-terminal peptide contains a six histidine (His*6) tag that
allows purification on Ni2+ containing resins or other metal affinity resins such as Talon Metal
Affinity Resin . The N-terminal peptide provided by the pRSET-A vector also contains a
protease cleavage site for the protease enzyme Enterokinase. The cloning strategy used for
cloning mPPARα-DBD was not directional, therefore clones positive for an insert were
screened for correct orientation using a Kpn I digest. Figure 3.40 two shows DNA digests of two
pRSET-A-mPPARα-DBD positive clones. The Pst I digest releases the mPPARα-DBD DNA,
producing a 317 bp fragment. The Kpn I digest of pRSET-A-mPPARα-DBD DNA will yield
two DNA fragments. If the insert is in the correct orientation a 274 bp and a 2962 bp fragment
will be produced, but if the insert is in the wrong orientation a 64bp fragment and a 3172 bp
fragment will be released. The two pRSET-A-mPPARα-DBD clones in figure 3.40 are in the
correct orientation. The Kpn I digest has released 274 bp and 2962 bp DNA fragments.
Σεχτιον 3.6.1 Προκαρψοτιχ εξπρεσσιον οφ mΠΠΑΡα −DΒD
pRSET-A-mPPARα-DBD plasmid DNA was transformed into BL21 (DE3)pLys S E.coli cells.
3054 bp
398 bp
344 bp
298 bp
220 bp
201 bpPKPK
DNA prep 21
P = Pst I
K = Kpn I
Figure 3.40 Cloning of mPPARα-DBD into pRSET-A vector. pRSET-A-mPPARα-DBD clones were digested
with Pst I and Kpn I restriction enzymes. The products of each restriction digest were analysed on a 2% agarose ge
run in 0.5* TBE at 100v for 2 hours. DNA bands were visulaised by ethidium bromide staining. DNA fragments were
sized using a 1kb DNA marker ladder.
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Small scale (10 ml ) cultures of BL21 (DE3)pLysS-pRSET-A-mPPARα-DBD were grown in
LB-broth in a shaking incubator. Cutlures of OD600nm = 0.6-0.8 were induced for expression
of His*6 tagged mPPARα-DBD protein by the addition of IPTG to the culture medium. Total
cell extracts from induced and uninduced BL21 (DE3) pLysS and BL21 (DE3)pLysS-pRSET-A-
mPPARα-DBD were analysed by SDS-PAGE. Figure 3.41 shows the analysis of such cell
extracts. The predicted molecular weight of the tagged mPPARα protein is 16.6 kDa. An
induced band of molecular weight < 20 kDa is observed in BL21 (DE3)pLysS-pRSET-A-
mPPARα-DBD cultures but not BL21(DE3)pLysS control cultures.
Two litres of BL21 (DE3)pLysS-pRSET-A-mPPARα-DBD culture was grown to an optical
OD600nm = 0.6. mPPARα-DBD protein expression was induced by the addition of IPTG to
a final concentration of 0.5 mM. Cells were harvested by centrifugation. The cell pellet was
resuspended in 1* Talon Binding Buffer, freeze-thawed once, and then sonicated to disrupt the
cell membrane. Soluble and insoluble material was clarified by ultra-centrifugation. Proteins
from the soluble and insoluble fractions were analysed by SDS-PAGE. Figure 3.42 demonstrates
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Figure 3.41 Induction of mPPARα-DBD protein. SDS-PAGE analysis of total cell extracts of induced and un-
induced BL21 (DE3) pLysS (A) and BL21 (DE3)pLysS-pRSET-A-mPPARα-DBD (B and C). 0.5 mM IPTG (final concen-
tration) was used for induced cultures. Proteins were run on a 15% SDS-polyacrylamide gel, in 1* laemmli buffer at
a constant 70 mA for 1 hour. Proteins were visulised by Coomassie Blue staining.
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that the induced mPPARα-DBD protein segregates into the insoluble fraction.
Σεχτιον 3.6.2 Εφφεχτ οφ λοωερ τεmπερατυρε ον προτειν σολυβιλιτψ
BL21 (DE3)pLysS-pRSET-A-mPPARα-DBD cultures were grown at 30 C and 37 C and were
induced for the expression of mPPARα-DBD protein by the addition of IPTG to a final
concentration of 0.5 mM. Figure 3.43 demonstrates that mPPARα-DBD protein induced at 30
C did not seggregate into the insoluble or soluble fraction differently than mPPARα-DBD
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Figure 3.42 SDS-PAGE of purified proteins from induced cultures. Approximately 12.5mg of soluble and in-
soluble protein extract, isolated from an induced BL21 (DE3) pLysS-pRSET-A-mPPARα-DBD culture were run on a
15% SDS-polyacrylamide gel, in 1* laemmli buffer at 70 mA for 1 hour. Proteins were visualised by Coomassie Blue
Staining.
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Figure 3.43 Induction of mPPARα-DBD at 37 C and 30 C. SDS-PAGE analysis of total cell extracts (T), sol-
uble cell extracts (S) and insoluble cell ectracts (P) of uninduced (gel A) and induced (gel B) BL21 (DE3)pLysS-pRSET-
A-mPPARα-DBD cultures grown at 37 C. Cultures analysed in A and B were grown in a shaking incubator. SDS-PAGE
analysis of total cell extracts (T), soluble cell extracts (S) and insoluble cell extracts (P) of induced BL21 (DE3)pLysS-
pRSET-A-mPPARα-DBD cultures grown at 30 C (gel C) and 37 C (gel D). Cultures analysed in C and D were grown in
waterbaths, without mechanical shaking. 0.5 mM IPTG (final concentration) was used for induced cultures. Proteins
were run on a 15% SDS-polyacrylamide gel, in 1* laemmli buffer at a constant 70 mA for 1 hour. Proteins were visu-
lised by Coomassie Blue staining.
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protein induced at 37 C. Induction at a 30 C did not alter the solublity of over-expressed
mPPARα-DBD protein.
Σεχτιον 3.6.3 Αφ⇒νιτψ πυρι⇒χατιον οφ mΠΠΑΡα−DΒD προτειν
The soluble fraction of proteins produced from a 37 C, IPTG induced culture of BL21
(DE3)pLysS-pRSET-A-mPPARα-DBD was passed through Talon Metal Affinity Resin. No
trace levels or low levels of soluble His*6 tagged mPPARα-DBD bound to the affinity resin.
Figure 3.44 shows that no proteins from the soluble fraction bound to the affinity resin. This
result demonstrates that all mPPARα-DBD protein produced segregated into the insoluble
fraction. Insoluble proteins were solubilised in 1* Talon Binding Buffer containing 6M
Guanidine. His*6 tagged mPPARα-DBD protein was purified from the resolublised protein
fraction using Talon metal affinity resin. Elution fractions 1 and 2 were dialysed against a 25 mM
Hepes, 100 mM NaCl, 0.4 mM ZnSO4 solution, pH=7.6 using a “Slide-a-lyzer” dialysis cassette
with molecular weight cut off of 10 000 Da. Renatured His*6 tagged mPPARα-DBD was
analysed for purity by SDS-PAGE. Figure 3.45 shows highly purified His*6 tagged mPPARα-
DBD protein. The total amout of protein in elution fractions 1 and 2 was 432 mg and 516 mg
T Un E1 E2 E3 MaMa
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Figure 3.44 Purification of protein  using Talon  resin. SDS-PAGE analysis of soluble proteins from a 37 C,
IPTG induced culture of BL21 (DE3)pLysS-pRSET-A-mPPARα-DBD , purified on Talon metal affinity resin. Total soluble
proteins (T), unbound soluble proteins (Un) , eluted proteins (fractions E1, E2 and E3) and marker proteins (Ma)
were run on a 20 % SDS-polyacrylamide gel, in 1* laemmli buffer at a constant 35 mA for 1 hour. Proteins were
visulised by Coomassie Blue staining.
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respectively.
Σεχτιον 3.6.4 Ρεmοϖαλ οφ Ηισ∗6 Ταγ φροm mΠΠΑΡα−DΒD 
Enterokinase protease enzyme was used to cleave off the His*6 tag from the His*6 tagged
mPPARα-DBD fusion protein. 88mg of DBD protein was treated with enterokinase. Analysis
of the cleavage of the fusion protein was done by sampling small aliquots of the protease digestion
reaction at 1 hour intervals. Figure 3.46 demonstrates that cleavage of a significant proportion of
the fusion protein occured within one hour of protease treatment. A proportion of fusion protein
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Figure 3.45 Purification of mPPARα-DBD from resolubilised proteins. SDS-PAGE analysis of His*6 tagged
mPPARα-DBD proteins purified from the isloated insoluble protein fraction of a 37 C, IPTG induced culture of BL21
(DE3)pLysS-pRSET-A-mPPARα-DBD. Talon metal affinity resin was used to purify resolubilised His*6 tagged protein.
Eluted fractions E1 and E2 were dialsyed against dialysis buffer: 25 mM Hepes (pH=7.6), 100mM NaCl, 400mM
ZnSO4 to remove denaturing agent. 50 ml of each dialysed fraction was run on a 20 % SDS-polyacrylamide gel, in 1*
laemmli buffer at a constant 35 mA for 1 hour. Proteins were visulised by Coomassie Blue staining.
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Figure 3.46 Cleavage of His*6 tag from mPPARα-DBD. 88 mg of His*6 tagged mPPARα-DBD in buffer (25
mM Hepes pH=7.6, 100 mM NaCl, 0.4 mM ZnSO4), protein was treated with 1.8 mg of Enterokinase protease in a
final volume of 1 ml. 40 ml of this reaction was collected at 1 hour intervals. Protein samples were run on a 20%
SDS-polyacrylamide gel in 1* laemmli buffer at 35 mA for 1 hour. Proteins were visualised by Coomassie blue stain-
ing.
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remained resisitant to protease treatment over the six hour incubation period. 
Σεχτιον 3.6.5 Ελεχτροmοβιλιτψ σηιφτ ασσαψ οφ mΠΠΑΡα−DΒD
An oligonucleotide containing the cytochrome P450 4A6 gene z element PPRE with consensus
5’ flanking sequence (5∏−ΧΑΑΑΑΧΤΑΓΓΤΧΑΑΑΓΓΤΧΑΓΓΓ−3∏) was used to make a [32P]
labelled PPRE probe. This probe termed con-4A6-PPRE was tested for binding to purified
His*6 tagged mPPARα-DBD and untagged mPPARα-DBD protein in an electromobility shift
assay. Figure 3.47 demonstrates that His*6 tagged mPPARα-DBD protein did not bind to the
con-4A6-PPRE probe, even in the absence of non-specific competitor DNA. Figure 3.48
shows that untagged mPPARα-DBD protein does not bind to the con-4A6-PPRE. The con-
4A6-PPRE was tested for binding to mouse liver nuclear proteins and was found to a suitable
DNA substrate for electromobility shift assays (data not shown).
Unbound 
Probe
p(dI-dC.dI-dC) + -
mPPARα
-DBD
-
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-
Figure 3.47 Binding of His*6 tagged mPPARα-DBD  to con-4A6z PPRE. 0.41 pmol [32P]-con-4A6-PPRE
was incubated with between 54 and 486 ng of purified His*6 tagged mPPARα-DBD protein in 1* Tris EMSA buffer
(10 mM Tris-HCl pH=8.0, 5% Glycerol (v/v), 0.1 mM EDTA, 0.4 mM DTT, 100 mM PMSF, 50 mM KCl) in the presence
or absence of 0.1 mg p(dI-dC.dI-dC). Gel was fixed and dried and exposed to hyperfilm overnight.
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Σεχτιον 3.6.6 Χλονινγ οφ τηιορεδοξιν−mΠΠΑΡα−DΒD
mPPARα-DBD DNA was cloned into pThio-His.A prokaryotic expression vector. pThio-
His.A contains the coding sequence for an in frame fusion of E.coli thioredoxin protein. The
resultant thioredoxin-mPPARα-DBD fusion protein has a predicted molecular weight of 27
Unbound
Probe
p(dI-dC.dI-dC) + - + - - -
[ KCl ] mM 50 100 50 100
Figure 3.48 Binding of untagged mPPARα-DBD to con-4A6z PPRE. 0.41 pmol [32P]-con-4A6-PPRE was in-
cubated with between 54 and 486 ng of purified His*6 tagged mPPARα-DBD protein in 1* Tris EMSA buffer (10 mM
Tris-HCl pH=8.0, 5% Glycerol (v/v), 0.1 mM EDTA, 0.4 mM DTT, 100 mM PMSF, 50 mM or 100 mM KCl) in the pres-
ence or absence of 0.1 mg p(dI-dC.dI-dC). Gel was fixed and dried and exposed to hyperfilm overnight.
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Figure 3.49 DNA digests of putative pThio-His.A-mPPARα-DBD clones. Putative pThio-His.A-mPPARα-
DBD clones were screened for the presence of an insert DNA by Pst I restriction digestion (gel A). The same clones
(numbers 1-7) were restriction digested with Bgl II restriction enzyme to determine the orientaion of the inserts (gel
B). pThio-HIS.A vector was cut with Pst I and Bgl II as an internal control. Products of each restriction digest were
run on a 1.5 % agarose gel run in 0.5* TBE at 100v for 1.5 hours. DNA bands were visualised by ethidium bromide
staining. DNA fragments were sized using a 1kb marker ladder.
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kDa. The thioredoxin domain has been modified at E31 and Q63. These two residues have been
changed to Histidine residues, which in the native folded protein forms a “His-patch” which can
bind to metal affinity resins (Invitrogen pThio-His.A manual). The cloning of mPPARα-DBD
DNA into pThio-His.A was non-directional. Therefore putative clones had to be screened for
the presence and orientation of the insert. Figure 3.49 (A) shows Pst I digests of seven putative
pThio-His.A-mPPARα-DBD clones. All seven are positive for a DNA insert. A Bgl II digest
was carried out on these seven clones. An insert in the correct orientation will yield a 288 bp
fragment and a 4448 bp fragment. An insert in the wrong orientation will yield a 112 bp fragment
and a 4624 bp fragment. Figure 3.49 (B) shows that only clone 5 is positive for an insert in the
right orientation. Clone 4 contains a single insert in the wrong orientation, and all other clones
have 2 or more concatenated inserts in various orientaions. Clone 5 was used for thioredoxin-
mPPARα-DBD fusion protein expression studies.
Σεχτιον 3.6.7 Εξπρεσσιον οφ τηιορεδοξιν−mΠΠΑΡα−DΒD  προτειν
pThio-His.A-mPPARα-DBD expression vector was transformed into Bl21 (DE3)pLysS E.coli.
Fusion protein expression was induced by the addition of IPTG to the culture medium. Small
scale cultures of Bl21 (DE3)pLysS pThio-His.A-mPPARα-DBD were induced to express fusion
protein at a final IPTG concentration of 1.5 mM. Cells from induced cultures were pelleted and
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Figure 3.50 Induction of  thioredoxin-mPPARα-DBD protein in E.coli. Proteins from total cell extract of unin
duced cultures (UT) and induced cultures (IT), and soluble (S) and insoluble (P) proteins from induced cultures o
BL21(De3)pLysS-pThio-His.A-mPPARα-DBD were analysed on a 12% SDS-polyacrylamide gel. The running conditions
were 1* laemmli buffer, constant 50 mA for 1 hour. Proteins were visualised by Coomassie blue staining.
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sonicated to disrupt the cell wall. Soluble and insoluble proteins were clarified by
ultracentrifugation, and then analysed by SDS-PAGE. Figure 3.50 shows that an induced protein
of approximate molecular weight 30 kDa was present in abundance in the insoluble fraction.
Expression of fusion protein cannot be seen in the soluble fraction. The molecular weight of the
induced band is approximately 3 kDa gretaer in size from the theoretically calculated molecular
weight of the thioredoxin-mPPARα-DBD fusion protein.
The possibility that low levels of soluble thioredoxin-mPPARα-DBD fusion protein were not
produced could not be eliminated by the SDS-PAGE analysis of soluble and insoluble fractions.
The presence of soluble thioredoxin-mPPARα-DBD protein was tested by binding soluble
protein extracts to two types of metal affinity resin. Invitrogens nickel-charged sepharose resin
and Clontechs Talon metal affinity resin were used. Figure 3.51 shows the unbound and bound
soluble proteins that were eluted from the nickel-charged affinity resin at different concentrations
of imidazole. The eluted fractions demonstrate that the nickel-charged sepharose resin bound
most soluble proteins in a non-specific manner. This resin was unable to specifically bind any
UT IT S P NB
[Imidazole] mM
50 200 350 500
Eluted fractions
thioredoxin-
mPPARα-DBD
Figure 3.51 Purification of soluble thioredoxin-mPPARα protein. ProBond nickel charged sepharose resin
was used to purify fusion protein from the soluble protein fraction as described in the methods section. Proteins
were analysed on a 12% SDS-PAGE gel, run in 1* laemmli buffer at 35mA for 1 hour. Proteins were visulised by
Coomassie Blue staining. Lanes marked UT and IT are uninduced total cell extract and IPTG induced total cell extract.
Lanes marked S and P are soluble (S) and insoluble (P) protein fractions clarifed from induced total cell extract. Lane
marked NB are soluble proteins which did not bind to the ProBond resin. The proteins eluted from the ProBond resin
at specific imidazole concentrations are indicated.
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soluble thioredoxin-mPPARα-DBD protein that may have been present. Figure 3.52
demonstrates that no soluble thioredoxin-mPPARα-DBD protein bound to Talon metal affinity
resin. Comparison of the lanes marked S for soluble proteins and NB, non-bound proteins shows
that few soluble proteins bound to Talon metal affinity resin in a non-specific manner. The
eluted fractions E1 and E2 contained very little protein. These two purification experiments
indicate that the induced thioredoxin-mPPARα-DBD protein exclusively segregated into the
insoluble protein fraction. The presence of the thioredoxin protein in the fusion protein did not
increase the solubility of the mPPARα-DBD protein. 
Σεχτιον 3.6.8 Ιν ϖιτρο σψντηεσισ οφ mΠΠΑΡα−DΒD προτειν 
A third strategy was used to make soluble mPPARα-DBD protein. The expression vector
pRSET-A-mPPARα-DBD contains a T7 RNA polymersase binding site which can be utilised
in in vitro transcription / translation experiments. Rabbit reticulocyte lysate extracts were used
with T7 RNA polymerase to produce mPPARα-DBD protein from pRSET-A-mPPARα-
DBD expression vector. Full length mPPARα and mRXRα were also produced. Figure 3.53
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Figure 3.52 Purification of soluble thioredoxin-mPPARα-DBD  protein using Talon resin. Talon metal
affinity resin was used to purify fusion protein from the soluble protein fraction as described in the methods section.
Proteins were analysed on a 12% SDS-PAGE gel, run in 1* laemmli buffer at 35mA for 1 hour. Proteins were visulised
by Coomassie Blue staining. Lanes marked UT and IT are uninduced total cell extract and IPTG induced total cell
extract. Lanes marked S and P are soluble (S) and insoluble (P) protein fractions clarifed from induced total cell
extract. Lane marked NB are soluble proteins which did not bind to the Talon resin. The proteins eluted from the
Talon resin at a lower pH buffer are indicated by E1 and E2.
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shows SDS-PAGE analysis of in vitro translated mPPARα-DBD, mPPARα and mRXRα. 
These in vitro translated proteins were tested for their capacity to bind to PPRE probes in
electromobility shift assays. No specific protein-DNA complexes were observed for mPPARα-
DBD, mPPARα-DBD/mRXRα heterodimers, mPPARα, mRXRα, and mPPARα/
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Figure 3.53 Invitro expression of mPPARα, mRXRα and  mPPARα-DBD proteins. In vitro translated [35-
S] Methionine labelled mPPARα (lane 1), mRXRα (lane 2) and His*6 tagged mPPARα-DBD (lane 3) were produced
from pT7-mPPARα, pGEM5-mRXRα and pRSET-A-mPPARα-DBD expression vectors using rabbit reticulocyte lysate ex-
tract. T7 RNA polymerase was used for the transcriptional component of the synthesis reaction. 5 ml of each tran-
scription / translation reaction was analysed on a 12% SDS-PAGE gel run in 1* laemmli buffer at 50 mA for 1 hour.
The gel was dried and exposed to hyperfilm at -70 C for 2 days.
NS
NS
NS
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
Figure 3.54 Binding of  in vitro translated proteins to con-4A6-PPRE. In vitro translated mPPARα-DBD,
mPPARα and mRXRα proteins were assayed for binding to 0.41 pmol [32P]-con4A6-PPRE 1*Hepes EMSA buffer
(10mM Hepes (pH=7.9), 125 mM NaCl, 1mM EDTA, 7% v/v BSA, 1 mM DTT, 150mM PMSF). A total of 2.5 ml of
translation reaction extract was used per assay. No non-specific competitor DNA was added. Protein-DNA complexes
were resolved on a 7% native acrylamide gel run in 0.25*TBE at a constant 100v. Lane 1 contains mRXRα, lane 2
mPPARα (preparation 2), lane 3 mPPARα (preparation 1), lane 4 no in vitro translation reaction proteins, lane 5 mP-
PARα(2)/mRXRα, lane 6 mPPARα(1)/mRXRα, lane 7 mPPARα-DBD (1), lane 8 mPPARα-DBD(2), lane 9 mPPARα-DBD
(3), lane 10 control reticulocyte lysate extract, lane 12 mRXRα, lane 13 mRXRα/mPPARα-DBD(1), lane 14 mRXRα/
mPPARα-DBD(2), lane 15 mRXRα/mPPARα-DBD(3) and lane 16 control reticulocyte lysate extract. NS are non-spe-
cific shifted protein-DNA complexes. Radioactivity was detected by phosphor-imaging.
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mRXRα heterodimers with con4A6-PPRE probe, see figure 3.54. Independent batches of in
vitro translated proteins were assayed to show reproducibility. Wild type and mutant rat acyl-CoA
oxidase probes and mutant con4A6-PPRE probes were also assayed. No specific protein-DNA
complexes were observed under any of the conditions tested (data not shown).
His*6 tagged mPPARα-DBD and thioredoxin-mPPARα fusion proteins were successfully
produced in BL21 (DE3)pLys S E.coli cultures. However the induced fusion proteins segregated
into the insoluble inclusion body particles in these E.coli. No readily soluble mPPARα-DBD was
produced that could be purified using Metal ion affinity resins. Attempts to denature and renature
insoluble mPPARα-DBD fusion protein did not yield a protein which could bind to a PPRE in
electromobility shift assays. Therefore synthesis of a functional soluble mPPARα-DBD was done
using a rabbit reticulocyte in vitro coupled transcription / translation kit. The in vitro synthesised
mPPARα-DBD also did not bind to a PPRE in an electromobility shift assay.
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Chapter 4 Discussion
Σεχτιον 4.1 Τηε mολεχυλαρ mεχηανισm οφ περοξισοmε προλιφερατιον
During the past seven years a large amount of knowledge about the molecular aspects of
peroxisome proliferation have been elucidated. The effects of peroxisome proliferators are
mediated by a transcription factor called peroxisome proliferator activated receptor α (PPARα)
(Issemann, I. and Green, S. 1990 and Lee, S. S-T. et al 1995). PPARα is part of a large family of
transcription factors known as the nuclear steroid hormone receptor superfamily. PPARα is
highly expressed in the liver (Jones, P. et al 1995) and works by interacting with specific DNA
response elements (Tugwood, J.D. et al 1992), present in genes that are modulated by peroxisome
proliferators (Osumi, T. et al 1991, Zhang, B. et al 1992, Muerhoff, A.S. et al 1992). 
At the onset of the work presented here, peroxisome proliferators were considered to be
activators of PPARα, as evidence for a direct interaction with peroxisome proliferators had not
been found, and no endogenous ligand had been determined. An aim of my work was to
investigate any changes in the interaction of nuclear proteins from animals dosed with a
peroxisome proliferator with a DNA response element for the PPARα receptor.
Σεχτιον 4.1.1 ΕΜΣΑ οφ ΛΝΠ βινδινγ το DΝΑ ρεσπονσε ελεmεντσ
The rat acyl-CoA oxidase gene PPRE (ACO-PPRE) was characterised by Osumi, T. et al 1993
using liver nuclear protein extracts in both DNAse I footprinting assays and electromobility shift
assays (EMSA’s). The EMSA assay is a suitable assay for examining the effects of peroxisome
proliferators on the expression of liver nuclear proteins which bind to DNA response elements.
If peroxisome proliferators were to increase the expression of PPARα, as has been suggested by
certain research groups (Gebel, T. et al 1992 and McNae, F. et al 1994) the assay would detect
the formation of more DNA-PPARα /RXRα complexes in assays using LNP extracts from
peroxisome proliferator treated animals. The assay could also detect if the effect of peroxisome
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proliferators caused a pre-existing population of receptors to have enhanced DNA binding
capabilities, caused possibly by post-translational modification such as phosphorylation (Shalev,
A. et al 1996). EMSA assays though would not be able to discriminate between these two
possibilities. 
Σεχτιον 4.1.2 Σεθυενχε−σπεχι⇒χ προτειν βινδινγ το αν αχψλ−ΧοΑ οξιδασε ΠΠΡΕ
Purified rat liver nuclear protein extracts (rLNP) were assayed for binding to a DNA probe
containing the A region (-578 to -553) of the rat acyl-CoA oxidase gene (ACO-PPRE). Specific
controls were carried out first using rat liver nuclear extracts to demonstrate that the EMSA
results obtained by Osumi, T. et al 1993 could be repeated. Figure 3.1 demonstrates that a shifted
complex between rLNP and ACO-PPRE probe is formed. The binding of rLNP to ACO-
PPRE was specific as a >500 fold excess of non-specific competitor DNA did not abolish the
formation of the shifted complex. Osumi, T et al 1993 observed a similar single shifted complex
when using the A region as an EMSA probe. Figure 3.2 shows that a molar excess of unlabelled
ACO-PPRE can abolish the shifted complex observed in the EMSA assay, demonstrating that
rLNP binding to PPRE is saturable. The effect of temperature on the formation of shifted
complex was assayed by carrying out rLNP / ACO-PPRE incubations at room temperature (~20
C) and on ice (< 4 C). Figure 3.3 shows that no change in the amount of protein-DNA complex
or pattern of protein-DNA complexes was observed by altering the incubation temperature to
< 4 C. The specificity of binding of rLNP to PPRE was demonstrated using PPREs that
contained either a single mutation in the 5’ half site (mACO-PPRE) or a double mutation in the
5’ half site (dmACO-PPRE). Figure 3.4 (A), lanes 2 and 3 shows that an excess of [3H] labelled
mACO-PPRE is a poor competitor DNA compared to [3H] labelled ACO-PPRE, indicating
that mACO-PPRE has a much reduced affinity for rLNP. Figure 3.4 (B) demonstrates that
rLNP-PPRE complex does not form when [32P]-mACO-PPRE is used as a substrate in the
presence of an excess of non-specific competitor DNA. Figure 3.5 confirms that the binding of
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rLNP to PPRE is specific to the sequence of the DNA, as rLNP shows no binding to a [32P]-
dmACO-PPRE (lane 2, figure 3.5).
Evidence to confirm the importance of the sequence specificity of the PPARα / RXRα-PPRE
interaction has come from two sources. Issemann, I. et al 1993 demonstrated that mutation of a
PPRE in a reporter gene construct abolished PPAR and peroxisome proliferator dependent
induction of the reporter gene in transfected Hepa1c1c7 cells. Further to this, the binding of
bacterially produced PPARα and RXRα receptors in EMSA assays can be abolished by
mutation of three nucleotides within the CYP 4A6 PPRE (Palmer, C.N.A. et al 1995). The
binding of in vitro translated PPARα and RXRα receptors to the Apolipoprotein AI PPRE is
abolished by mutation of a nucleotide in each half-site of the PPRE (Vu-Dac, N. et al 1994).
None of these experiments however show the importance of sequence specificity of the PPRE
to the binding of endogenous in vivo receptors. The results in figures 3.4 and 3.5 demonstrate
that the electromobility shift assay can be used to demonstrate that specific binding of liver
nuclear proteins to a PPRE is dependent on the DNA sequence of the response element. 
It is assumed that the complex observed in the EMSA assays of rLNP with ACO-PPRE is
comprised of PPARα and RXRα. The possibility that the shifted complex is made up of other
DNA binding proteins cannot be excluded. To test whether or not the shifted complex
contained either receptor, supershift assays could be performed using specific antibodies raised
against each receptor. This limitation in interpreting the results does not alter the usefulness of
the assay for detecting differences in LNP binding to response elements from control and
peroxisome proliferator treated animals.
Σεχτιον 4.1.3 Περοξισοmε προλιφερατορσ δο νοτ αφφεχτ ΛΝΠ βινδινγ το α ΠΠΡΕ
It has been reported that peroxisome proliferators induce the expression of hepatic PPARα
(Gebel, T. et al 1992 and McNae, F. et al 1994). Other researchers such as Jones, P. et al 1995
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and Miller, R. et al 1996 found no such evidence for the induction of PPARα expression by
peroxisome proliferators. Measuring an induction in the amount of mRNA transcribed from a
gene or the amount of translated product from this RNA by western blotting does not show if
an increase in functional protein has occurred. It was decided to examine this discrepancy
between the literature using a technique that examines the amount of functional receptor in a
protein extract. Electromobility shift assays were used to examine whether or not a potent
peroxisome proliferator, methylclofenapate (Bell, D.R. et al 1991) induced the amount of
functional PPARα receptor in C57 Bl / 6 mice liver, as measured by enhanced DNA binding
of liver nuclear proteins in an in vitro EMSA assay. Mouse liver nuclear proteins (mLNP) were
tested for binding to ACO-PPRE in the presence of an excess of non-specific competitor DNA.
Figure 3.6 demonstrates that mLNP forms a similar shifted complex to rLNP when assayed under
the same conditions. Lanes 1 to 4, figure 3.6 show that as the amount of mLNP increases per
assay, the amount of shifted complex increases. This demonstrates that the experimental
conditions under which LNP binding was tested produced a linear binding response. mLNP was
purified from mice dosed with methylclofenapate (10mg / kg body weight) for 3 days, and tested
for binding to wild type ACO-PPRE and a double mutant ACO-PPRE. Figure 3.7
demonstrates that the same pattern of specific shifted complexes was observed for control mLNP
binding to wild type ACO-PPRE as for dosed mLNP binding to wild type ACO-PPRE. No
shifted complex was observed for mLNP from control and MCP treated mice binding to a [32P]-
dmACO-PPRE (see figure 3.8). This result shows that peroxisome proliferator treatment of
mice does not relax the sequence specific binding properties of liver nuclear proteins to PPREs.
Figure3.8 demonstrates that the amount of binding of control and MCP treated mice LNP
samples to a wild type ACO-PPRE does not differ. The amount of shifted complex formed by
each type of mLNP was measured by phosphor-imaging. The total amount of mLNP-PPRE
from control and treated animals was compared using a students t-test and was found to be not
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significantly different. This result is important as it supports the findings of Jones, P. et al 1995
and Miller, R. et al 1996. It strongly supports the theory that peroxisome proliferators act through
a pre-existing pool of PPARα receptor to cause peroxisome proliferation. There is however a
limitation to the interpretation of the findings of the electromobility shift assay studies presented
here. It is possible that peroxisome proliferators induce phosphorylation modification of the
PPARα receptor and that this modification is required for enhanced binding of the receptor to
a PPRE. The protein purification protocol did not contain any phosphatase inhibitors and thus
during purification dephosphorylation of activated PPARα may occur. Therefore any difference
in the pool of activated PPARα receptor from control and treated animals would disappear. The
resulting mLNP samples when assayed would exhibit no difference in the total amount of
binding to PPRE.
Using an in vitro electromobility shift assay rodent liver nuclear proteins have been shown to bind
to DNA response elements in a sequence specific manner and that LNP samples from peroxisome
proliferator treated mice do not have enhanced binding to a PPRE. These results suggest that in
methylclofenapate treated mice, PPARα levels with functional DNA binding do not increase.
In studies showing peroxisome proliferator induction of PPARα expression, it is possible that
the observed induction is a result of stress caused by the dose of that particular peroxisome
proliferator. Lemberger, T. et al 1996 demonstrated that stress was able to induce the expression
of PPARα.
Σεχτιον 4.1.4 Μουσε ΠΠΑΡα προτειν λεϖελσ δο νοτ χηανγε αχροσσ α 24 ηουρ (διυρναλ) 
περιοδ
It has been demonstrated that methylclofenapate does not induce PPARα protein levels in C57
Bl / 6 mice liver. Peroxisome proliferation must occur as a result of the interaction of peroxisome
proliferator with endogenous levels of PPARα. It was discovered that PPARα receptor levels in
rat liver were upregulated in response to glucocorticoid dosing (Lemberger, T et al 1994 and
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Steineger, H.H. et al 1994). This finding led to the hypothesis that endogenous corticosteroid
hormones may regulate the expression of PPARα receptor. Glucocorticoid, a corticoid steroid
hormone, is regulated in rats in a diurnal manner, with peak levels occurring around the light to
dark switch in the evening. Lemberger, T. et al 1996 measured in rat liver, a peak of expression
of rat PPARα protein at 5.30 PM, approximately coinciding with the peak of corticoid steroid
hormone. It could be hypothesised that the higher levels of PPARα in the early evening in rat
are critical for the peroxisome proliferation response. The PPARα protein levels may have to
reach a threshold level in order to facilitate the peroxisome proliferation response, and that this
threshold level occurs in the evening as a result of diurnal variation in expression. Lemberger, T
et al 1996 only examined the diurnal expression of PPARα receptor in one strain of rat (Fischer
344) and at time points across a nine hour period, not a full 24 hour period. With this limited
amount of data it is not possible to conclude that diurnal regulation of PPARα is general
phenomenon that occurs in all rodent species, or to what role any differences in expression of
PPARα across a 24 hour period would have on species responsiveness to peroxisome
proliferators
The expression of mouse PPARα in liver, across a 24 hour period was examined to see if this
receptor’s expression was diurnally regulated. Mouse liver nuclear proteins (mLNP) were
purified from mouse liver tissue isolated at 6.00 AM, 12.00 Noon, 6.00 PM and 12.00 Midnight.
Livers from 4 male C57 Bl / 6 mice sacrificed at each time point were pooled and processed
together to eliminate individual variance in expression of PPARα proteins. mLNP extracts were
analysed by SDS-PAGE to see if there was observable diurnal differences in the proteins
expressed at each time point. Figure 3.9 demonstrates that there is a difference in the protein
banding patterns of high molecular weight (> 116 kDa) proteins, indicated by arrow A. A protein
of approximate molecular weight 97 kDa (marked by arrow B) increases in expression at 6.00
PM and at 12.00 Midnight. There is also a difference in the banding pattern of 50 kDa proteins
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in the region marked by arrow C across the diurnal period. These results clearly demonstrate that
some mouse liver nuclear proteins are regulated in a diurnal manner. 
PPARα protein levels in mouse liver were examined by immunoblotting to see if diurnal
variation in expression of PPARα protein occurred in rodent species highly responsive to
peroxisome proliferators. Figure 3.11 demonstrates that the anti-mPPARα antibody used was
sensitive enough to detect as little as 20 ng PPARα receptor on a western blot.
No observable difference was found in the expression of mPPARα protein in liver across a
diurnal period, see figure 3.12. It is possible that corticosteroid hormone levels in the C57 Bl/ 6
mice do not exhibit diurnal variation, leading to a lack of diurnal variation in PPARα expression.
The circulating blood levels of corticosteroid hormone in this mouse strain would need to be
determined, to validate this hypothesis. It could also be possible that the glucocorticoid
regulation of PPARα in C57 Bl / 6 mice is impaired. Thus any rise and fall in circulating blood
corticosteroid hormone levels would not cause any change in PPARα expression. The dosing of
C57 Bl / 6 mice with glucocorticoid hormone, followed by determination of PPARα expression
levels should be done to test this hypothesis. C57 Bl /6 mice have been shown to be highly
responsive to peroxisome proliferators (Permadi, H. et al 1992 and Budroe, J.D. et al 1992), and
thus the response to peroxisome proliferators in this strain of mouse will be mediated by steady
state levels of expression of PPARα protein. 
The expression of a rat liver transcription factor, D-site binding protein (DBP) follows a circadian
rhythm, with levels rising in the afternoon and peaking at 8.00 PM (Wuarin, J. and Schibler, U.
1990). However, the regulation of liver DBP by glucocorticoids differs from glucocorticoid
regulation of rPPARα, by having its expression suppressed by high levels of this hormone. The
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diurnal expression of rat PPARα has only been examined in the Fisher 344 (F344) strain of rat.
Dhabhar, F.S et al 1993 examined corticosteroid levels in three strains of rat, Sprague-Dawley,
Fischer 344 and Lewis rats, and found differences in the diurnal levels of corticosteroid hormone
in these strains. F344 rats exhibited the largest evening peak levels of corticosteroid hormone,
whereas Lewis rats failed to show the expected evening rise in corticosteroid hormone levels. As
some strains of rat do not exhibit diurnal corticosteroid regulation, the diurnal regulation of
PPARα by corticosteroid cannot be a ubiquitous phenomenon. 
There are physiological and environmental factors which can influence the circulating blood
levels of corticosteroid hormones. Female Wistar rats in the estrous cycle have higher levels of
corticosteroid hormone, but do not have an altered diurnal rhythmicity, compared to non estrous
female, or male rats (Atkinson, H.C. and Waddell, B.J. 1997). Food restriction in rats (a
parameter which could induce stress) causes corticosteroid levels to rise in Han-Wistar rats
(Holmes, M.C. et al 1997). It is therefore important when interpreting the results of receptor
expression across a diurnal period in relation to the physiological function of that receptor, that
diet, stress, sex and reproductive state (in females) are considered as influencing factors.
Σεχτιον 4.1.5 Αντι−mΠΠΑΡα αντιβοδψ δετεχτσ α προτειν ιν γυινεα πιγ λιϖερ
Guinea pigs and humans are considered to be non-responsive to peroxisome proliferators
(Cornu, M.C. et al 1992, Reo, N.V. et al 1994, De La Inglesia, F.A et al 1982 and Blumcke, S.
et al 1983). The lack of peroxisome proliferator responsiveness in both species could be due to a
lack of expression of a functional PPARα gene. In humans, a PPARα gene has been cloned and
shown to be functional in reporter gene assays (Sher, T. et al 1993), and that recombinantly
expressed hPPARα can bind to PPREs in in vitro assays (Jow, L. and Mukherjee, R. 1995).
However, it is not known if guinea pigs have a functional, expressed PPARα receptor. To
examine the possibility that guinea pigs have a PPARα protein expressed in liver, guinea pig liver
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nuclear proteins were isolated and tested to see if an immunoreactive protein corresponding to
the size of known PPARα proteins, was present. 
Guinea pig LNP (gpLNP) samples were purified from livers isolated at 6.00 AM, 12 Noon, 6.00
PM and 12.00 Midnight. The expression of a putative guinea pig PPARα protein is
demonstrated in figure 3.14. The anti-mPPARα antibody detects an immunoreactive protein in
gpLNP samples that has the same electrophoretic mobility as purified recombinant mPPARα
and mPPARα in mLNP samples. The anti-PPARα antibody used was known to be specific for
the α isoform, versus the β and γ isoforms (Savory, R. Ph.D thesis), and so it is likely that the
immunoreactive band is an α- variant of PPAR. However, immunoreactivity against an antibody
raised against mPPARα is itself not sufficient proof to demonstrate the presence of a guinea pig
PPARα, as cross reactivity with an unrelated protein is still a possibility. 
gpLNP extract from liver tissue isolated at each time point was analysed for variation in protein
expression across a diurnal period by SDS-PAGE. Figure 3.10 demonstrates that a protein of
approximate molecular weight 50 kDa (marked by arrow A) increases in expression at 6.00 AM
and 12.00 Noon. This result indicates that some guinea pig liver nuclear proteins are regulated
in a diurnal manner. Anti-mouse PPARα antibody was then used to probe immunoblots of
guinea pig liver nuclear proteins for expression of a the PPARα protein. Figure 3.13 shows that
a protein of approximate molecular weight 52 kDa was detected by anti-mPPARα antibody.
The expression of this 52 kDa protein did not vary in guinea pig nuclear protein extracts isolated
from livers taken at 6.00 AM, 12.00 Noon, 6.00 PM and 12.00 Midnight. The results in figure
3.13 and 3.14 strongly suggest that guinea pigs have a PPARα receptor expressed in the liver.
However, in order to prove the existence of a guinea pig PPARα receptor it was necessary to
clone a cDNA corresponding to guinea pig PPARα. If a cDNA corresponding to guinea pig
PPARα cannot be isolated, it would suggest that the putative gPPARα detected by western
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blotting was an artifact generated by fortuitous cross reactivity of the anti-mPPARα antibody
with a guinea pig protein.
Σεχτιον 4.2 Χλονινγ οφ γυινεα πιγ ΠΠΑΡα χDΝΑ
Σεχτιον 4.2.1 Dεσιγν οφ γυινεα πιγ ΠΠΑΡα ΠΧΡ πριmερσ
Human, mouse and xenopus PPARα protein sequences were aligned and examined for regions
of identity between all three PPARα sequences. Regions of exact identity between an amphibian
PPARα protein, a rodent PPARα protein and a primate PPARα protein are likely to be
important functionally and therefore likely to be conserved in a putative guinea pig PPARα
protein. A total of 13 regions comprising of a stretch of seven or more amino acids was identified
to be identical in all three PPARα’s. The DNA coding sequence of these regions was then
examined to see which were the most conserved at the DNA level. One region in the DNA
binding domain was selected, one in the ligand binding domain region and the DNA sequence
encoding the stretch of amino acids at the C-terminal end were found to be highly conserved
(see figure 3.16). Where there was a difference in the DNA sequence between the PPARs the
most common nucleotide was chosen. From the aligned cDNA sequences of human, mouse and
xenopus PPARα’s, consensus PCR primers were designed and used for amplifying putative
guinea pig PPARα cDNAs. 
Σεχτιον 4.2.2 Αmπλι⇒χατιον οφ γυινεα πιγ χDΝΑσ
cDNA pools produced from total and poly A+ mRNA template were investigated for the
presence of a cDNA encoding a guinea pig PPARα (gPPARα) receptor. Primers GPIGP3 and
GPIGP4 were expected to amplify a cDNA fragment 1056 bp long if guinea pigs have a PPARα
receptor the same length as other species. Figure 3.18, lanes 1 to 4 shows that a guinea pig cDNA
fragment approximately 1 kb long was amplified from cDNAs derived from both total and poly
A+ RNA. A 436 bp putative gPPARα cDNA fragment was amplified by PCR using the same
C-terminal end primer (GPIGP3) as used for the 1kb product amplification, and a primer
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(GPIGP2) designed from a region of amino acid identity in the ligand binding domain (figure
3.17). Analysis of the complete double strand DNA sequence of the 1kb putative gPPARα
cDNA confirmed that a partial gPPARα cDNA had been cloned. Where double stranded
sequence of the 436bp putative gPPARα cDNA clones was obtained it was found that two of
the clones were identical to the 1 kb clone. The clone termed GP4 was a gPPARα partial cDNA
fragment, but was different as it contained a 5 nucleotide insert in the middle of the fragment. 
A 5’ Rapid Amplification of cDNA Ends system (5’RACE) was used to clone 5’ cDNA of
gPPARα. Figure 3.19 shows that several 5’ cDNA fragments were amplified by primers GPIGP6
and Universal Amplification Primer. Seven 5’ cDNA clones, varying in size from 302 bp to 582
bp were obtained and sequenced. Five of the cDNA clones corresponded to the 5 ‘ end of
gPPARα. The remaining two 5’ RACE clones showed high sequence identity with the
expressed sequence tags, accession numbers MMAA25380 and AA668556 deposited in the
genembl databank.
Σεχτιον 4.3 Σεθυενχε αναλψσισ οφ τηε χλονεδ γυινεα πιγ χDΝΑσ
The open reading frame of gPPARα contains two putative methionine translational start sites
separated by 3 amino acids (figure 3.22). To determine which methionine start site is the most
probable initiator of translation, the DNA sequence around each Met (ATG) start codon was
analysed for similarity to the Kozak consensus translational start sequence (Kozak, M. 1994 and
1995). Met 1 has 4 nucleotides out of 6 conserved and Met 2 has 3 nucleotides out of 6
conserved, therefore Met 1 is considered to be the translational start site. Initiation of translation
of the guinea pig mRNA at Met 1 would result in a 467 amino acid protein being produced.
The predicted molecular weight of this 467 amino acid gPPARα was determined to be 52 290
Da.
The gPPARα predicted protein sequence was compared to known PPAR protein sequences and
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was found to have amino acid identity of 88% to human, mouse and rat PPARα’s. The identity
of gPPARα with rPPARδ and mPPARγ was lower, being 71% and 72% respectively. A detailed
protein sequence comparison was done between the domains of gPPARα and domains of other
PPAR receptors to verify that the cloned cDNA was a PPARα isoform. Table 3.1 shows the
results of these sequence comparisons. 
The DNA binding domain (DBD) of gPPARα is identical to human and mouse PPARα DBD.
The sequence comparison of the gPPARα DBD includes the 10 amino acids derived from the
consensus primer GPIGP4. Amino acid sequence identity with the DBD of a δ and γ PPAR
isoforms was much lower. This evidence proves that the cloned guinea pig cDNA is a member
of the PPAR family of steroid hormone nuclear receptors and indicates that it is most likely to
be a PPARα isoform. The DNA binding domain of PPAR receptors contain a feature which
make the PPAR family a distinct sub-family from other steroid hormone receptors. PPAR’s only
have three amino acids in the D-box of the second zinc finger of the DNA binding domain,
other steroid hormone receptors have five amino acids in the D-box (Laudet, V. et al 1992 and
Motojima, K. 1993). The complete identity of gPPARα DBD with hPPARα and mPPARα
DBD’s would suggest that the gPPARα will have the ability to bind to DNA. A change in a
single amino within the DNA binding domain can result in a loss of DNA binding activity. This
has been shown for the Hepatic Nuclear Factor-4 receptor (Taylor, D.G. et al 1996). 
Strong evidence to confirm that it is a PPARα isoform comes from analysis of the ligand binding
domain (LBD). The deduced gPPAR protein sequence shows the highest identity (93%) to rat
and mouse PPARα LBDs. rPPARδ and mPPARγ show much lower identity, 70% and 66%
respectively in this region. This LBD sequence identity evidence firmly suggests the cloned
guinea pig cDNA is an α isoform. 
The greatest amount of variation in the gPPARα sequence and the other PPARα’s occurs in the
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A/B domain and the hinge domain. The putative transcriptional activation domain (A/B
domain) of the guinea pig PPARα has a greater identity with hPPARα than with either
mPPARα or rPPARα. The non-responsive nature of human and guinea pigs could be due to
their PPARα’s containing a less functional transactivation domain compared to rat and
mPPARα’s in vivo. 
gPPARα protein is 1 amino acid shorter than other mammalian PPARα’s due to a deletion of
a lysine (K) residue at position 447. The loss of this amino acid in the ligand binding domain is
only observed in the guinea pig. Peroxisome proliferators at physiological pH would have their
carboxylate anion, ionized to form a COO- moiety (Lewis, D. and Lake, B. 1993). This COO-
moiety could form electrostatic interactions with a positively charged amino group (NH3+) of
a lysine residue. It is therefore possible that peroxisome proliferators exhibit a weaker interaction
with guinea pig PPARα and thus are less responsive. Dowell, P. et al 1997 modelled the C-
terminal end of mPPARα with the solved crystal structure of human RXRα (Bourguet, W. et
al 1995). The deletion of K447 in guinea pig PPARα would lie in helix 11 of the modelled
structure. Helix 11 in human RXRα forms part of the ligand dependent transcriptional
activation function (AF 2) domain (Bourguet, W. et al 1995). If PPAR’s have a similar AF2
domain, then a deletion of an amino acid in this domain could have a deleterious effect on its
function.
Analysis of the heterodimerisation and DNA binding properties of truncated mutants of
mPPARα by Dowell, P. et al 1997, demonstrated that the last 20 C-terminal amino acids of
mPPARα are not necessary for heterodimerisation with RXRα but add stability of the
heterodimeric complex when bound to DNA. The deletion of lysine 447 in gPPARα may result
in a less stable heterodimer of gPPARα / RXRα being formed.
Detailed analysis of the differences in amino acid sequences of the PPARα’s from responsive and
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non-responsive species identified 22 amino acid residues which are conserved between rat and
mouse PPARα but are different in guinea pig and human PPARα (Figure 3.23). Of these
changes 14 are conserved between guinea pig and human PPARα. The amino acid at position
83 in gPPARα and hPPARα is a tyrosine residue, compared to a cysteine residue in rPPARα
and gPPARα. This change could have implications for the functioning of the PPARα receptor
in vivo in guinea pig and humans. The loss of a cysteine residue could result in the loss of an
important disulphide bridge, changing the tertiary structure of the receptor. A change in the
charge properties of a particular residue may also impact on the functioning of a receptor. Again
alterations in tertiary structure are possible, changes in the stability of ligand binding or altered
protein-protein interactions could result from a change in the charge property of an amino acid
residue. At position 196, the gPPARα and hPPARα contains a glutamate residue (negatively
charged), compared to a lysine residue (positively charged) in mPPARα and rPPARα. At
position 211 a positively charged histidine residue in mPPARα and rPPARα is changed for a
bulky, aromatic tyrosine residue in gPPARα and hPPARα, and at position 264 in gPPARα, a
positive arginine residue is present, in hPPARα a glutamine residue (polar uncharged) is present,
but in mPPARα and rPPARα and negatively charged glutamate residue is present. These
differences between the receptors of non-responsive and responsive species may be important in
determining the in vivo response to peroxisome proliferators.
The presence of endogenous activators of wild type PPARα in cell culture causes transcriptional
activation of PPRE reporter gene constructs in vitro. A mutant mPPARα cDNA was cloned in
which the glutamate 282 residue is changed for a glycine residue, has demonstrated how a loss
of a charged residue in a PPARα receptor can alter its functional properties. This mutant
mPPARα termed PPAR-G does not exhibit peroxisome proliferator independent
transcriptional activation of a reporter gene in vitro (Muerhoff, A.S et al 1992). The PPAR-G
mutant may have much lower affinity for endogenous activators, and is therefore unable to
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transcriptionally activate reporter gene expression in the absence of peroxisome proliferators.
Recently a mutant human cDNA has been cloned, which contains four different amino acids
compared to wild type hPPARα (Tugwood, J.D. et al 1996). In this mutant hPPARα, termed
hPPARα6/29 threonine 71 is changed to a methionine, lysine 123 to a methionine, valines 268
and 444 to alanine residues. hPPARα6/29 has been shown to bind to PPREs in in vitro DNA
binding assays, but has been shown to be unactivatable by peroxisome proliferators. Restoration
of methionine 123 and alanine 444 in hPPARα6/29 to the wild type amino acids restored
peroxisome proliferator induced transcriptional activation (Myers, K.A. et al 1997). The
gPPARα receptor does not contain any of these described mutations. However, there are still
several amino acid differences between gPPARα and hPPARα, mPPARα and rPPARα which
could render the gPPARα receptor non-responsive to peroxisome proliferators. 
Σεχτιον 4.4 Πηψλογενετιχ αναλψσισ οφ mαmmαλιαν ΠΠΑΡα γενεσ
The relationship of the PPARα genes from mouse, rat, guinea pig and human were examined
using phylogenetic analysis. The technique used was the maximum likelihood method, a method
which is robust enough to include genes evolving at different rates. Felsenstein, J. 1978
demonstrated that the maximum-parsimony method can produce misleading results when genes
evolving at different rates are used. Alignment of the mammalian PPARα protein sequences was
done in tandem with xenopus PPARα, an evolutionary distant PPARα, and PPARβ and
PPARγ genes as well. In order to examine the relationship between the mammalian PPARα
genes we need to be able to include in the analysis, genes which are related to PPARα but which
are known to have evolved before the divergence of the genes being examined. The inclusion
of genes which have evolved before the evolution of the mammalian PPARα genes adds
perspective to the analysis. The PPARβ and PPARγ genes have been found in the xenopus
species, an amphibian species. It can be concluded that these two PPAR genes must have
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diverged from the PPARα gene before the evolutionary separation of amphibians and mammals.
PPARβ and PPARγ genes are therefore ideal as outgroups to root the analysis and to give
phylogenetic perspective to the analysis. 
Figure 3.24 shows that the guinea pig PPARα gene is evolving more rapidly, nearly 14 fold faster
than either the human, mouse or rat PPARα genes. The guinea pig hepatic lipoprotein lipase
gene has also been shown to have a higher rate of evolution compared to mouse and human
hepatic lipoprotein lipase genes (Semenkovich, C.F. et al 1989). The phylogenetic tree in figure
3.24 positions the guinea pig PPARα gene between the human and mouse, rat genes, with a
bootstrap probability of ~0.93. There is insufficient resolution in the phylogenetic analysis to
place the exact evolutionary position of the guinea pig species in relation to the mouse and rat
species. This is due to the number of rodent species analysed being too small a sample and that
only a single gene has been examined. But it is interesting to note that ~7% of the remaining
phylogenetic PPARα trees produced excluded the monophyletic relationship of the guinea pig
with the mouse and rat order (Myomorph order). 
Σεχτιον 4.4.1 Ισ τηε γυινεα πιγ α ροδεντ?
If the guinea pig is more closely related genetically to humans than to mouse or rat, it would lend
support for the use of the guinea pig as a more appropriate experimental model species for
modelling the human response to peroxisome proliferators. Currently there is much debate about
the evolution of the guinea pig species and its relationship to other rodents, lagomorphs and
primates. Morphological, biochemical and genetic analyses have all been used to address this
problem.
Guinea pigs cannot synthesise L-ascorbic acid (Burns, J.J. 1957), have an insulin which shows
very low biological activity (Blundell, T.L. and Wood, S.P. 1975) and an alanine:glyoxylate
amino transferase with limited substrate specificity (Nogochi, T et al 1994), making them
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biochemically distinct from other rodent species. Based on biochemical comparisons between
rodents Noguchi, T. et al 1994 concluded that guinea pigs are distinct from other rodents.Their
conclusion contradicts the traditional view of rodent monophyly, based on comparative
morphology (Luckett, W.L. and Hartenberger, J.-L. 1985). Several groups have examined the
evolutionary relationship of the guinea pig within the rodent order using various molecular
evolution analysis methods, but the relationship of the guinea pig species within the myomorph
rodent order remains a subject of controversy. Graur, D. et al 1991 using maximum parsimony
methods concluded that the rodent order was polyphyletic, with the guinea pigs having a separate
evolutionary origin to rodents such as rat or mouse. Goto, K. et al 1994 and Nakatani, T et al
1995 analysed the phylogeny of α-1-Antiproteinase gene from several rodent species and
concluded that the guinea pig was more closely related to the rabbit (lagomorph) order, forming
a distinct clade. The analyses of α-1-Antiproteinase gene failed to calculate any bootstrap
statistical significance to their phylogenetic trees, and admitted to the limited nature of analysing
a single gene in order to place the evolutionary position of a species. Bulow, H.E. et al 1996
examined the genetic phylogeny of cytochrome P450 11B-hydroxylase gene by maximum
parsimony and neighbour joining method. The results from each method were contradictory,
with the neighbour-joining method supporting monophyly and the maximum parsimony
method supporting polyphyly leading to the conclusion that a definitive branching order could
not be established from the data. Work by Cao, Y. et al 1994 and 1997, Kuma, K. and Miyata,
T. 1994 and Frye, M.S. and Blair-Hedges, S. 1995 have all demonstrated weaknesses in the
analysis by Graur, D. et al 1991, concluding that the rodent monophyly hypothesis cannot yet be
excluded. D’Erchia, A.M. et al 1996 examined the phylogeny problem of the guinea pigs by
examining mitochondrial gene evolution. They used all three methods, the maximum-
parsimony method, the maximum-likelihood and the neighbour joining method and found that
the phylogenetic trees produced with the highest bootstrap probability separated the rodents into
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polyphyly.
The evolutionary position of the guinea pigs is still unresolved, but from the analysis of the
PPARα genes presented here we know that the speed of evolution of individual genes from the
different rodent species can differ dramatically. Further work on the phylogenetic analysis of
genes from many rodent species needs to be carried out before we can confidently position the
guinea pig species in the evolution of rodents.
Σεχτιον 4.5 Εϖιδενχε φορ αλτερνατιϖε σπλιχινγ οφ γΠΠΑΡα mΡΝΑ
The assembled 5’ cDNA sequence of gPPARα, derived from DNA sequence of clones GP11
and GP12 was analysed against the cDNA sequence AJ000222 (a putative gPPARα) which
became available in the genembl DNA sequence database, when this thesis was in preparation.
The sequences were identical for 39 nucleotides 5’ to the ATG (Met 1) translational start site,
whereas DNA sequence 5’ to these 39 nucleotides are different. The translated gPPARα and
AJ000222 cDNA sequences are aligned and shown in figure 3.25. The amino acid sequence of
gPPARα in the region marked (A) is derived from double strand DNA sequence of two
independently cloned cDNAs that were identical over this stretch, but amino acid sequence N-
terminal to region (A) was derived from a single cDNA clone. This sequence is less robust, as it
was not possible to eliminate the possibility of PCR amplification artifacts or DNA sequencing
artifacts. The difference in the 5’ cDNA sequence of the cloned gPPARα and AJ000222
sequences could be due to differential splicing of gPPARα mRNA, giving rise to two distinct
transcripts.
The viability of the differential splicing theory was investigated by aligning the DNA sequence
of exon 3 of mouse PPARα (x75289) with the 5’ gPPARα cDNA sequence. It was found that
the region of N-terminal identity between gPPARα and AJ000222 sequence exhibited high
identity with the 5’ end of mouse PPARα exon 3 (Figure 3.26). The 5’ end of the identical N-
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terminal amino acid sequence of gPPARα and AJ000222 aligns with the site of an intron / exon
boundary found in mPPARα mRNA. Therefore the differences between the cloned gPPARα
and AJ000222 sequence is probably due to differential splicing. It is important that the more 5’
gPPARα cDNA cloning is done in order to verify the possibility that guinea pigs have a novel
PPARα subtype.
Preliminary DNA sequence data indicated the presence of a translation stop codon N-terminal
to Met 1, so cloning work of the 467 amino acid open reading frame was started. Complete
detailed DNA sequence analysis revealed that there was no translation stop codon found in the
amino acid sequence upstream of Met 1. 
If the 5’ DNA sequence beyond region (A) is correct, the identified 467 amino acid open reading
frame from Met 1 is extended a further 58 amino acids to another putative methionine
translational start site. This would make this receptor a novel PPARα subtype, possibly with
altered functionality. A N-terminal transactivation domain has not been defined for PPARα
receptors, but has for PPARγ receptors (Werman, A. et al 1997). The PPARγ receptor in mouse
and humans is produced as two distinct isoforms, PPARγ1 and PPARγ2 (Zhu, Y. et al 1995 and
Elbrecht, A. et al 1996), produced from alternative use of promoters within the PPARγ gene.
mPPARγ2 has 30 additional N-terminal amino acids to the Met translational start in mPPARγ1.
The transcriptional activity of PPARγ 1 and γ2 N-terminal domains has been characterised, with
the activation function of PPARγ2 being 6-fold greater than PPARγ1(Werman, A. et al 1997).
Thus the extra 30 N-terminal amino acids in PPARγ2 are involved in the enhanced activation
function activity. The amino acid sequence identity between gPPARα and mPPARγ N-
terminal A/B domains is very low, therefore extrapolation of activation function activity in
PPARα using amino acid sequence comparisons is not possible.
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Σεχτιον 4.5.1 ΓΠ4 γΠΠΑΡα χDΝΑ χλονε χονταινσ διφφερεντιαλ σπλιχινγ
DNA sequence alignment of the 436 bp GP4 gPPARα cDNA clone with the assembled
gPPARα cDNA sequence revealed the presence of a 5 nucleotide insert in the ligand binding
domain region (see figure 3.27). The 5 nucleotide insert causes a frame shift in the open reading
frame, leading to a change in the last seven translatable amino acids and a premature stop codon,
resulting in the loss of 74 amino acids. The truncation of 74 amino acids in the ligand binding
domain would almost certainly affect the binding of peroxisome proliferators and
heterodimerisation properties of the receptor. Significant expression of this mutant gPPARα
could explain the non-responsive phenotype observed in guinea pigs. 
The GP4 cDNA could arise from alternative splicing of gPPARα mRNA. The possibility of
differential spicing was investigated by comparing the GP4 cDNA sequence with mPPARα
exons 7 and 8 DNA sequence. Figure 3.28 shows that from alignment of gPPARα cDNA with
exons 7 and 8 that the 5 nucleotide insert occurs at the end of mPPARα exon 7 and beginning
of mPPARα exon 8. It is possible that the donor GT site of the intron between exons 7 and 8
has differentially spliced with another AG acceptor site 4 nucleotides of the correct AG acceptor
site. The resultant alternatively spliced mRNA contains intron sequence being left within the
normal coding region. Figure 3.28 shows a cartoon of the proposed mechanism of differential
splicing that gave rise to the mRNA that was PCR amplified to give clone GP4. Three 1.056
kb gPPARα and two 436 bp gPPARα cDNA clones were obtained that did not contain the five
nucleotide insert. Therefore it is most probable that the mRNA species from which the GP4
cDNA clone was derived is a rare gPPARα mRNA species, arising from differential splicing.
Ebihara, K. et al 1996 identified and characterised a novel vitamin D receptor (VDR1) in rat
which is produced from differential splicing of VDR mRNA. VDR1 is translated from a mRNA
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in which intron 8 is retained within the final spliced mRNA species. A premature stop codon
causes truncation of the receptor by 86 amino acids at the C-terminal end. VDR1 receptor can
bind to vitamin D response elements but is unable to bind ligand. Expression of VDR1 in cell
culture demonstrated that this receptor can act in a dominant negative manner over VDR.
Expression of VDR1 was found to 1/15 th of the expression of VDR in adult rat, therefore it is
possible that the VDR1 isoform functions physiologically to negatively modulate vitamin D
signalling pathways. Differential splicing of the human glucocorticoid receptor (hGR) mRNA
produces two distinct transcripts, which when translated yields two receptors hGRα and hGRβ.
The hGRα isoform binds glucocorticoids and mediates glucocorticoid signalling, whereas hGRβ
does not bind glucocorticoid ligand and acts as a dominant negative suppressors of hGRα. The
difference between the two proteins occurs at the C-terminal end. The last 50 amino acids in
hGRα are changed for 15 different amino acids in hGRβ (Bamberger, C.M et al 1995, Oakley,
R.H. et al 1997). These two examples demonstrate the effect of differential splicing for normal
receptor functionality. It is interesting to speculate if in guinea pigs a truncated PPARα receptor
is expressed, and if so does this receptor impinge on PPARα mediated signalling pathways.
Σεχτιον 4.6 Χλονινγ οφ φυλλ λενγτη γΠΠΑΡα χDΝΑ
A 1.4 kb gPPARα cDNA encompassing the coding region from Met 1 was generated by over
lapping PCR, and was cloned into a eukaryotic protein expression vector pBK-CMV. The
gPPARα-pBK-CMV construct contains T3 and T7 RNA polymerase promoter sites which can
be utilised in in vitro coupled transcription / translation reactions. To verify that the cDNA
sequence of gPPARα from Met 1 encoded a full length open reading frame of 467 amino acids,
gPPARα protein was produced from gPPARα-pBK-CMV in an in vitro coupled transcription
/ translation reaction. [35S]-Methionine labelled gPPARα was produced in such a reaction and
was analysed by SDS-PAGE. Figure 3.32, lane 1 shows that a protein of approximate molecular
weight 52 kDa was synthesised, demonstrating that the 1.4kb gPPARα cDNA encoded a
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polypeptide of the same molecular weight as known mammalian PPARα proteins. After
demonstrating that the gPPARα cDNA encoded a full length polypeptide, experiments to
determine if gPPARα was functional were carried out.
Σεχτιον 4.7 Φυνχτιοναλ τεστινγ οφ γΠΠΑΡα ιν α mαmmαλιαν χελλ βασεδ 
ρεπορτερ σψστεm
It was reasoned that guinea pigs may not respond to peroxisome proliferators in the same way as
rats and mice because guinea pigs did not express a PPARα receptor or that if a PPARα was
expressed it did not have the capacity to bind and be activated by peroxisome proliferators. The
data already presented here shows that guinea pigs have a PPARα gene expressed and that
gPPARα protein can be detected in guinea pig liver. However a functional characterisation of
the cloned gPPARα needed to be done to either support or reject the hypothesis of a
disfunctional PPARα receptor being the cause of non-responsiveness to peroxisome
proliferators. gPPARα was tested for peroxisome proliferator induced transcriptional activation
of gene expression through a PPRE. Demonstration of activation of a PPRE containing reporter
construct by gPPARα and peroxisome proliferators would show that gPPARα had similar
functional capabilities to other mammalian PPARα’s which have been assayed in a similar
manner (Isseman, I. et al 1993, Marcus, S.L. et al 1993 and Mukherjee, R. et al 1994). 
A luciferase reporter gene system was used in human embryonic kidney 293 cells (293 cells). This
cell line is derived from kidney cells which have been transformed with sheared human
adenovirus (Ad5) DNA, and is suitable for transfection studies. 293 cells have been used for
functional studies of thyroid hormone receptor (TR), a member of the nuclear steroid hormone
receptor superfamily. Bigler, J. and Eisenman, R.N. 1995 analysed novel TR response elements
in the presence of exogenously expressed TR. TR signalling through a TR response element
was observed in the absence of co-expression of retinoid X receptor (RXR). Van der Leede, B-
J. M. et al 1993 demonstrated that RXRα is expressed in 293 cells. The levels of RXRα in 293
Alex R. Bell Section 4.7.1
Page 179
cells are sufficient for TR signalling of a TR response element containing reporter gene. RXRα
is an essential component of PPARα signalling through a PPRE, and sufficient endogenous
levels of RXR would be required for gPPARα functionality studies. It was concluded that 293
cells would be a suitable host cell line for gPPARα functionality studies
A tandem repeat of two copies of the rat acyl-CoA oxidase gene PPRE (Osumi, T. et al 1991)
was inserted into the polylinker of pGL3-Luc vector, producing the construct (ACO-
PPRE)2.pGL3-Luc. Multiple copies of a PPRE have been demonstrated to give a high response
when testing peroxisome proliferator induced gene transcription through a PPARα and PPRE.
Gearing, K.L. et al 1993 and Marcus, S.L. et al 1993 successfully used a reporter gene containing
two copies of an ACO-PPRE, and Kliewer, S.A. et al 1994 have used and tested a reporter gene
containing three copies of an ACO-PPRE. 
Σεχτιον 4.7.1 Ινδυχτιον οφ λυχιφερασε βψ ΠΠΑΡα ανδ περοξισοmε προλιφερατορσ
Firefly reporter gene expression was determined for cells transfected with PPARα alone, cells
dosed with Wy-14,643 alone, or in cells transfected with PPARα and dosed with Wy-14,643.
Figure 3.33 shows that the presence of both PPARα receptor and peroxisome proliferator,
induced firefly reporter gene expression greater then when either was present alone. Firefly
reporter gene expression from (ACO-PPRE)2.pGL3-Luc in the absence of PPARα or
peroxisome proliferator was the same as reporter gene expression measured for pGL3-Luc vector
containing no PPRE in the presence of PPARα and presence or absence of peroxisome
proliferator. These results demonstrate the requirement of the PPRE in (ACO-PPRE)2.pGL3-
Luc for PPARα and peroxisome proliferator mediated induction of reporter gene expression.
The amount of transfected plasmid containing CMV based promoters was lowered to see if the
induction of reporter gene in (ACO-PPRE)2.pGL3-Luc could be augmented to give a greater
response to peroxisome proliferator and PPARα. Equivalent amounts of hPPARα-pBK-CMV
Alex R. Bell Section 4.7.2
Page 180
vector and pRL-CMV vector from 0 to 0.3 mg were transfected per flask. Figure 3.34 shows that
increasing amounts of these two vectors caused a reduction in the amount of normalised firefly
reporter gene expressed. The peroxisome proliferator methylclofenapate (MCP) was tested at a
final concentration of 50 mM to see if could activate hPPARα and induce reporter gene
expression. No induction over DMSO vehicle control was seen, but substantial peroxisome
proliferator independent induction of firefly reporter gene expression was observed. 
Σεχτιον 4.7.2 Γυινεα πιγ ΠΠΑΡα ισ αχτιϖατεδ βψ α περοξισοmε προλιφερατορ
293 cells were transfected with gPPARα-pBK-CMV plasmid DNA in increasing amounts from
0 mg to 0.1mg. (ACO-PPRE)2.pGL3-Luc was co-transfected with these amounts of gPPARα
expression vector at 1mg and 0.1mg levels per flask. Induction of Firefly reporter gene was assayed
in the presence and absence of the peroxisome proliferator Wy-14,643. Figure 3.35 demonstrates
that reducing the amount of PPRE containing reporter vector 10-fold, reduces reporter gene
expression 10-fold at all levels of gPPARα expression vector tested. Peroxisome proliferator
induced expression of reporter gene does not occur in the absence of exogenous expression of
gPPARα receptor, indicating that 293 cells have very low levels of endogenous PPARα
receptor. Flasks transfected with 0.05 mg of gPPARα-pBK-CMV plasmid DNA exhibited
significant peroxisome proliferator induced expression of reporter gene expression. 100 mM Wy-
14,643 induced reporter activity 3.4 fold (p=0.02, df=2) in flasks transfected with 0.05 mg of
gPPARα-pBK-CMV and 0.1 mg of (ACO-PPRE)2.pGL3-Luc. The degrees of freedom used
to determine the statistical significance of the data was low due to the low number of replicate
flasks used. Therefore the experimental conditions which showed a 3.4-fold rise in reporter gene
activity were repeated using more flasks in order to give a higher degree of statistical accuracy.
Figure 3.36 shows the results of the repeated experiment using more culture flasks. 100 mM Wy-
14,643 induced (ACO-PPRE)2.pGL3-Luc reporter vector 2.3-fold (P=0.001, df=6) in the
presence of exogenous expression of gPPARα receptor.
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It has been demonstrated that the cloned guinea pig PPARα receptor can be activated to induce
transcription of a gene under the control of a PPRE by a potent peroxisome proliferator. The
size of induction of reporter gene was not large, but was statistically significant. A full
characterisation of several peroxisome proliferators, at a wide range of concentrations will need
to be done for the gPPARα receptor. This will allow the identification of possible structural
differences between gPPARα and other mammalian PPARα’s which cause functional
differences to be observed. 
Both gPPARα and hPPARα exhibited substantial peroxisome proliferator independent
transcriptional activation of reporter gene activity in the reporter gene system used. Other
researchers have observed a similar a phenomenon for mPPARα and rPPARα (Muerhoff, A.S.
et al 1992, Bardot, O. et al 1993, Marcus, S.L. et al 1993 and Aldridge, T.C. et al 1995). Table 5
summarises experimental work which has tested peroxisome proliferator activated transcription
of a reporter gene, mediated by a PPARα receptor and PPRE. The magnitude of the observed
inductions by peroxisome proliferator over control drug delivery vehicle are generally low, with
inductions less than 2-fold being reported (McNae, F. et al 1994). Results by Kliewer, S.A. et al
1994 are exceptions to this as they observed very large induction in reporter gene activity by
different peroxisome proliferators. The species type of PPARα receptor used, type of reporter
gene construct used, and type of cell line transfected varies considerably. Marcus, S.L 1993 et al
did compare mPPARα and rPPARα in the same cell line, using two types of peroxisome
proliferator and two types of PPRE containing reporter gene construct. rPPARα was shown to
be slightly more responsive to peroxisome proliferators than mPPARα. It is not clear whether
this difference in activation observed in an artificial system would make a biological significance
in vivo to the way each species responds to peroxisome proliferators. Mukherjee, R. et al 1994
compared the dose response of clofibric acid, Wy-14,643 and 5,8,11,14-eicosatetraynoic acid
(ETYA) activation of transcription mediated by both rPPARα and hPPARα in CV-1 cell,
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HepG2 cells and H4IIEC3 cells. In CV-1 cells (a monkey Kidney cell line) and HepG2 cells (a
human hepatoma cell line) Wy-14,643 was a more potent activator of rPPARα than hPPARα.
Each PPARα receptor demonstrated a similar dose response to clofibric acid in HepG2 cells, but
in these cells ETYA was a more potent activator of hPPARα compared to rPPARα. In H4IIEC3
cells (a rat hepatoma cell line) only rPPARα exhibited a dose dependent response to Wy14,643.
These results show that different PPARα receptors respond differently to various peroxisome
proliferators, depending on the type of cell line used. These differences in responsiveness could
be due to differences in the affinities of peroxisome proliferator binding to the PPARα’s, or
different metabolic processing of the peroxisome proliferator, or due to the requirement of cell
type specific co-activators. Recent studies by Keller, H. et al 1997 have shown that in vitro species
differences in response to peroxisome proliferators are mediated primarily by the ligand binding
domain. The amino acid residues I272 and T279 are crucial in hPPARα for mediating its higher
sensitivity to ETYA, than Wy-14,643, when compared to mPPARα. In guinea pig PPARα
position 272 is also an isoleucine, but position 279 is a valine, different to that found in both
hPPARα and mPPARα. It is not possible to tell by sequence identity, whether or not guinea
pig PPARα will exhibit ligand sensitivity more similar to human or mouse PPARα.
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10mΜ Ναφενοπιν
10mΜ Χιπρο⇒βρατε
10mΜ mετηψλχλοφενα−
πατε
14
11
6
4.5
Ισσεmανν, 
Ι. ετ αλ 1993
Table 4.1 Overview of PPARα mediated induction of reporter genes. 
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Σεχτιον 4.8 Γυινεα πιγ ΠΠΑΡα ισ εξπρεσσεδ ιν λιϖερ τισσυε
The fact that gPPARα receptor gene was cloned from cDNA derived from liver tissue mRNA
demonstrates that the gPPARα gene is expressed. PCR is a sensitive technique which can
mΠΠΑΡα Χοσ 1 πΗD−
ΠΠΡΕ(∗3)Λυχ
πΑΧΟ−
ΠΠΡΕ(∗2)Λυχ
100mΜ Wψ14,643
500mΜ Χιπρο⇒βρατε
100mΜ Wψ14,643
500mΜ Χιπρο⇒βρατε
2
< 0.5
2.5
2
Μαρχυσ, 
Σ.Λ. ετ αλ 
1993
mΠΠΑΡα Η4ΙΙΕ
Χ3
πΑΧΟ(−1273/−
470)ΧΑΤ
10mΜ Wψ14,643 <2 ΜχΝαε, Φ. 
ετ αλ 1994
mΠΠΑΡα Χς−1 πΑΧΟ−
ΠΠΡΕ(∗3)−τκ−Λυχ
5 mΜ Wψ14,643 >10 0 Κλιεωερ, 
Σ.Α. ετ αλ 
1994
ρΠΠΑΡα Χοσ 1 πΗD−
ΠΠΡΕ(∗3)Λυχ
πΑΧΟ−
ΠΠΡΕ(∗2)Λυχ
100mΜ Wψ14,643
500mΜ Χιπρο⇒βρατε
100mΜ Wψ14,643
500mΜ Χιπρο⇒βρατε
3.3
4.5
4
2.5
Μαρχυσ, 
Σ.Λ. ετ αλ 
1993
ηΠΠΑΡα Χς−1 πΑΧΟ−
ΠΠΡΕ(∗3)−τκ−Λυχ
1 mΜ Χλο⇒βριχ Αχιδ 9 Μυκηερϕεε, 
Ρ. ετ αλ 
1994
ηΠΠΑΡα Ηεπα 1 πΑΧΟ(−640/−
472)−τκ−ΧΑΤ
πΧΨΠ4Α6ζ−
ΠΠΡΕ(∗3) −τκ−
ΧΑΤ
300 mΜ Χλο⇒βριχ 
Αχιδ
300 mΜ Χλο⇒βριχ 
Αχιδ
4.9
3.7
Πινεαυ, Τ. 
ετ αλ 1996
ξΠΠΑΡα ΗεΛα πΑΧΟ−ΠΠΡΕ−τκ−
λυχ
πΗD−ΠΠΡΕ−τκ−
Λυχ
πΧψπ4Α6ζ−
ΠΠΡΕ−τκ−Λυχ
100 mΜ Wψ14,643
100 mΜ Wψ14,643
100 mΜ Wψ14,643
3
6.4
4.7
Κρεψ, Γ. ετ 
αλ 1993
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amplify DNA from very low levels of template DNA. Thus the fact that a guinea pig PPARα
cDNA was amplified does not give any indication as to the extent of expression of the gene.
Therefore RNase protection assays, a sensitive technique used for determining the level of gene
expression was used to determine the levels of expression of gPPARα in liver tissue. The
expression of mPPARα gene in mouse liver was also determined, so that a direct comparison of
the expression of each gene could be made from a peroxisome proliferator responsive species and
non-responsive species. mPPARα and gPPARα anti-sense ribo-probes were synthesised, with
the mouse probe being twice the length of the guinea pig probe, but each with the same specific
activity. Therefore to generate the equivalent signal two guinea pig ribo-probes need to be
protected to every one mPPARα ribo-probe. An excess of each probe was hybridised with liver
RNA samples so that all PPARα mRNA species would anneal to their respective probes. Figure
3.37 (A) demonstrates that mPPARα is highly expressed in mouse liver, and figure 3.37 (B)
shows that guinea pig PPARα is expressed in guinea pig liver. Each gel was exposed for the same
amount of time on hyperfilm and are directly comparable as the probes had the same specific
activity. It is clear by comparing panel (A) with panel (B) that the amount of mPPARα ribo-
probe protected is much greater than twice the amount of gPPARα ribo-probe protected.
Therefore mPPARα gene expression is much greater than gPPARα gene expression in the liver
of each respective species. The species difference in responsiveness to peroxisome proliferators
could be due to the differences in expression levels of PPARα. 
The expression of gPPARα gene was determined in liver tissue isolated at 6.00 AM, 12.00
Noon, 6.00 PM and 12.00 Midnight using an RNase protection assay. Figure 3.38 shows that
gPPARα mRNA expression does not vary greatly across a 24 hour period. These results support
the results of gPPARα protein expression determined by immunoblot analysis shown in figure
3.14. The pattern of expression of the 52kDa protein detected by anti-mPPARα antibody in
guinea pig liver nuclear extracts is the same as the pattern of gPPARα mRNA expression as
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determined by RNase protection analysis. 
Σεχτιον 4.9 Εϖιδενχε φορ α φυνχτιοναλ ΠΠΑΡα ιν γυινεα πιγ ιν ϖιϖο
Further evidence to support that guinea pigs respond to peroxisome proliferators in the same
manner as humans has been demonstrated in experiments in which guinea pigs were dosed with
two peroxisome proliferator hypolipidaemic drugs Wy-14,643 and methylclofenapate. Both
drugs were shown to lower serum triglyceride levels significantly (Bell, A.R. et al 1998, in press).
It is known that Wy-14,643 and methylclofenapate are selective activators of PPARα, as
opposed to β and γ (Kliewer, S.A. et al 1994 and 1997, Forman, B.M. et al 1997), and it is
therefore likely that the peroxisome proliferator induced hypolipidaemia is mediated through
gPPARα.
Σεχτιον 4.10 Γυινεα πιγσ mοδελ τηε νον−ρεσπονσιϖενεσσ πηενοτψπε ιν 
ηυmανσ
The molecular basis whereby rat and mouse undergo peroxisome proliferation in response to
peroxisome proliferators, but humans and guinea pigs do not, is of critical importance to the
hazard assessment of peroxisome proliferators to humans. A suitable laboratory model system is
required so that the molecular differences between responsive and non-responsive species can be
elucidated. Guinea pigs are proposed to model the human response to peroxisome proliferators,
but it is not known if guinea pigs have the same molecular characteristics of the mechanism of
peroxisome proliferation that has been determined in humans. 
It has been demonstrated that the guinea pig has a functional PPARα which is expressed in the
liver. The gPPARα mediates transcriptional activation through the PPRE of the rat acyl-CoA
oxidase gene enhancer. Transcriptional activation of gPPARα was observed in the absence of
exogenous peroxisome proliferator, but addition of the potent peroxisome proliferator led to a
significant induction of transcriptional activation. This demonstrates that the guinea pig PPARα
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is capable of responding to peroxisome proliferators. The non-responsive phenotype observed in
guinea pigs is not due to an absence of gPPARα expression, as it was found that gPPARα is
expressed both at RNA and protein levels in guinea pig liver.
The guinea pig models the human response to peroxisome proliferators, both in the observed
peroxisome proliferation phenotype and in the peroxisome proliferator induced hypolipidaemic
response. The guinea pig has a functional PPARα gene expressed in the liver, the same as is
observed for humans. Therefore the guinea pig offers a model system for understanding
peroxisome proliferator induced hypolipidaemia and peroxisome proliferator responsiveness in
humans.
Alex R. Bell Section 4.11.1
Page 187
Σεχτιον 4.11 Στεροιδ ηορmονε DΝΑ βινδινγ δοmαινσ
Human Retinoid X Receptor α (hRXRα) DNA binding domain (DBD), amino acids 130F -
223T has been cloned, expressed and purified as a soluble DNA binding protein. Detailed NMR
studies have been performed with this protein, elucidating the tertiary structure of hRXRα DBD
(Lee, M.S. et al 1993 and 1994). Zechel, C. et al 1994 and Mader, S. et al 1993 cloned and
expressed in bacteria the DNA binding domains of Retinoid X Receptor α (135-237), Retinoic
Acid Receptor α1 (83-187) and Thyroid hormone receptor α (46-150). Both Zechel, C. et al
1994 and Mader, S. et al 1993 demonstrated that these receptor DBD’s were soluble in crude
bacterial extracts and could bind to DNA in electromobility shift assays. PPARα DNA binding
domain (PPARα-DBD) is highly similar to other nuclear steroid hormone binding domains.
NMR, x-ray crystallographic and DNA binding studies have not been performed on PPARα
DNA binding domain. Structural analysis of PPARα-DBD should reveal detailed molecular
information about the PPARα receptor, which hopefully can be related to the functioning of
this receptor in molecular signalling and control of gene expression. An example of where
structural studies by NMR or x-ray crystallography on PPARα is needed, is to elucidate the
function of the D-box of PPARα receptors. The PPAR D-box in the DBD is two amino acids
shorter than the D-boxes found in other types of steroid hormone receptor (Laudet, V. et al 1992
and Motojima, K. 1993), and the significance of this has yet to be determined. Thus the cloning
and expression of soluble functioning mouse PPARα-DBD was attempted. 
Σεχτιον 4.11.1 Χλονινγ οφ mΠΠΑΡα−DΒD
The DNA binding domain of mPPARα has only been defined by homology to other steroid
hormone receptors. Issemann, I. and Green, S. 1990 defined the DBD starting from amino acid
102 to 166 in mPPARα. A structural characterisation of mPPARα has not been done, so the
exact boundaries of the DBD in mPPARα are not known. A region of mPPARα cDNA
encompassing the DNA binding domain, residues 95 G to 198 S was amplified and cloned into
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prokaryotic expression vectors. The cloned fragment contains extra residues both N- and C-
terminal to the defined mPPARα-DBD (amino acids 102 to 166). The G at position 95 is
mutated to a cysteine residue by the mPPARα-P1 mismatch primer, so that a Pst I restriction
site was engineered in the amplified PCR product.
pRSET A prokaryotic expression vector (Invitrogen) contains a multiple cloning site 3’ to a
protein leader sequence that contains a tract of six histidine residues (His*6 motif) and an
enterokinase protease cleavage site. mPPARα-DBD DNA was cloned in frame with this leader
sequence, producing a mPPARα-DBD fusion protein expression plasmid. An extra N-terminal
41 amino acids are added to the mPPARα-DBD protein. The His*6 motif functions as a useful
tool for purification of expressed protein, as it forms a metal binding domain in the translated
protein that can bind to metal affinity resins. The expressed protein can be purified by one step
affinity chromatography on Ni2+ containing resins or other metal ion based affinity resins such
as Clontech’s Talon Metal Affinity Resin. The enterokinase protease cleavage site allows the
removal of the N-terminal protein leader sequence by digestion of the expressed protein with
enterokinase protease enzyme.
Σεχτιον 4.11.2 Εξπρεσσιον οφ mΠΠΑΡα−DΒD ιν ΒΛ21 (DΕ3)πΛψσΣ Ε.χολι
Figure 3.41 demonstrates that an induced protein of molecular weight < 20 kDa was expressed
in cultures treated with IPTG. Cultures grown without the addition of IPTG did not exhibit any
induced protein expression. Cultures of BL21 (DE3)pLys S cells treated with IPTG did not have
any low molecular weight proteins induced.Figure 3.42 demonstrates that induced mPPARα-
DBD separated into the insoluble protein fraction.
It has been found that expression of recombinant interferon proteins in E.coli cultured at 30 C
produces significantly higher yields of soluble protein (Schein, C.H. 1989). Similar results have
been obtained for P22 tailspike protein, diphtheria toxin, basic fibroblast growth factor and pro-
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subtilisin proteins (Haase-Pettingwell, C.A. and King, J. 1988, Bishai, W.R. et al 1987, Squires,
C.H. et al 1988 and Takagi, H. et al 1988). The effect of culturing BL21(DE3)pLys S-pRSET-
A-mPPARα-DBD E.coli at 30 C on the solubility of expressed mPPARα-DBD protein was
investigated. Figure 3.43 demonstrates that mPPARα-DBD protein expression induced at 30 C
did not segregate into the insoluble or soluble protein fraction differently than mPPARα-DBD
protein expression induced at 37 C. Induction at 30 C did not increase the solubility of
overexpressed mPPARα-DBD protein. Low level expression of soluble mPPARα-DBD in
BL21(DE3)pLys S-pRSET-A-mPPARα-DBD E.coli induced at 37 C was not detected by SDS-
PAGE, using Coomassie Blue staining. It was possible that low levels of soluble mPPARα-DBD
were produced, therefore the soluble protein fraction was subjected to metal affinity
chromatography to purify any soluble His*6 tagged mPPARα-DBD present. Figure 3.44 shows
that no proteins from the soluble protein fraction bound to Talon Metal Affinity Resin. 
Σεχτιον 4.11.3 Πυρι⇒χατιον οφ δενατυρεδ mΠΠΑΡα−DΒD
mPPARα-DBD present in the insoluble protein fraction was purified by denaturing metal
affinity chromatography, using the denaturing agent 6M guanidine and Talon Metal Affinity
Resin. Proteins specifically eluted from the Talon resin were dialysed against a low salt buffer,
containing Zn 2+ ions, to remove the denaturing agent, and potentially refold proteins into a
functional conformation. The dialysed eluted proteins were analysed by SDS-PAGE. Figure 3.45
(A) and (B) shows highly purified mPPARα-DBD protein was obtained after dialysis of eluted
denatured proteins. The total amount of renatured mPPARα-DBD purified was 848 mg. A
sample of His*6 tagged mPPARα-DBD protein was treated with enterokinase protease enzyme
to remove the His*6 tag. Progression of the cleavage was determined by sampling aliquots of the
reaction at hourly intervals and analysing these samples by SDS-PAGE. Figure 3.46 demonstrates
that cleavage of the His*6 tag from a significant proportion of mPPARα-DBD occurred within
1 hour. A proportion of the purified mPPARα-DBD remained resistant to protease digestion
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after six hours. The protein band marked un-tagged mPPARα-DBD diminishes in intensity after
1 hour, indicating that degradation of untagged mPPARα-DBD protein by enterokinase
increased with time.
Σεχτιον 4.11.4 Ελεχτροmοβιλιτψ σηιφτ ασσαψσ οφ mΠΠΑΡα−DΒD
The binding of tagged and untagged mPPARα-DBD to a PPRE was tested by electromobility
shift assays. A suitable DNA substrate had to be chosen so that binding of a monomer or dimer
could be accommodated. It has been shown for receptors such as Rev-ErbAα, NGFI-B and
ROR, which bind to DNA response elements as a monomer that DNA sequence immediately
5’ to the core binding site is important for receptor binding (Harding, H.P. and Lazar, M.A.
1993, Wilson, T.E. et al 1993 and Giguere, V. et al 1994). Palmer, C.N.A et al 1995 demonstrated
that the seven nucleotides immediately 5’ to the core PPRE in the Cyp4A6z element are
important for binding of PPARα/RXRα heterodimers. A PPRE containing a consensus 5’
flanking region designed from genes containing PPREs and the Cyp4A6z element core PPRE
was shown to be more effective at binding PPARα/RXRα heterodimers than native PPREs
(Palmer, C.N.A. et al 1995). This consensus Cyp4A6z PPRE was chosen as a substrate for EMSA
assays of mPPARα-DBD as it contains extended 5’ flanking sequence. Figures 3.47 and 3.48
show that neither tagged or untagged mPPARα-DBD bind to the con-4A6z PPRE DNA, even
in the absence of non-specific competitor DNA. The lack of even non-specific DNA binding
by purified mPPARα-DBD protein suggests that the purified protein did not refold into a
conformation that could bind DNA. The removal of the His*6 tag did alter the conformation of
mPPARα-DBD into a protein which could bind DNA. 
Σεχτιον 4.11.5 Ρεχοϖερψ οφ φυνχτιοναλ DΝΑ βινδινγ δοmαιν προτεινσ
Reducing agents such as β-mercaptoethanol or dithiothreitol were not added at the solubilisation
stage due to incompatibilites with the metal affinity resins. Therefore if the mPPARα-DBD had
formed insoluble aggregates due to disulphide bond formation between mPPARα-DBD
Alex R. Bell Section 4.11.6
Page 191
monomers, or formed aggregates of incorrectly folded monomers caused by incorrect intra-
molecular disulphide bridges, the solubilisation process would not break these disulphide bonds.
The denatured mPPARα-DBD was refolded by removal of the 6M Guanidinium HCl by
dialysis into a Hepes-Zinc based buffer containing no denaturant, or reducing agents. The
cysteine residues in the zinc finger regions do not form disulphide bridges in the native protein,
but are tetrahedrally co-ordinated to a Zn2+ ion (Freedman, L.P and Luisi, B.F. 1993). If these
cysteine residues have formed disulphide bridges, they will need to be broken first by reduction,
then allowed to coordinately bind to a zinc ion. It is a possibility that the extra cysteine
engineered in by the mismatch primer was causing incorrect disulphide bridge formation during
expression of the protein. The purification process used to isolate, denature and renature
mPPARα-DBD contained no reducing agents, and therefore would not be able break erroneous
disulphide bond formation. Denaturation of the insoluble mPPARα-DBD in the presence of
reducing agents, then dialysis into a zinc containing buffer (devoid of denaturant and reducing
agent) should be attempted to refold mPPARα-DBD, before purification this particular His*6
tagged mPPARα-DBD on a metal affinity resin. The production of soluble mPPARα-DBD
during the initial culturing or a successful renaturation strategy will be important for obtaining a
functional DNA binding protein.
Σεχτιον 4.11.6 Χλονινγ ανδ εξπρεσσιον οφ τηιορεδοξιν−mΠΠΑΡα−DΒD φυσιον προτειν
To increase the solubility of mPPARα-DBD protein expressed in E.coli it was decided to make
a fusion protein of E.coli thioredoxin (trxA) and mPPARα-DBD using the commercial
expression vector pThioHis (Invitrogen). Thioredoxin is a small (11.7 kDa) highly soluble
protein which when N-terminally attached to a heterologous protein confers increased solubility
to the heterologous protein when over expressed in E.coli (LaVallie, E.R. et al 1993). Proteins
can be isolated from inclusion bodies by denaturation, but the resolubilised proteins then require
to be correctly refolded, often a very difficult process to achieve (Schein, C.H 1989). The
Alex R. Bell Section 4.11.7
Page 192
expression of eukaryotic proteins fused to thioredoxin has been found to circumvent the problem
of inclusion body formation (LaVallie, E.R. 1993). Human interferon gamma receptor α chain,
T cell receptor chains α and β, and human fatty acid synthase, three very different eukaryotic
proteins have all been expressed as highly soluble thioredoxin fusion proteins (Williams, G. et al
1995, Schodin, B.A. et al 1996 and Jayakumar, A. et al 1996).
DNA was amplified from mPPARα cDNA by PCR, corresponding to the DNA binding
domain of mPPARα (95G-198S), and was cloned into the Pst I site of pThioHis A vector. The
5’ Pst I site in the DBD PCR fragment was generated by a mismatch primer and resulted in 95
G being mutated to 95 C. A translational stop codon was also engineered into the 3’ mPPARα-
DBD PCR primer. Putative pThioHis.A-mPPARα-DBD clones were screened for the
orientation of the DBD insert by digestion with Bgl II restriction enzyme, see figure 3.49 (B).
Clone 5 was chosen for thioredoxin-mPPARα-DBD fusion protein expression studies.
Σεχτιον 4.11.7 Προκαρψοτιχ εξπρεσσιον οφ τηιορεδοξιν−mΠΠΑΡα−DΒD φυσιον προτειν
Large scale cultures (500 ml) of BL21(De3)pLysS-pThioHis.A-mPPARα-DBD were grown
until the growth of cells had reached an OD600nm =0.6. IPTG was added to the culture medium
to induce expression of thioredoxin-mPPARα fusion protein. Cells were pelleted and sonicated
in 1* Talon Bind buffer. Soluble and insoluble proteins were separated by ultracentrifugation,
and then analysed by SDS-PAGE. Figure 3.50 shows that an induced protein of approximate
molecular weight 30 kDa was present in abundance in the insoluble protein fraction. The
presence of fusion protein cannot be seen in the soluble protein fraction, but this does not
excluded the possibility of low levels of fusion protein being present in the soluble fraction. The
presence of thioredoxin-mPPARα-DBD in the soluble protein fraction was tested by binding
soluble protein extracts to two types of metal affinity resin. Invitrogens nickel charged sepharose
resin (ProBond Resin) and Clontech’s Talon Metal Affinity resin were used. Figure 3.51 shows
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SDS-PAGE analysis of uninduced and induced total cell extracts, insoluble and soluble protein
fractions, and unbound and eluted soluble proteins from the ProBond resin. Bound proteins were
eluted from the resin in buffers containing increasing amounts of imidazole. The gel
demonstrates that most soluble proteins bound to the ProBond resin in a non-specific manner,
and that this resin was unable to specifically purify any thioredoxin-mPPARα-DBD fusion
protein. Figure 3.52 demonstrates that Talon metal affinity resin did not bind any soluble
thioredoxin-mPPARα-DBD fusion protein. The lane marked NB for non-bound soluble
proteins shows that Talon metal affinity resin does not bind soluble proteins non-specifically to
the same extent as ProBond Resin. The results of the experiments shown in figure 3.51 and 3.52
demonstrate that the induced thioredoxin-mPPARα-DBD protein exclusively segregated into
the insoluble protein fraction. The fusion of thioredoxin to the mPPARα-DBD did not increase
its solubility, when over expressed in E.coli.
The insolubility of the thioredoxin-mPPARα-DBD fusion protein could have been caused by
the 95G to 95 C mutation. This cysteine residue is not native to mPPARα and could be causing
erroneous disulphide bridge formation, leading to aggregation of the expressed protein. Creating
a similar mPPARα-DBD fusion protein with the 95 C residue changed to a small unreactive
amino acid should be done in order to verify if it is the 95 C residue that is causing the solubility
problems. Other future experiments could attempt to produce soluble fusion protein by
culturing the IPTG induced E.coli cultures at a temperature lower than 30 C, possibly at 25 C.
Another strategy which could be investigated in order to produce soluble His*6 tagged
mPPARα-DBD or thioredoxin-mPPARα-DBD is that of adding sorbitol and glycyl betaine to
the E.coli growth medium. Blackwell, J.R. and Horgan, R 1991 demonstrated that recombinant
expression of Dimethylallylpyrophosphate:5’-AMP transferase in cultures of E.coli containing
sorbitol and glycyl betaine in the culture medium produced a soluble active protein instead of an
insoluble protein. It is believed that the E.coli cytoplasm took up the sorbitol and glycyl betaine
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osmolytes such that they generated a major proportion of the cytoplasmic osmotic balance. These
two substances can minimise protein-protein contacts, increasing the solubility of the expressed
protein.
Σεχτιον 4.11.8 Ιν ϖιτρο σψντηεσισ οφ mΠΠΑΡα−DΒD
His*6 tagged mPPARα-DBD protein was produced using an in vitro transcription / translation
reaction. This reaction contained reticulocyte lysate extracts which contain Heat shock proteins.
Heat shock proteins can aid the folding of nascent polypeptides in their correct tertiary structure.
Evidence to show that Heat shock proteins are required for the folding of transcription factors
such as the glucocorticoid receptor came from comparing the production of glucocorticoid
receptor in wheat germ extracts that lack heat shock proteins and in reticulocyte lysate extracts
which do contain Heat shock proteins. Glucocorticoid receptor translated in wheat germ extracts
could not bind glucocorticoid hormone, whereas receptor produce in reticulocyte lysate extract
did show high affinity hormone binding (Dalman, F.et al 1989). It was therefore hypothesised
that mPPARα-DBD produced using reticulocyte lysate extracts would produce soluble correctly
folded protein. Figure 3.53 shows SDS-PAGE analysis of His*6 tagged mPPARα, mPPARα
and RXRα proteins produced by in vitro transcription translation reactions using reticulocyte
lysate extracts. 
The reaction extracts containing the in vitro translated receptors were assayed for DNA binding
in electromobility shift assays. Figure 3.54 shows that mPPARα-DBD, mPPARα, mRXRα or
combinations of these receptors did not bind to con4A6z PPRE probes in an electromobility shift
assay. Independent batches of in vitro translated receptors, including human PPARα, guinea pig
PPARα as well as mPPARα, mRXRα and mPPARα-DBD were assayed for binding to wild
type and mutant rat acyl-CoA oxidase PPRE as well (data not shown). No specific DNA binding
was found for any of the receptors produced by in vitro transcription / translation reactions. The
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same assay conditions that were used to show specific binding of liver nuclear protein extracts
were also used for in vitro translated receptors. Thus as no receptor binding was observed it is not
possible to conclude if the mPPARα-DBD protein produced by in vitro transcription translation
reactions was correctly folded. The reason for the lack of in vitro translated receptor binding in
the electromobility shift assays was unable to be determined.
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